WHO Drug Information Vol. 27, No. 1, 2013                                                 Recommended INN: List 69



International Nonproprietary Names for
Pharmaceutical Substances (INN)
RECOMMENDED International Nonproprietary Names:
List 69
Notice is hereby given that, in accordance with paragraph 7 of the Procedure for the Selection of Recommended
International Nonproprietary Names for Pharmaceutical Substances [Off. Rec. Wld Health Org., 1955, 60, 3 (Resolution
EB15.R7); 1969, 173, 10 (Resolution EB43.R9); Resolution EB115.R4 (EB115/2005/REC/1)], the following names are
selected as Recommended International Nonproprietary Names. The inclusion of a name in the lists of Recommended
International Nonproprietary Names does not imply any recommendation of the use of the substance in medicine or
pharmacy.
Lists of Proposed (1–105) and Recommended (1–66) International Nonproprietary Names can be found in Cumulative List
No. 14, 2011 (available in CD-ROM only).



Dénominations communes internationales
des Substances pharmaceutiques (DCI)
Dénominations communes internationales RECOMMANDÉES:
Liste 69
Il est notifié que, conformément aux dispositions du paragraphe 7 de la Procédure à suivre en vue du choix de
Dénominations communes internationales recommandées pour les Substances pharmaceutiques [Actes off. Org. mond.
Santé, 1955, 60, 3 (résolution EB15.R7); 1969, 173, 10 (résolution EB43.R9); résolution EB115.R4 (EB115/2005/REC/1)]
les dénominations ci-dessous sont choisies par l’Organisation mondiale de la Santé en tant que dénominations communes
internationales recommandées. L’inclusion d’une dénomination dans les listes de DCI recommandées n’implique aucune
recommandation en vue de l’utilisation de la substance correspondante en médecine ou en pharmacie.
On trouvera d’autres listes de Dénominations communes internationales proposées (1–105) et recommandées (1–66) dans
la Liste récapitulative No. 14, 2011 (disponible sur CD-ROM seulement).



Denominaciones Comunes Internacionales
para las Sustancias Farmacéuticas (DCI)
Denominaciones Comunes Internacionales RECOMENDADAS:
Lista 69
De conformidad con lo que dispone el párrafo 7 del Procedimiento de Selección de Denominaciones Comunes
Internacionales Recomendadas para las Sustancias Farmacéuticas [Act. Of. Mund. Salud, 1955, 60, 3 (Resolución
EB15.R7); 1969, 173, 10 (Resolución EB43.R9); Résolution EB115.R4 (EB115/2005/REC/1) EB115.R4
(EB115/2005/REC/1)], se comunica por el presente anuncio que las denominaciones que a continuación se expresan han
sido seleccionadas como Denominaciones Comunes Internacionales Recomendadas. La inclusión de una denominación en
las listas de las Denominaciones Comunes Recomendadas no supone recomendación alguna en favor del empleo de la
sustancia respectiva en medicina o en farmacia.
Las listas de Denominaciones Comunes Internacionales Propuestas (1–105) y Recomendadas (1–66) se encuentran
reunidas en Cumulative List No. 14, 2011 (disponible sólo en CD-ROM).


                                                                                                                  41
Recommended INN: List 69                                                     WHO Drug Information Vol. 27, No. 1, 2013




 Latin, English, French, Spanish:
 Recommended INN                    Chemical name or description; Molecular formula; Graphic formula

 DCI Recommandée                    Nom chimique ou description; Formule brute; Formule développée

 DCI Recomendada                    Nombre químico o descripción; Fórmula molecular; Fórmula desarrollada




 actoxumabum #
 actoxumab                                 immunoglobulin G1-kappa, anti-(Clostridium difficile toxin A), Homo
                                           sapiens monoclonal antibody;
                                           gamma1 heavy chain (1-449) [Homo sapiens VH (IGHV5-51*01
                                           (94.90%) -(IGHD)-IGHJ3*02) [8.8.12] (1-119) -IGHG1*03 (120-449)],
                                           (222-215')-disulfide with kappa light chain (1'-215') [Homo sapiens
                                           V-KAPPA (IGKV3-20*01 (100.00%) -IGKJ1*01) [7.3.9] (1'-108') -
                                           IGKC*01 (109'-215')]; (228-228'':231-231'')-bisdisulfide dimer

 actoxumab                                 immunoglobuline G1-kappa, anti-(Clostridium difficile toxine A),
                                           Homo sapiens anticorps monoclonal;
                                           chaîne lourde gamma1 (1-449) [Homo sapiens VH (IGHV5-51*01
                                           (94.90%) -(IGHD)-IGHJ3*02) [8.8.12] (1-119) -IGHG1*03 (120-449)],
                                           (222-215')-disulfure avec la chaîne légère kappa (1'-215') [Homo
                                           sapiens V-KAPPA (IGKV3-20*01 (100.00%) -IGKJ1*01) [7.3.9] (1'-
                                           108') -IGKC*01 (109'-215')]; dimère (228-228'':231-231'')-bisdisulfure

 actoxumab                                 inmunoglobulina G1-kappa, anti-(toxina A de Clostridium difficile),
                                           anticuerpo monoclonal de Homo sapiens ;
                                           cadena pesada gamma1 (1-449) [Homo sapiens VH (IGHV5-51*01
                                           (94.90%) -(IGHD)-IGHJ3*02) [8.8.12] (1-119) -IGHG1*03 (120-449)],
                                           (222-215')-disulfuro con la cadena ligera kappa (1'-215') [Homo
                                           sapiens V-KAPPA (IGKV3-20*01 (100.00%) -IGKJ1*01) [7.3.9] (1'-
                                           108') -IGKC*01 (109'-215')]; dímero (228-228'':231-231'')-bisdisulfuro

                                            Heavy chain / Chaîne lourde / Cadena pesada
                                            EVQLVQSGAE VKKSGESLKI SCKGSGYSFT                  SYWIGWVRQM       PGKGLEWMGI       50
                                            FYPGDSSTRY SPSFQGQVTI SADKSVNTAY                  LQWSSLKASD       TAMYYCARRR      100
                                            NWGNAFDIWG QGTMVTVSSA STKGPSVFPL                  APSSKSTSGG       TAALGCLVKD      150
                                            YFPEPVTVSW NSGALTSGVH TFPAVLQSSG                  LYSLSSVVTV       PSSSLGTQTY      200
                                            ICNVNHKPSN TKVDKRVEPK SCDKTHTCPP                  CPAPELLGGP       SVFLFPPKPK      250
                                            DTLMISRTPE VTCVVVDVSH EDPEVKFNWY                  VDGVEVHNAK       TKPREEQYNS      300
                                            TYRVVSVLTV LHQDWLNGKE YKCKVSNKAL                  PAPIEKTISK       AKGQPREPQV      350
                                            YTLPPSREEM TKNQVSLTCL VKGFYPSDIA                  VEWESNGQPE       NNYKTTPPVL      400
                                            DSDGSFFLYS KLTVDKSRWQ QGNVFSCSVM                  HEALHNHYTQ       KSLSLSPGK       449

                                            Light chain / Chaîne légère / Cadena ligera
                                            EIVLTQSPGT LSLSPGERAT LSCRASQSVS                  SSYLAWYQQK       PGQAPRLLIY 50
                                            GASSRATGIP DRFSGSGSGT DFTLTISRLE                  PEDFAVYYCQ       QYGSSTWTFG 100
                                            QGTKVEIKRT VAAPSVFIFP PSDEQLKSGT                  ASVVCLLNNF       YPREAKVQWK 150
                                            VDNALQSGNS QESVTEQDSK DSTYSLSSTL                  TLSKADYEKH       KVYACEVTHQ 200
                                            GLSSPVTKSF NRGEC                                                              215

                                            Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
                                            Intra-H 22-96        146-202 263-323        369-427
                                                     22''-96'' 146''-202'' 263''-323'' 369''-427''
                                            Intra-L 23'-89'      135'-195'
                                                     23'''-89''' 135'''-195'''
                                            Inter-H-L 222-215' 222''-215'''
                                            Inter-H-H 228-228'' 231-231''

                                            N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación
                                            H CH2 N84.4:
                                            299, 299''




42
WHO Drug Information Vol. 27, No. 1, 2013                                             Recommended INN: List 69




 aladorianum
 aladorian                                  (7-methoxy-2,3-dihydro-1,4-benzothiazepin-4(5H)-yl)oxoacetic acid

 aladorian                                  acide (7-méthoxy-2,3-dihydro-1,4-benzothiazépin-
                                            4(5H)-yl)oxoacétique

 aladorián                                  ácido (7- metoxi-2,3-dihidro-1,4-benzotiazepin-4(5H)-il)oxoacético

                                            C12H13NO4S

                                                           S


                                            H3CO               N
                                                                    CO2H
                                                               O




 alirocumabum #
 alirocumab                                 immunoglobulin G1-kappa, anti-[Homo sapiens PCSK9 (proprotein
                                            convertase subtilisin/kexin type 9)], Homo sapiens monoclonal
                                            antibody;
                                            gamma1 heavy chain (1-447) [Homo sapiens VH (IGHV3-23*04
                                            (89.80%) -(IGHD)-IGHJ2*01 [8.8.11] (1-118) -IGHG1*01 CHS
                                            K2>del (119-447)], (221-220')-disulfide with kappa light chain (1'-
                                            220') [Homo sapiens V-KAPPA (IGKV4-1*01 (94.10%) -IGKJ2*01)
                                            [12.3.9] (1'-113') -IGKC*01 (114'-220')]; (227-227'':230-230'')-
                                            bisdisulfide dimer

 alirocumab                                 immunoglobuline G1-kappa, anti-[Homo sapiens PCSK9
                                            (proprotéine convertase subtilisine/kexine type 9)], Homo sapiens
                                            anticorps monoclonal;
                                            chaîne lourde gamma1 (1-447) [Homo sapiens VH (IGHV3-23*04
                                            (89.80%) -(IGHD)-IGHJ2*01 [8.8.11] (1-118) -IGHG1*01 CHS
                                            K2>del (119-447)], (221-220')-disulfure avec la chaîne légère kappa
                                            (1'-220') [Homo sapiens V-KAPPA (IGKV4-1*01 (94.10%) -
                                            IGKJ2*01) [12.3.9] (1'-113') -IGKC*01 (114'-220')]; dimère (227-
                                            227'':230-230'')-bisdisulfure

 alirocumab                                 inmunoglobulina G1-kappa, anti-[PCSK9 de Homo sapiens
                                            (proproteína convertasa subtilisina/kexina tipo 9)], anticuerpo
                                            monoclonal de Homo sapiens;
                                            cadena pesada gamma1 (1-447) [Homo sapiens VH (IGHV3-23*04
                                            (89.80%) -(IGHD)-IGHJ2*01 [8.8.11] (1-118) -IGHG1*01 CHS
                                            K2>del (119-447)], (221-220')-disulfuro con la cadena ligera kappa
                                            (1'-220') [Homo sapiens V-KAPPA (IGKV4-1*01 (94.10%) -
                                            IGKJ2*01) [12.3.9] (1'-113') -IGKC*01 (114'-220')]; dímero (227-
                                            227'':230-230'')-bisdisulfuro




                                                                                                                  43
Recommended INN: List 69                                     WHO Drug Information Vol. 27, No. 1, 2013




                           Heavy chain / Chaîne lourde / Cadena pesada
                           EVQLVESGGG LVQPGGSLRL SCAASGFTFN                  NYAMNWVRQA       PGKGLDWVST       50
                           ISGSGGTTNY ADSVKGRFII SRDSSKHTLY                  LQMNSLRAED       TAVYYCAKDS      100
                           NWGNFDLWGR GTLVTVSSAS TKGPSVFPLA                  PSSKSTSGGT       AALGCLVKDY      150
                           FPEPVTVSWN SGALTSGVHT FPAVLQSSGL                  YSLSSVVTVP       SSSLGTQTYI      200
                           CNVNHKPSNT KVDKKVEPKS CDKTHTCPPC                  PAPELLGGPS       VFLFPPKPKD      250
                           TLMISRTPEV TCVVVDVSHE DPEVKFNWYV                  DGVEVHNAKT       KPREEQYNST      300
                           YRVVSVLTVL HQDWLNGKEY KCKVSNKALP                  APIEKTISKA       KGQPREPQVY      350
                           TLPPSRDELT KNQVSLTCLV KGFYPSDIAV                  EWESNGQPEN       NYKTTPPVLD      400
                           SDGSFFLYSK LTVDKSRWQQ GNVFSCSVMH                  EALHNHYTQK       SLSLSPG         447

                           Light chain / Chaîne légère / Cadena ligera
                           DIVMTQSPDS LAVSLGERAT INCKSSQSVL                  YRSNNRNFLG       WYQQKPGQPP 50
                           NLLIYWASTR ESGVPDRFSG SGSGTDFTLT                  ISSLQAEDVA       VYYCQQYYTT 100
                           PYTFGQGTKL EIKRTVAAPS VFIFPPSDEQ                  LKSGTASVVC       LLNNFYPREA 150
                           KVQWKVDNAL QSGNSQESVT EQDSKDSTYS                  LSSTLTLSKA       DYEKHKVYAC 200
                           EVTHQGLSSP VTKSFNRGEC                                                         220

                           Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
                           Intra-H 22-96 145-201              262-322  368-426
                                    22''-96'' 145''-201'' 262''-322'' 368''-426''
                           Intra-L 23'-94' 140'-200'
                                    23'''-94''' 140'''-200'''
                           Inter-H-L 221-220' 221''-220'''
                           Inter-H-H 227-227'' 230-230''

                           N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación
                           H CH2 N84.4:
                           298, 298''




 antithrombinum gamma #
 antithrombin gamma        afucosylated antithrombin; human antithrombin-III (ATIII, serpin C1)
                           expressed in fucosyl transferase-negative Chinese Hamster Ovary
                           (CHO) cells (glycoform gamma)

 antithrombine gamma       antithrombine afucosylée; antithrombine-III humaine (ATIII, serpine
                           C1) obtenue à partir de culture de cellules ovariennes d'hamster
                           chinois (CHO) n'exprimant pas la fucosyl transférase (glycoforme
                           gamma)

 antitrombina gamma        antitrombina afucosilada; antitrombina-III humana (ATIII, serpina C1)
                           obtenida a partir de cultivo de células ováricas de hamster chino
                           (CHO) que no expresan la fucosil transferasa (glicoforma gamma)

                           HGSPVDICTA      KPRDIPMNPM       CIYRSPEKKA       TEDEGSEQKI       PEATNRRVWE       50
                           LSKANSRFAT      TFYQHLADSK       NDNDNIFLSP       LSISTAFAMT       KLGACNDTLQ       100
                           QLMEVFKFDT      ISEKTSDQIH       FFFAKLNCRL       YRKANKSSKL       VSANRLFGDK       150
                           SLTFNETYQD      ISELVYGAKL       QPLDFKENAE       QSRAAINKWV       SNKTEGRITD       200
                           VIPSEAINEL      TVLVLVNTIY       FKGLWKSKFS       PENTRKELFY       KADGESCSAS       250
                           MMYQEGKFRY      RRVAEGTQVL       ELPFKGDDIT       MVLILPKPEK       SLAKVEKELT       300
                           PEVLQEWLDE      LEEMMLVVHM       PRFRIEDGFS       LKEQLQDMGL       VDLFSPEKSK       350
                           LPGIVAEGRD      DLYVSDAFHK       AFLEVNEEGS       EAAASTAVVI       AGRSLNPNRV       400
                           TFKANRPFLV      FIREVPLNTI       IFMGRVANPC       VK                                432

                           Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
                           8-128 21-95 247-430

                           Modified residue / Résidu modifié / Residuo modificado
                                    S                              H   NH2
                                   36                O       O
                            O-phosphonoSer              P               CO2H

                                                       HO    OH


                           Glycosylation sites (N) / Sites de glycosylation (N) / Posiciones de glicosilación (N)
                           Asn-96 Asn-135 Asn-155 Asn-192

                           -Sia3--Gal3--Gl-N2--Man6-
                                                                   -Man4--Gl-N4--Gl-NN
                           -Sia3--Gal3--Gl-N2--Man3-




44
WHO Drug Information Vol. 27, No. 1, 2013                                                         Recommended INN: List 69


 asudemotidum
 asudemotide                                human DEP domain-containing protein 1A-(294-302)-peptide

 asudémotide                                protéine 1A humaine contenant le domaine DEP-(294-302)-peptide

 asudemotida                                proteína 1A humana que contiene el dominio DEP-(294-302)-péptido

                                            C58H80N10O17

                                            H Glu      Tyr      Tyr    Glu   Leu   Phe   Val      Asn   Ile OH

 auriclosenum
 auriclosene                                2-(dichloroamino)-2-methylpropane-1-sulfonic acid

 auriclosène                                acide 2-(dichloroamino)-2-méthylpropane-1-sulfonique

 auricloseno                                ácido 2-(dicloroamino)-2-metilpropano-1-sulfónico

                                            C4H9Cl2NO3S

                                                 H3C   CH3
                                            Cl                  SO3H
                                                 N
                                                 Cl

 avatrombopagum
 avatrombopag                               1-(3-chloro-5-{[4-(4-chlorothiophen-2-yl)-5-(4-cyclohexylpiperazin-
                                            1-yl)-1,3-thiazol-2-yl]carbamoyl}pyridin-2-yl)piperidine-4-carboxylic
                                            acid

 avatrombopag                               acide 1-(3-chloro-5-{[4-(4-chlorothiophén-2-yl)-
                                            5-(4-cyclohexylpipérazin-1-yl)-1,3-thiazol-2-yl]carbamoyl}pyridin-
                                            2-yl)pipéridine-4-carboxylique

 avatrombopag                               ácido 1-(3-cloro-5-{[5-(4-ciclohexilpiperazin-1-il)-4-(4-clorotiofen-2-il)-
                                            1,3-tiazol-2-il]carbamoil}piridin-2-il)piperidina-4-carboxílico

                                            C29H34Cl2N6O3S2




                                                       N                      O          N
                                                                 N      S                         N         CO2H
                                                                              NH
                                                            S           N                    Cl


                                                       Cl

 balugrastimum #
 balugrastim                                human serum albumin (585 residues) fusion protein with des-
                                            (1-alanine,37-valine,38-serine,39-glutamic acid)-human granulocyte
                                            colony-stimulating factor (pluripoietin)

 balugrastim                                albumine sérique humaine (585 résidus) protéine de fusion avec le
                                            dès-(1-alanine,37-valine,38-sérine,39-acide glutamique)-facteur de
                                            stimulation des colonies de granulocytes humain (pluripoïétine)

 balugrastim                                albumina sérica humana (585 residuos) proteína de fusión con el
                                            des-(1-alanina,37-valina,38-serina,39-ácido glutámico)-factor
                                            humano estimulante de las colonias de granulocitos (pluripoyetina)


                                                                                                                        45
Recommended INN: List 69                                        WHO Drug Information Vol. 27, No. 1, 2013



                           DAHKSEVAHR       FKDLGEENFK         ALVLIAFAQY    LQQCPFEDHV       KLVNEVTEFA      50
                           KTCVADESAE       NCDKSLHTLF         GDKLCTVATL    RETYGEMADC       CAKQEPERNE      100
                           CFLQHKDDNP       NLPRLVRPEV         DVMCTAFHDN    EETFLKKYLY       EIARRHPYFY      150
                           APELLFFAKR       YKAAFTECCQ         AADKAACLLP    KLDELRDEGK       ASSAKQRLKC      200
                           ASLQKFGERA       FKAWAVARLS         QRFPKAEFAE    VSKLVTDLTK       VHTECCHGDL      250
                           LECADDRADL       AKYICENQDS         ISSKLKECCE    KPLLEKSHCI       AEVENDEMPA      300
                           DLPSLAADFV       ESKDVCKNYA         EAKDVFLGMF    LYEYARRHPD       YSVVLLLRLA      350
                           KTYETTLEKC       CAAADPHECY         AKVFDEFKPL    VEEPQNLIKQ       NCELFEQLGE      400
                           YKFQNALLVR       YTKKVPQVST         PTLVEVSRNL    GKVGSKCCKH       PEAKRMPCAE      450
                           DYLSVVLNQL       CVLHEKTPVS         DRVTKCCTES    LVNRRPCFSA       LEVDETYVPK      500
                           EFNAETFTFH       ADICTLSEKE         RQIKKQTALV    ELVKHKPKAT       KEQLKAVMDD      550
                           FAAFVEKCCK       ADDKETCFAE         EGKKLVAASQ    AALGLTPLGP       ASSLPQSFLL      600
                           KCLEQVRKIQ       GDGAALQEKL         CATYKLCHPE    ELVLLGHSLG       IPWAPLSSCP      650
                           SQALQLAGCL       SQLHSGLFLY         QGLLQALEGI    SPELGPTLDT       LQLDVADFAT      700
                           TIWQQMEELG       MAPALQPTQG         AMPAFASAFQ    RRAGGVLVAS       HLQSFLEVSY      750
                           RVLRHLAQP           759

                           Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
                           53-62 75-91 90-101 124-169 168-177 200-246 245-253
                           265-279 278-289 316-361 360-369 392-438 437-448 461-477
                           476-487 514-559 558-567 621-627 649-659




 baricitinibum
 baricitinib               {1-(ethanesulfonyl)-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-
                           1-yl]azetidin-3-yl}ethanenitrile

 baricitinib               {1-(éthanesulfonyl)-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-
                           1-yl]azétidin-3-yl}éthanenitrile

 baricitinib               {1-(etanosulfonil)-3-[4-(7H-pirrolo[2,3-d]pirimidin-4-il)-1H-pirazol-
                           1-il]azetidin-3-il}etanonitrilo

                           C16H17N7O2S

                                                       O
                                                   O       S     CH3
                                                           N
                                N       N
                                                                 CN
                           HN                       N
                                                   N



 bevenopranum
 bevenopran                5-[2-methoxy-4-({[2-(oxan-
                           4-yl)ethyl]amino}methyl)phenoxy]pyrazine-2-carboxamide

 bévénopran                5-[2-méthoxy-4-({[2-(oxan-
                           4-yl)éthyl]amino}méthyl)phénoxy]pyrazine-2-carboxamide

 bevenoprán                5-[2-metoxi-4-({[2-(oxan-4-il)etil]amino}metil)fenoxi]pirazina-
                           2-carboxamida

                           C20H26N4O4

                           O                                                       O
                                                                            N
                                               N                                        NH2
                                               H
                                                                      O     N
                                                               OCH3




46
WHO Drug Information Vol. 27, No. 1, 2013                                                           Recommended INN: List 69


 bezlotoxumabum #
 bezlotoxumab                               immunoglobulin G1-kappa, anti-[Clostridium difficile toxin B)], Homo
                                            sapiens monoclonal antibody;
                                            gamma1 heavy chain (1-449) [Homo sapiens VH (IGHV5-51*01
                                            (94.90%) -(IGHD)-IGHJ3*02) [8.8.12] (1-119) -IGHG1*03 (120-449)],
                                            (222-215')-disulfide with kappa light chain (1'-215') [Homo sapiens
                                            V-KAPPA (IGKV3-20*01 (100.00%) -IGKJ1*01) [7.3.9] (1'-108') -
                                            IGKC*01 (109'-215')]; (228-228'':231-231'')-bisdisulfide dimer

 bezlotoxumab                               immunoglobuline G1-kappa, anti-[Clostridium difficile toxine B)],
                                            Homo sapiens anticorps monoclonal;
                                            chaîne lourde gamma1 (1-449) [Homo sapiens VH (IGHV5-51*01
                                            (94.90%) -(IGHD)-IGHJ3*02) [8.8.12] (1-119) -IGHG1*03 (120-449)],
                                            (222-215')-disulfure avec la chaîne légère kappa (1'-215') [Homo
                                            sapiens V-KAPPA (IGKV3-20*01 (100.00%) -IGKJ1*01) [7.3.9] (1'-
                                            108') -IGKC*01 (109'-215')]; dimère (228-228'':231-231'')-bisdisulfure

 bezlotoxumab                               inmunoglobulina G1-kappa, anti-[toxina B de Clostridium difficile)],
                                            anticuerpo monoclonal de Homo sapiens;
                                            cadena pesada gamma1 (1-449) [Homo sapiens VH (IGHV5-51*01
                                            (94.90%) -(IGHD)-IGHJ3*02) [8.8.12] (1-119) -IGHG1*03 (120-449)],
                                            (222-215')-disulfuro con la cadena ligera kappa (1'-215') [Homo
                                            sapiens V-KAPPA (IGKV3-20*01 (100.00%) -IGKJ1*01) [7.3.9] (1'-
                                            108') -IGKC*01 (109'-215')]; dímero (228-228'':231-231'')-bisdisulfuro

                                            Heavy chain / Chaîne lourde / Cadena pesada
                                            EVQLVQSGAE VKKSGESLKI SCKGSGYSFT                  SYWIGWVRQM       PGKGLEWMGI       50
                                            FYPGDSSTRY SPSFQGQVTI SADKSVNTAY                  LQWSSLKASD       TAMYYCARRR      100
                                            NWGNAFDIWG QGTMVTVSSA STKGPSVFPL                  APSSKSTSGG       TAALGCLVKD      150
                                            YFPEPVTVSW NSGALTSGVH TFPAVLQSSG                  LYSLSSVVTV       PSSSLGTQTY      200
                                            ICNVNHKPSN TKVDKRVEPK SCDKTHTCPP                  CPAPELLGGP       SVFLFPPKPK      250
                                            DTLMISRTPE VTCVVVDVSH EDPEVKFNWY                  VDGVEVHNAK       TKPREEQYNS      300
                                            TYRVVSVLTV LHQDWLNGKE YKCKVSNKAL                  PAPIEKTISK       AKGQPREPQV      350
                                            YTLPPSREEM TKNQVSLTCL VKGFYPSDIA                  VEWESNGQPE       NNYKTTPPVL      400
                                            DSDGSFFLYS KLTVDKSRWQ QGNVFSCSVM                  HEALHNHYTQ       KSLSLSPGK       449

                                            Light chain / Chaîne légère / Cadena ligera
                                            EIVLTQSPGT LSLSPGERAT LSCRASQSVS                  SSYLAWYQQK       PGQAPRLLIY 50
                                            GASSRATGIP DRFSGSGSGT DFTLTISRLE                  PEDFAVYYCQ       QYGSSTWTFG 100
                                            QGTKVEIKRT VAAPSVFIFP PSDEQLKSGT                  ASVVCLLNNF       YPREAKVQWK 150
                                            VDNALQSGNS QESVTEQDSK DSTYSLSSTL                  TLSKADYEKH       KVYACEVTHQ 200
                                            GLSSPVTKSF NRGEC                                                              215

                                            Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
                                            Intra-H 22-96        146-202       263-323  369-427
                                                      22''-96'' 146''-202'' 263''-323'' 369''-427''
                                            Intra-L 23'-89' 135'-195'
                                                     23'''-89''' 135'''-195'''
                                            Inter-H-L 222-215' 222''-215'''
                                            Inter-H-H 228-228'' 231-231''

                                            N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación
                                            H CH2 N84.4:
                                            299, 299''



 birinapantum
 birinapant                                 N,N'-[(6,6'-difluoro[1H,1'H-2,2'-biindole]-
                                            3,3'-diyl)bis{methylene[(2R,4S)-4-hydroxypyrrolidine-2,1-diyl][(2S)-
                                            1-oxobutane-1,2-diyl} bis[(2S)-2-(methylamino)propanamide]

 birinapant                                 N,N'-[(6,6'-difluoro[1H,1'H-2,2'-biindole]-
                                            3,3'-diyl)bis{méthylène[(2R,4S)-4-hydroxypyrrolidine-2,1-diyl][(2S)-
                                            1-oxobutane-1,2-diyl}]bis[(2S)-2-(méthylamino)propanamide]

 birinapant                                 N,N'-[(6,6'-difluoro[1H,1'H-2,2'-biindol]-3,3'-diil)bis{metileno[(2R,4S)-
                                            4-hidroxiporrolidina-2,1-diil][(2S)-1-oxobutano-1,2-diilo}bis[(2S)-
                                            2-(metilamino)propanamida]



                                                                                                                                        47
Recommended INN: List 69                                  WHO Drug Information Vol. 27, No. 1, 2013




                            C42H56F2N8O6

                                                                     F
                                                          HO
                                                CH3            H
                                        O        H
                                   H
                                   N                  N
                             H3C            N
                                            H                        NH
                                    H CH3         O       H

                                    H CH3         O       H
                                            H                        NH
                             H3C            N
                                   N                  N
                                   H
                                        O        H
                                                CH3            H
                                                          HO
                                                                     F




blisibimodum #
blisibimod                 B-cell activating factor (BAFF)-binding peptide fragment/human IgG1
                           Fc fusion protein;
                           glycyl-L-cysteinyl-L-lysyl-L-tryptophyl-{[29-isoleucine(V>I),30-
                           lysine(R>K),31-glutamine(H>Q)]human tumor necrosis factor
                           receptor superfamily member 13C (BAFF receptor, CD268)-(26-31)-
                           peptidyl}-L-tryptophyl-L-valyl-L-cysteinyl-L-aspartyl-L-prolyl-
                           L-leucylglycyl-L-serylglycyl-L-seryl-L-alanyl-L-threonylglycylglycyl-
                           L-serylglycyl-L-seryl-L-threonyl-L-alanyl-L-seryl-L-serylglycyl-
                           L-serylglycyl-L-seryl-L-alanyl-L-threonyl-L-histidyl-L-methionyl-
                           L-leucyl-L-prolylglycyl-L-cysteinyl-L-lysyl-L-tryptophyl-
                           {[29-isoleucine(V>I),30-lysine(R>K),31-glutamine(H>Q)]human
                           tumor necrosis factor receptor superfamily member 13C (BAFF
                           receptor, CD268)-(26-31)-peptidyl}-L-tryptophyl-L-valyl-L-cysteinyl-
                           L-aspartyl-L-prolyl-L-leucylpentaglycyl-L-valyl-(human
                           immunoglobulin heavy constant gamma 1 Fc-(6-232)-peptide) dimer
                           (69-69':72-72')-bisdisulfide

blisibimod                 protéine de fusion entre le fragment Fc de l'immunoglobuline G1
                           humaine et un fragment du peptide se liant au facteur d'activation
                           des cellules B (BAFF);
                           glycyl-L-cystéinyl-L-lysyl-L-tryptophyl-{[29-isoleucine(V>I),30-
                           lysine(R>K),31-glutamine(H>Q)]membre 13C de la superfamille des
                           récepteurs humains du facteur de nécrose tumorale (TNF)
                           (récepteur du BAFF, CD268)-(26-31)-peptidyl}-L-tryptophyl-L-valyl-
                           L-cystéinyl-L-aspartyl-L-prolyl-L-leucylglycyl-L-serylglycyl-L-séryl-
                           L-alanyl-L-thréonylglycylglycyl-L-sérylglycyl-L-séryl-L-thréonyl-
                           L-alanyl-L-séryl-L-sérylglycyl-L-sérylglycyl-L-séryl-L-alanyl-L-thréonyl-
                           L-histidyl-L-méthionyl-L-leucyl-L-prolylglycyl-L-cystéinyl-L-lysyl-
                           L-tryptophyl-{[29-isoleucine(V>I),30-lysine(R>K),31-
                           glutamine(H>Q)]membre 13C de la superfamille des récepteurs
                           humains du TNF (récepteur du BAFF, CD268)-(26-31)-peptidyl}-
                           L-tryptophyl-L-valyl-L-cystéinyl-L-aspartyl-L-prolyl-L-leucylpentaglycyl-
                           L-valyl-(fragment Fc de la chaîne lourde gamma 1 de
                           l'immunoglobuline humaine-(6-232)-peptide), (69-69':72-72')-
                           bisdisulfure du dimère




48
WHO Drug Information Vol. 27, No. 1, 2013                                                           Recommended INN: List 69


 blisibimod                                 proteína de fusión entre el fragmento Fc de la inmunoglobulina G1
                                            humana y un fragmento del péptido que se une al factor de
                                            activación de las células B (BAFF);
                                            glicil-L-cisteinil-L-lisil-L-triptofil-{[29-isoleucina(V>I),30-lisina(R>K),31-
                                            glutamina(H>Q)]miembro 13C de la superfamilia de receptores
                                            humanos del factor de necrosis tumoral (TNF) (receptor del BAFF,
                                            CD268)-(26-31)-peptidil}-L-triptofil-L-valil-L-cisteinil-L-aspartil-L-prolil-
                                            L-leucilglicil-L-serilglicil-L-seril-L-alanil-L-treonilglicilglicil-L-serilglicil-
                                            L-seril-L-treonil-L-alanil-L-seril-L-serilglicil-L-serilglicil-L-seril-L-alanil-
                                            L-treonil-L-histidil-L-metionil-L-leucil-L-prolilglicil-L-cisteinil-L-lisil-
                                            L-triptofil-{[29-isoleucina(V>I),30-lisina(R>K),31-
                                            glutamina(H>Q)]miembro 13C de la superfamilia de receptores
                                            humanos del TNF (receptor del BAFF, CD268)-(26-31)-peptidil}-
                                            L-triptofil-L-valil-L-cisteinil-L-aspartil-L-prolil-L-leucilpentaglicil-L-valil-
                                            (fragmento Fc de la cadena pesada gamma 1 de la inmunoglobulina
                                            humana-(6-232)-péptido), (69-69':72-72')-bisdisulfuro del dímero

                                            Monomer / Monomère / Monómero
                                            GCKWDLLIKQ WVCDPLGSGS ATGGSGSTAS                  SGSGSATHML       PGCKWDLLIK      50
                                            QWVCDPLGGG GGVDKTHTCP PCPAPELLGG                  PSVFLFPPKP       KDTLMISRTP      100
                                            EVTCVVVDVS HEDPEVKFNW YVDGVEVHNA                  KTKPREEQYN       STYRVVSVLT      150
                                            VLHQDWLNGK EYKCKVSNKA LPAPIEKTIS                  KAKGQPREPQ       VYTLPPSRDE      200
                                            LTKNQVSLTC LVKGFYPSDI AVEWESNGQP                  ENNYKTTPPV       LDSDGSFFLY      250
                                            SKLTVDKSRW QQGNVFSCSV MHEALHNHYT                  QKSLSLSPGK                       290

                                            Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
                                            2-13 2'-13' 43-54 43'-54' 69-69' 72-72' 104-164 104'-164' 210-268 210'-268'



 burlulipasum #
 burlulipase                                lipase (triacylglycerol lipase, EC-3.1.1.3) which amino acids
                                            sequence is common to Burkholderia plantarii and Burkholderia
                                            glumae

 burlulipase                                lipase (triacylglycérol lipase, EC-3.1.1.3) dont la séquence d'acides
                                            aminés est commune à Burkholderia plantarii et Burkholderia
                                            glumae

 burlulipasa                                lipasa (triacilglicerol lipasa, EC-3.1.1.3) cuya secuencia de
                                            aminoácidos es comune a Burkholderia plantarii y Burkholderia
                                            glumae

                                            ADTYAATRYP       VILVHGLAGT        DKFANVVDYW         YGIQSDLQSH        GAKVYVANLS        50
                                            GFQSDDGPNG       RGEQLLAYVK        QVLAATGATK         VNLIGHSQGG        LTSRYVAAVA        100
                                            PQLVASVTTI       GTPHRGSEFA        DFVQDVLKTD         PTGLSSTVIA        AFVNVFGTLV        150
                                            SSSHNTDQDA       LAALRTLTTA        QTATYNRNFP         SAGLGAPGSC        QTGAATETVG        200
                                            GSQHLLYSWG       GTAIQPTSTV        LGVTGATDTS         TGTLDVANVT        DPSTLALLAT        250
                                            GAVMINRASG       QNDGLVSRCS        SLFGQVISTS         YHWNHLDEIN        QLLGVRGANA        300
                                            EDPVAVIRTH       VNRLKLQGV                                                                319

                                            Disulfide bridge location / Position du pont disulfure / Posición del puente disulfuro
                                            190-269



 cebranopadolum
 cebranopadol                               trans-6'-fluoro-N,N-dimethyl-4-phenyl-4',9'-dihydro-
                                            3'H-spiro[cyclohexane-1,1'-pyrano[3,4-b]indol]-4-amine

 cébranopadol                               trans-6'-fluoro-N,N-diméthyl-4-phényl-4',9'-dihydro-
                                            3'H-spiro[cyclohexane-1,1'-pyrano[3,4-b]indol]-4-amine

 cebranopadol                               trans-4-fenil-6'-fluoro-N,N-dimetil-4',9'-dihidro-
                                            3'H-espiro[ciclohexano-1,1'-pirano[3,4-b]indol]-4-amina




                                                                                                                                       49
Recommended INN: List 69                                    WHO Drug Information Vol. 27, No. 1, 2013




                           C24H27FN2O

                                       CH3
                                       N
                                 H3C

                                  H
                                  N
                                             O




                           F

 cindunistatum
 cindunistat               S-[2-(acetimidoylamino)ethyl]-2-methyl-L-cysteine

 cindunistat               S-[2-(acétimidoylamino)éthyl]-2-méthyl-L-cystéine

 cindunistat               S-[2-(acetimidoilamino)etil]-2-metil-L-cisteina

                           C8H17N3O2S

                                 NH                  H 3C   NH2
                                                 S
                           H3C         N                    CO2H
                                       H

 clazakizumabum #
 clazakizumab              immunoglobulin G1-kappa, anti-[Homo sapiens IL6 (interleukin 6,
                           IL-6)], humanized monoclonal antibody;
                           gamma1 heavy chain (1-450) [humanized VH (Homo sapiens
                           IGHV3-66*01 (83.50%) -(IGHD)-IGHJ3*02 M123>L (115)) [8.8.14]
                           (1-120) -Homo sapiens IGHG1*03 CH2 N84.4>A (300) (121-450)],
                           (223-217')-disulfide with kappa light chain (1'-217') [humanized
                           V-KAPPA (Homo sapiens IGKV1-39*01 (89.10%) -IGKJ4*01)
                           [6.3.12] (1'-110') -Homo sapiens IGKC*01 (111'-217')]; (229-
                           229":232-232")-bisdisulfide dimer

 clazakizumab              immunoglobuline G1-kappa, anti-[Homo sapiens IL6 (interleukine 6,
                           IL-6)], anticorps monoclonal humanisé;
                           chaîne lourde gamma1 (1-450) [VH humanisé (Homo sapiens
                           IGHV3-66*01 (83.50%) -(IGHD)-IGHJ3*02 M123>L (115)) [8.8.14]
                           (1-120) -Homo sapiens IGHG1*03 CH2 N84.4>A (300) (121-450)],
                           (223-217')-disulfure avec la chaîne légère kappa (1'-217') [V-KAPPA
                           humanisé (Homo sapiens IGKV1-39*01 (89.10%) -IGKJ4*01)
                           [6.3.12] (1'-110') -Homo sapiens IGKC*01 (111'-217')]; dimère (229-
                           229":232-232")-bisdisulfure

 clazakizumab              inmunoglobulina G1-kappa, anti-[IL6 de Homo sapiens (interleukina
                           6, IL-6)], anticuerpo monoclonal humanizado;
                           cadena pesada gamma1 (1-450) [VH humanizado (Homo sapiens
                           IGHV3-66*01 (83.50%) -(IGHD)-IGHJ3*02 M123>L (115)) [8.8.14]
                           (1-120) -Homo sapiens IGHG1*03 CH2 N84.4>A (300) (121-450)],
                           (223-217')-disulfuro con la cadena ligera kappa (1'-217') [V-KAPPA
                           humanizado (Homo sapiens IGKV1-39*01 (89.10%) -IGKJ4*01)
                           [6.3.12] (1'-110') -Homo sapiens IGKC*01 (111'-217')]; dímero (229-
                           229":232-232")-bisdisulfuro




50
WHO Drug Information Vol. 27, No. 1, 2013                                                            Recommended INN: List 69


                                            Heavy chain / Chaîne lourde / Cadena pesada
                                            EVQLVESGGG LVQPGGSLRL SCAASGFSLS                  NYYVTWVRQA       PGKGLEWVGI       50
                                            IYGSDETAYA TSAIGRFTIS RDNSKNTLYL                  QMNSLRAEDT       AVYYCARDDS      100
                                            SDWDAKFNLW GQGTLVTVSS ASTKGPSVFP                  LAPSSKSTSG       GTAALGCLVK      150
                                            DYFPEPVTVS WNSGALTSGV HTFPAVLQSS                  GLYSLSSVVT       VPSSSLGTQT      200
                                            YICNVNHKPS NTKVDKRVEP KSCDKTHTCP                  PCPAPELLGG       PSVFLFPPKP      250
                                            KDTLMISRTP EVTCVVVDVS HEDPEVKFNW                  YVDGVEVHNA       KTKPREEQYA      300
                                            STYRVVSVLT VLHQDWLNGK EYKCKVSNKA                  LPAPIEKTIS       KAKGQPREPQ      350
                                            VYTLPPSREE MTKNQVSLTC LVKGFYPSDI                  AVEWESNGQP       ENNYKTTPPV      400
                                            LDSDGSFFLY SKLTVDKSRW QQGNVFSCSV                  MHEALHNHYT       QKSLSLSPGK      450

                                            Light chain / Chaîne légère / Cadena ligera
                                            AIQMTQSPSS LSASVGDRVT ITCQASQSIN                  NELSWYQQKP       GKAPKLLIYR 50
                                            ASTLASGVPS RFSGSGSGTD FTLTISSLQP                  DDFATYYCQQ       GYSLRNIDNA 100
                                            FGGGTKVEIK RTVAAPSVFI FPPSDEQLKS                  GTASVVCLLN       NFYPREAKVQ 150
                                            WKVDNALQSG NSQESVTEQD SKDSTYSLSS                  TLTLSKADYE       KHKVYACEVT 200
                                            HQGLSSPVTK SFNRGEC                                                            217

                                            Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
                                            Intra-H 22-95       147-203 264-324         370-428
                                                     22''-95'' 147''-203'' 264''-324'' 370''-428''
                                            Intra-L 23'-88'      137'-197'
                                                     23'''-88''' 137'''-197'''
                                            Inter-H-L 223-217' 223''-217'''
                                            Inter-H-H 229-229'' 232-232''

                                            N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación
                                            None : H CH2 N84.4>A



 cobimetinibum
 cobimetinib                                [3,4-difluoro-2-(2-fluoro-4-iodoanilino)phenyl]{3-hydroxy-
                                            3-[(2S)-piperidin-2-yl]azetidin-1-yl}methanone

 cobimétinib                                [3,4-difluoro-2-(2-fluoro-4-iodoanilino)phényl]{3-hydroxy-
                                            3-[(2S)-pipéridin-2-yl]azétidin-1-yl}méthanone

 cobimetinib                                [3,4-difluoro-2-(2-fluoro-4-iodoanilino)fenil]{3-hidroxi-
                                            3-[(2S)-piperidin-2-il]azetidin-1-il}metanona

                                            C21H21F3IN3O2
                                                                   F
                                            I              F


                                                           N
                                                           H
                                                   F
                                                               O       N
                                                                                    N
                                                                                  H H
                                                                             OH

 crisantaspasum #
 crisantaspase                              L-asparaginase (EC 3.5.1.1, L-asparagine amidohydrolase) Erwinia
                                            chrysanthemi tetramer α4

 crisantaspase                              L-asparaginase  (EC 3.5.1.1, L-asparagine amidohydrolase) Erwinia
                                            chrysanthemi, tétramère α4

 crisantaspasa                              L-asparaginasa (EC 3.5.1.1, L-asparagina amidohidrolasa) de
                                            Erwinia chrysanthemi, tetrámero α4

                                            C1546H2510N432O476S9 (monomer)
                                            Monomer / Monomère / Monómero
                                            ADKLPNIVIL ATGGTIAGSA ATGTQTTGYK                      AGALGVDTLI        AVPEVKKLA         50
                                            NVKGEQFSNM ASENMTGDVV LKLSQRVNEL                      LARDDVDGVV        ITHGTDTVEE        100
                                            SAYFLHLTVK SDKPVVFVAA MRPATAISAD                      GPMNLLEAVR        VAGDKQSRGR        150
                                            GVMVVLNDRI GSARYITKTN ASTLDTFKAN                      EEGYLGVIIG        NRIYYQNRID        200
                                            KLHTTRSVFD VRGLTSLPKV DILYGYQDDP                      EYLYDAAIQH        GVKGIVYAGM        250
                                            GAGSVSVRGI AGMRKAMEKG VVVIRSTRTG                      NGIVPPDEEL        PGLVSDSLNP        300
                                            AHARILLMLA LTRTSDPKVI QEYFHTY                                                             327



                                                                                                                                         51
Recommended INN: List 69                                    WHO Drug Information Vol. 27, No. 1, 2013




 dactolisibum
 dactolisib                2-methyl-2-(4-{3-methyl-2-oxo-8-(quinolin-3-yl)-
                           2,3-dihydroimidazo[4,5-c]quinolin-1-yl}phenyl)propanenitrile

 dactolisib                2-méthyl-2-{4-[3-méthyl-2-oxo-8-(quinoléin-3-yl)-
                           2,3-dihydroimidazo[4,5-c]quinoléin-1-yl]phényl}propanenitrile

 dactolisib                2-metil-2-(4-{3-metil-2-oxo-8-(quinolin-3-il)-2,3-dihidroimidazo[4,5-
                           c]quinolin-1-il}fenil)propanonitrilo

                           C30H23N5O

                                               CN
                                     H3C
                                        H 3C

                                                               O
                                    N
                                                        N
                                                               N CH
                                                                   3



                                                        N



 danirixinum
 danirixin                 1-(4-chloro-2-hydroxy-3-{[(3S)-piperidine-3-sulfonyl]phenyl}-
                           3-(3-fluoro-2-methylphenyl)urea

 danirixine                1-(4-chloro-2-hydroxy-3-{[(3S)-pipéridine-3-sulfonyl]phényl}-
                           3-(3-fluoro-2-méthylphényl)urée

 danirixina                1-(4-cloro-2-hidroxi-3-{[(3S)-piperidina-3-sulfonil]fenil}-3-(3-fluoro-
                           2-metilfenil)urea

                           C19H21ClFN3O4S

                                                                   F
                                    Cl                   H 3C
                           HN                           O
                                     H
                                    S               N         N
                                                    H         H
                                   O O         OH



 demcizumabum #
 demcizumab                immunoglobulin G2-kappa, anti-[Homo sapiens DLL4 (delta-like 4)],
                           humanized monoclonal antibody;
                           gamma2 heavy chain (1-444) [humanized VH (Homo sapiens
                           IGHV1-18*01 (85.70%) -(IGHD)-IGHJ6*01 T123>L (114) [8.8.12] (1-
                           119) -Homo sapiens IGHG2*01 CHS K2>del (120-444)], (133-218')-
                           disulfide with kappa light chain (1'-218') [humanized V-KAPPA
                           (Homo sapiens IGKV4-1*01 (76.20%) -IGKJ1*01 Q120>G (104))
                           [10.3.9] (1'-111') -Homo sapiens IGKC*01 (112'-218')]; (221-
                           221":222-222":225-225":228-228")-tetrakisdisulfide dimer




52
WHO Drug Information Vol. 27, No. 1, 2013                                                           Recommended INN: List 69


 demcizumab                                 immunoglobuline G2-kappa, anti-[Homo sapiens DLL4 (delta-like 4)],
                                            anticorps monoclonal humanisé;
                                            chaîne lourde gamma2 (1-444) [VH humanisé (Homo sapiens
                                            IGHV1-18*01 (85.70%) -(IGHD)-IGHJ6*01 T123>L (114) [8.8.12] (1-
                                            119) -Homo sapiens IGHG2*01 CHS K2>del (120-444)], (133-218')-
                                            disulfure avec la chaîne légère kappa (1'-218') [V-KAPPA humanisé
                                            (Homo sapiens IGKV4-1*01 (76.20%) -IGKJ1*01 Q120>G (104))
                                            [10.3.9] (1'-111') -Homo sapiens IGKC*01 (112'-218')]; dimère (221-
                                            221":222-222":225-225":228-228")-tétrakisdisulfure

 demcizumab                                 inmunoglobulina G2-kappa, anti-[DLL4 (delta-like 4) de Homo
                                            sapiens ], anticuerpo monoclonal humanizado;
                                            cadena pesada gamma2 (1-444) [VH humanizado (Homo sapiens
                                            IGHV1-18*01 (85.70%) -(IGHD)-IGHJ6*01 T123>L (114) [8.8.12] (1-
                                            119) -Homo sapiens IGHG2*01 CHS K2>del (120-444)], (133-218')-
                                            disulfuro con la cadena ligera kappa (1'-218') [V-KAPPA humanizado
                                            (Homo sapiens IGKV4-1*01 (76.20%) -IGKJ1*01 Q120>G (104))
                                            [10.3.9] (1'-111') -Homo sapiens IGKC*01 (112'-218')]; dímero (221-
                                            221":222-222":225-225":228-228")-tetrakisdisulfuro

                                            Heavy chain / Chaîne lourde / Cadena pesada
                                            QVQLVQSGAE VKKPGASVKI SCKASGYSFT                   AYYIHWVKQA      PGQGLEWIGY       50
                                            ISSYNGATNY NQKFKGRVTF TTDTSTSTAY                   MELRSLRSDD      TAVYYCARDY      100
                                            DYDVGMDYWG QGTLVTVSSA STKGPSVFPL                   APCSRSTSES      TAALGCLVKD      150
                                            YFPEPVTVSW NSGALTSGVH TFPAVLQSSG                   LYSLSSVVTV      PSSNFGTQTY      200
                                            TCNVDHKPSN TKVDKTVERK CCVECPPCPA                   PPVAGPSVFL      FPPKPKDTLM      250
                                            ISRTPEVTCV VVDVSHEDPE VQFNWYVDGV                   EVHNAKTKPR      EEQFNSTFRV      300
                                            VSVLTVVHQD WLNGKEYKCK VSNKGLPAPI                   EKTISKTKGQ      PREPQVYTLP      350
                                            PSREEMTKNQ VSLTCLVKGF YPSDIAVEWE                   SNGQPENNYK      TTPPMLDSDG      400
                                            SFFLYSKLTV DKSRWQQGNV FSCSVMHEAL                   HNHYTQKSLS      LSPG            444

                                            Light chain / Chaîne légère / Cadena ligera
                                            DIVMTQSPDS LAVSLGERAT ISCRASESVD                   NYGISFMKWF      QQKPGQPPKL 50
                                            LIYAASNQGS GVPDRFSGSG SGTDFTLTIS                   SLQAEDVAVY      YCQQSKEVPW 100
                                            TFGGGTKVEI KRTVAAPSVF IFPPSDEQLK                   SGTASVVCLL      NNFYPREAKV 150
                                            QWKVDNALQS GNSQESVTEQ DSKDSTYSLS                   STLTLSKADY      EKHKVYACEV 200
                                            THQGLSSPVT KSFNRGEC                                                           218

                                            Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
                                            Intra-H 22-96 146-202              259-319  365-423
                                                     22''-96'' 146''-202'' 259''-319'' 365''-423''
                                            Intra-L 23'-92' 138'-198'
                                                     23'''-92''' 138'''-198'''
                                            Inter-H-L 133-218' 133''-218'''
                                            Inter-H-H 221-221'' 222-222'' 225-225'' 228-228''

                                            N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación
                                            H CH2 N84.4:
                                            295, 295''



 elbimilastum
 elbimilast                                 N-(3,5-dichloropyridin-4-yl)-2-{1-[(4-fluorophenyl)methyl]-
                                            1H-pyrrolo[2,3-b]pyridin-3-yl}-2-oxoacetamide

 elbimilast                                 N-(3,5-dichloropyridin-4-yl)-2-{1-[(4-fluorophényl)méthyl]-
                                            1H-pyrrolo[2,3-b]pyridin-3-yl}-2-oxoacétamide

 elbimilast                                 N-(3,5-dicloropiridin-4-il)-2-{1-[(4-fluorofenil)metil]-1H-pirrolo[2,3-
                                            b]piridin-3-il}-2-oxoacetamida

                                            C21H13Cl2FN4O2
                                                                      O               Cl
                                                                               H
                                                                               N
                                                           N
                                                                          O                N
                                                                              Cl
                                                            N

                                            F


                                                                                                                                        53
Recommended INN: List 69                                     WHO Drug Information Vol. 27, No. 1, 2013




 elubrixinum
 elubrixin                 1-(2-chloro-3-fluorophenyl)-3-[4-chloro-2-hydroxy-3-(piperazine-
                           1-sulfonyl)phenyl]urea

 élubrixine                1-(2-chloro-3-fluorophényl)-3-[4-chloro-2-hydroxy-3-(pipérazine-
                           1-sulfonyl)phényl]urée

 elubrixina                1-(2-cloro-3-fluorofenil)-3-[4-cloro-2-hidroxi-3-(piperazina-
                           1-sulfonil)fenil]urea

                           C17H17Cl2FN4O4S
                                                                          F
                                         Cl                      Cl
                           HN                                O
                                     N
                                       S                 N        N
                                                         H        H
                                      O O         OH


 empegfilgrastimum #
 empegfilgrastim           [1-(N-{4-[ω-methoxypoly(oxyethylene)]butyl}-L-methionine)]human
                           granulocyte colony-stimulating factor (pluripoietin)

 empegfilgrastim           [1-(N-{4-[ω-méthoxypoly(oxyéthylène)]butyl}-L-méthionine)]facteur
                           de stimulation des colonies de granulocytes humain (pluripoïétine)

 empegfilgrastim           [1-(N-{4-[ω-metoxipoli(oxietileno)]butil}-L-metionina)]factor humano
                           de estimulación de las colonias de granulocitos (pluripoyetina)


                           MTPLGPASSL         PQSFLLKCLE     QVRKIQGDGA ALQEKLCATY KLCHPEELVL 50
                           LGHSLGIPWA         PLSSCPSQAL     QLAGCLSQLH SGLFLYQGLL QALEGISPEL 100
                           GPTLDTLQLD         VADFATTIWQ     QMEELGMAPA LQPTQGAMPA FASAFQRRAG 150
                           GVLVASHLQS         FLEVSYRVLR     HLAQP                            175

                           Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
                           37-43 65-75

                           Modified residue / Résidu modifié / Resto modificado
                           M                                                                    S    CH3
                           1
                           PEG-Met                                              H
                                          H3C                O
                                                  O                                 N      CO2H
                                                                      n             H




 enobosarmum
 enobosarm                 (2S)-3-(4-cyanophenoxy)-N-[4-cyano-3-(trifluoromethyl)phenyl]-
                           2-hydroxy-2-methylpropanamide

 énobosarm                 (2S)-3-(4-cyanophénoxy)-N-[4-cyano-3-(trifluorométhyl)phényl]-
                           2-hydroxy-2-méthylpropanamide

 enobosarm                 (2S)-3-(4-cianofenoxi)-N-[4-ciano-3-(trifluorometil)fenil]-2-hidroxi-
                           2-metilpropanamida

                           C19H14F3N3O3

                                                  HO CH3
                                                             H
                                              O              N                CF3

                                                         O
                           NC                                                 CN


54
WHO Drug Information Vol. 27, No. 1, 2013                                                           Recommended INN: List 69




 enoticumabum #
 enoticumab                                 immunoglobulin G1-kappa, anti-[Homo sapiens DLL4 (delta-like 4)],
                                            Homo sapiens monoclonal antibody;
                                            gamma1 heavy chain (1-452) [Homo sapiens VH (IGHV3-33*01
                                            (90.80%) -(IGHD)-IGHJ5*02) [8.8.16] (1-123) -IGHG1*01 CHS
                                            K2>del (124-452)], (226-214')-disulfide with kappa light chain (1'-
                                            214') [Homo sapiens V-KAPPA (IGKV3-11*01 (98.90%) -IGKJ4*01)
                                            [6.3.9] (1'-107') -IGKC*01 (108'-214')]; (232-232'':235-235'')-
                                            bisdisulfide dimer

 énoticumab                                 immunoglobuline G1-kappa, anti-[Homo sapiens DLL4 (delta-like 4)],
                                            Homo sapiens anticorps monoclonal;
                                            chaîne lourde gamma1 (1-452) [Homo sapiens VH (IGHV3-33*01
                                            (90.80%) -(IGHD)-IGHJ5*02) [8.8.16] (1-123) -IGHG1*01 CHS
                                            K2>del (124-452)], (226-214')-disulfure avec la chaîne légère kappa
                                            (1'-214') [Homo sapiens V-KAPPA (IGKV3-11*01 (98.90%) -
                                            IGKJ4*01) [6.3.9] (1'-107') -IGKC*01 (108'-214')]; dimère (232-
                                            232'':235-235'')-bisdisulfure

 enoticumab                                 inmunoglobulina G1-kappa, anti-[Homo sapiens DLL4 (delta-like 4)],
                                            anticuerpo monoclonal de Homo sapiens;
                                            cadena pesada gamma1 (1-452) [Homo sapiens VH (IGHV3-33*01
                                            (90.80%) -(IGHD)-IGHJ5*02) [8.8.16] (1-123) -IGHG1*01 CHS
                                            K2>del (124-452)], (226-214')-disulfuro con la cadena ligera kappa
                                            (1'-214') [Homo sapiens V-KAPPA (IGKV3-11*01 (98.90%) -
                                            IGKJ4*01) [6.3.9] (1'-107') -IGKC*01 (108'-214')]; dímero (232-
                                            232'':235-235'')-bisdisulfuro


                                            Heavy chain / Chaîne lourde / Cadena pesada
                                            QVQLVESGGG VVQPGRSLRL SCAASGFTFS                  SYGMHWVRQA       PGKGLEWVSF       50
                                            LWYDGTNKNY VESVKGRFTI SRDNSKNMLY                  LEMNSLRAED       TAVYYCARDH      100
                                            DFRSGYEGWF DPWGQGTLVT VSSASTKGPS                  VFPLAPSSKS       TSGGTAALGC      150
                                            LVKDYFPEPV TVSWNSGALT SGVHTFPAVL                  QSSGLYSLSS       VVTVPSSSLG      200
                                            TQTYICNVNH KPSNTKVDKK VEPKSCDKTH                  TCPPCPAPEL       LGGPSVFLFP      250
                                            PKPKDTLMIS RTPEVTCVVV DVSHEDPEVK                  FNWYVDGVEV       HNAKTKPREE      300
                                            QYNSTYRVVS VLTVLHQDWL NGKEYKCKVS                  NKALPAPIEK       TISKAKGQPR      350
                                            EPQVYTLPPS RDELTKNQVS LTCLVKGFYP                  SDIAVEWESN       GQPENNYKTT      400
                                            PPVLDSDGSF FLYSKLTVDK SRWQQGNVFS                  CSVMHEALHN       HYTQKSLSLS      450
                                            PG                                                                                 452

                                            Light chain / Chaîne légère / Cadena ligera
                                            EIVLTQSPAT LSLSPGERAT LSCRASQSVS                  SYLAWYQQKP       GQAPRLLIYD 50
                                            ASNRATGIPA RFSGSGSGTD FTLTISSLEP                  EDFAVYYCQH       RSNWPPTFGG 100
                                            GTKVEIKRTV AAPSVFIFPP SDEQLKSGTA                  SVVCLLNNFY       PREAKVQWKV 150
                                            DNALQSGNSQ ESVTEQDSKD STYSLSSTLT                  LSKADYEKHK       VYACEVTHQG 200
                                            LSSPVTKSFN RGEC                                                               214

                                            Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
                                            Intra-H 22-96 150-206              267-327  373-431
                                                     22''-96'' 150''-206'' 267''-327'' 373''-431''
                                            Intra-L 23'-88'      134'-194'
                                                     23'''-88''' 134'''-194'''
                                            Inter-H-L 226-214' 226''-214'''
                                            Inter-H-H 232-232'' 235-235''

                                            N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación
                                            H CH2 N84.4:
                                            303, 303''



 ensereptidum
 ensereptide                                acetyl(human lactotransferrin-(15-39)-peptidamide)

 enséreptide                                acétyl(lactotransferrine humaine-(15-39)-peptidamide)

 ensereptida                                acetil(lactotransferrina humana-(15-39)-peptidamida)




                                                                                                                                         55
Recommended INN: List 69                                            WHO Drug Information Vol. 27, No. 1, 2013




                           EATKCFQWQR NMRKVRGPPV SCIKR                               25

                           Disulfide bridge location / Position du pont disulfure / Posición del puente disulfuro
                           5 - 22

                           Modified residues / Résidus modifiés / Restos modificados                     NH
                                                                   CO2H                           HN
                               E                                               R
                                                O              H               25                        NH2
                               1
                             Ac-Glu                                         Arg-NH2           H
                                          H3C         N
                                                      H                                            NH2
                                                               O                          N
                                                                                          H
                                                                                              O



 enzalutamidum
 enzalutamide              4-{3-[4-cyano-3-(trifluoromethyl)phenyl]-5,5-dimethyl-4-oxo-
                           2-sulfanylideneimidazolidin-1-yl}-2-fluoro-N-methylbenzamide

 enzalutamide              4-{3-[4-cyano-3-(trifluorométhyl)phényl]-5,5-diméthyl-4-oxo-
                           2-sulfanylidèneimidazolidin-1-yl}-2-fluoro-N-méthylbenzamide

 enzalutamida              4-{3-[4-ciano-3-(trifluorometil)fenil]-5,5-dimetil-4-oxo-
                           2-sulfanilidenoimidazolidin-1-il}-2-fluoro-N-metilbenzamida

                           C21H16F4N4O2S

                                      O         F                         CF3
                           H3C                                                  CN
                                  N                            S
                                  H
                                                           N        N

                                                    H 3C
                                                           CH3 O

 ertugliflozinum
 ertugliflozin             (1S,2S,3S,4R,5S)-5-{4-chloro-3-[(4-ethoxyphenyl)methyl]phenyl}-
                           1-(hydroxymethyl)-6,8-dioxabicyclo[3.2.1]octane-2,3,4-triol

 ertugliflozine            (1S,2S,3S,4R,5S)-5-{4-chloro-3-[(4-éthoxyphényl)méthyl]phényl}-
                           1-(hydroxyméthyl)-6,8-dioxabicyclo[3.2.1]octane-2,3,4-triol

 ertugliflozina            (1S,2S,3S,4R,5S)-5-{4-cloro-3-[(4-etoxifenil)metil]fenil}-
                           1-(hidroximetil)-6,8-dioxabiciclo[3.2.1]octane-2,3,4-triol

                           C22H25ClO7

                                      O         CH3




                                                Cl

                             HO

                                          O
                                 OH
                           HO                   O
                                      OH




56
WHO Drug Information Vol. 27, No. 1, 2013                                                                 Recommended INN: List 69


 etirinotecanum pegolum
 etirinotecan pegol                         tetrakis{(4S)-9-([1,4'-bipiperidine]-1'-carbonyloxy)-4,11-diethyl-
                                            3,14-dioxo-3,4,12,14-tetrahydro-1H-pyrano[3',4':6,7]indolizino[1,2-
                                            b]quinolin-4-yl} N,N′,N′′,N′′′-
                                            {methanetetrayltetrakis[methylenepoly(oxyethylene)oxy(1-
                                            oxoethylene)]}tetraglycinate

 étirinotécan pégol                         N,N',N'',N'''-
                                            {méthanetétrayltétrakis[méthylènepoly(oxyéthylène)oxy(1-
                                            oxoéthylène)]}tétraglycinate de tétrakis{(4S)-9-([1,4'-bipipéridine]-
                                            1'-carbonyloxy]-4,11-diéthyl-3,14-dioxo-3,4,12,14-tétrahydro-
                                            1H-pyrano[3',4':6,7]indolizino[1,2-b]quinoléin-4-yle}

 etirinotecán pegol                         N,N',N'',N'''-{metanotetrailtetrakis[metilenepoli(oxietilene)oxi(1-
                                            oxoetileno)]}tetraglicinato de tetrakis{(4S)-9-([1,4'-bipiperidina]-
                                            1'-carboniloxi]-4,11-dietil-3,14-dioxo-3,4,12,14-tetrahidro-
                                            1H-pirano[3',4':6,7]indolizino[1,2-b]quinolin-4-ilo}

                                            C153H176N20O36 [C8H16O4]n



                                                         N
                                                                           O
                                                             CH3
                                                                       N            O
                                                N
                                                                                         O
                                            O
                                                                   N           O        CH3
                                                 O
                                                                                              O
                                                                               O       HN
                                                                                                      O    =   R


                                                             R         O           O              R
                                                                           n                  n


                                                             R         O   n
                                                                                   O          n
                                                                                                  R


 evogliptinum
 evogliptin                                 (3R)-4-[(3R)-3-amino-4-(2,4,5-trifluorophenyl)butanoyl]-
                                            3-(tert-butoxymethyl)piperazin-2-one

 évogliptine                                (3R)-4-[(3R)-3-amino-4-(2,4,5-trifluorophényl)butanoyl]-
                                            3-(tert-butoxyméthyl)pipérazin-2-one

 evogliptina                                (3R)-4-[(3R)-3-amino-4-(2,4,5-trifluorofenil)butanoil]-
                                            3-(terc-butoximetil)piperazin-2-ona

                                            C19H26F3N3O3

                                                                       H
                                                                       N       O
                                                     F
                                            F                                      O          CH3
                                                              H    NH2 N
                                                                           H
                                                                                   H3C CH3
                                                                           O
                                                     F

 fasiglifamum
 fasiglifam                                 [(3S)-6-({(2',6'-dimethyl-4'-[3-(methanesulfonyl)propoxy]-
                                            [1,1'-biphenyl]-3-yl)}methoxy)-2,3-dihydro-1-benzofuran-3-yl]acetic
                                            acid




                                                                                                                                57
Recommended INN: List 69                                        WHO Drug Information Vol. 27, No. 1, 2013




 fasiglifam                acide [(3S)-6-({(2',6'-diméthyl-4'-[3-(méthanesulfonyl)propoxy]-
                           [1,1'-biphényl]-3-yl)}méthoxy)-2,3-dihydro-1-benzofuran-3-yl]acétique

 fasiglifam                ácido [(3S)-6-({(2',6'-dimetil-4'-[3-(metanosulfonil)propoxi]-
                           [1,1'-bifenil]-3-il)}metoxi)-2,3-dihidro-1-benzofuran-3-il]acético

                           C29H32O7S
                                O O                                                             O
                                  S                 O                CH3                                        CO2H
                           H3C                                                                             H

                                                                                      O
                                                            CH3


 fasinumabum #
 fasinumab                 immunoglobulin G4-kappa, anti-[Homo sapiens NGF (nerve growth
                           factor, nerve growth factor beta polypeptide, NGFB, beta-NGF)], Homo
                           sapiens monoclonal antibody;
                           gamma4 heavy chain (1-446) [Homo sapiens VH (IGHV1-24*01 (95.90%)
                           -(IGHD)-IGHJ5*01) [8.8.12] (1-119) -IGHG4*01 hinge S10>P (227) (120-
                           446)], (133-214')-disulfide with kappa light chain (1'-214') [Homo sapiens
                           V-KAPPA (IGKV1-17*01 (90.50%) -IGKJ1*01) [6.3.9] (1'-107') -IGKC*01
                           (108'-214')]; (225-225'':228-228'')-bisdisulfide dimer

 fasinumab                 immunoglobuline G4-kappa, anti-[Homo sapiens NGF (facteur de
                           croissance du nerf, facteur de croissance du nerf polypeptide bêta,
                           NGFB, bêta-NGF)], Homo sapiens anticorps monoclonal;
                           chaîne lourde gamma4 (1-446) [Homo sapiens VH (IGHV1-24*01
                           (95.90%) -(IGHD)-IGHJ5*01) [8.8.12] (1-119) -IGHG4*01 charnière
                           S10>P (227) (120-446)], (133-214')-disulfure avec la chaîne légère kappa
                           (1'-214') [Homo sapiens V-KAPPA (IGKV1-17*01 (90.50%) -IGKJ1*01)
                           [6.3.9] (1'-107') -IGKC*01 (108'-214')]; dimère (225-225'':228-228'')-
                           bisdisulfure

 fasinumab                 inmunoglobulina G4-kappa, anti-[NGF de Homo sapiens (factor de
                           crecimiento neuronal, factor de crecimiento neuronal polipéptido beta,
                           NGFB, beta-NGF)], anticuerpo monoclonal de Homo sapiens;
                           cadena pesada gamma4 (1-446) [Homo sapiens VH (IGHV1-24*01
                           (95.90%) -(IGHD)-IGHJ5*01) [8.8.12] (1-119) -IGHG4*01 bisagra S10>P
                           (227) (120-446)], (133-214')-disulfuro con la cadena ligera kappa (1'-214')
                           [Homo sapiens V-KAPPA (IGKV1-17*01 (90.50%) -IGKJ1*01) [6.3.9] (1'-
                           107') -IGKC*01 (108'-214')]; dímero (225-225'':228-228'')-bisdisulfuro

                           Heavy chain / Chaîne lourde / Cadena pesada
                           QVQLVQSGAE VKKPGASVKV SCKVSGFTLT                  ELSIHWVRQA       PGKGLEWMGG        50
                           FDPEDGETIY AQKFQGRVTM TEDTSTDTAY                  MELTSLRSED       TAVYYCSTIF       100
                           GVVTNFDNWG QGTLVTVSSA STKGPSVFPL                  APCSRSTSES       TAALGCLVKD       150
                           YFPEPVTVSW NSGALTSGVH TFPAVLQSSG                  LYSLSSVVTV       PSSSLGTKTY       200
                           TCNVDHKPSN TKVDKRVESK YGPPCPPCPA                  PEFLGGPSVF       LFPPKPKDTL       250
                           MISRTPEVTC VVVDVSQEDP EVQFNWYVDG                  VEVHNAKTKP       REEQFNSTYR       300
                           VVSVLTVLHQ DWLNGKEYKC KVSNKGLPSS                  IEKTISKAKG       QPREPQVYTL       350
                           PPSQEEMTKN QVSLTCLVKG FYPSDIAVEW                  ESNGQPENNY       KTTPPVLDSD       400
                           GSFFLYSRLT VDKSRWQEGN VFSCSVMHEA                  LHNHYTQKSL       SLSLGK           446

                           Light chain / Chaîne légère / Cadena ligera
                           DIQMTQSPSS LSASAGDRVT ITCRASQAIR                  NDLGWYQQKP       GKAPKRLIYA 50
                           AFNLQSGVPS RFSGSGSGTE FTLTISSLQP                  EDLASYYCQQ       YNRYPWTFGQ 100
                           GTKVEIKRTV AAPSVFIFPP SDEQLKSGTA                  SVVCLLNNFY       PREAKVQWKV 150
                           DNALQSGNSQ ESVTEQDSKD STYSLSSTLT                  LSKADYEKHK       VYACEVTHQG 200
                           LSSPVTKSFN RGEC                                                               214

                           Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
                           Intra-H 22-96 146-202              260-320  366-424
                                    22''-96'' 146''-202'' 260''-320'' 366''-424''
                           Intra-L 23'-88'      134'-194'
                                    23'''-88''' 134'''-194'''
                           Inter-H-L 133-214' 133''-214'''
                           Inter-H-H 225-225'' 228-228''

                           N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación
                           H CH2 N84.4:
                           296, 296''



58
WHO Drug Information Vol. 27, No. 1, 2013                                                            Recommended INN: List 69




 firtecanum pegolum
 firtecan pegol                             tetrakis[(4S)-4,11-diethyl-9-hydroxy-3,14-dioxo-3,4,12,14-tetrahydro-
                                            1H-pyrano[3',4':6,7]indolizino[1,2-b]quinolin-4-yl] N,N',N'',N'''-
                                            (oxybis{(propane-3,1,2-triyl)bis[poly(oxyethylene)oxy(1-
                                            oxoethylene)]})tetraglycinate

 firtécan pégol                             N,N',N'',N'''-(oxybis{(propane-3,1,2-triyl)bis[poly(oxyéthylène)oxy(1-
                                            oxoéthylène)]})tétraglycinate de tétrakis[(4S)-4,11-diéthyl-9-hydroxy-
                                            3,14-dioxo-3,4,12,14-tétrahydro-1H-pyrano[3',4':6,7]indolizino[1,2-
                                            b]quinoléin-4-yle]

 firtecán pegol                             N,N',N'',N'''-(oxibis{(propano-3,1,2-triil)bis[poli(oxietileno)oxi(1-
                                            oxoetileno)]})tetraglicinato de tetrakis[(4S)-4,11-dietil-9-hidroxi-3,14-
                                            dioxo-3,4,12,14-tetrahidro-1H-pirano[3',4':6,7]indolizino[1,2-
                                            b]quinolin-4-ilo]

                                            C110H106N12O33 (C2H4O)4n

                                                                           O

                                                 H3C                   N               O

                                                                                            O
                                                              N                O           CH3
                                            HO
                                                                                                 O
                                                                               O       HN
                                                                                                     O     =       R

                                                               O                                 O
                                                 R                 n           O                           nR

                                                 R                                                             R
                                                               O                                 O
                                                                   n                                       n




 fluralanerum
 fluralaner                                 4-[5-(3,5-dichlorophenyl)-5-(trifluoromethyl)-4,5-dihydro-1,2-oxazol-
                                            3-yl]-2-methyl-N-{2-oxo-2-[(2,2,2-
                                            trifluoroethyl)amino]ethyl}benzamide

 fluralaner                                 4-[(5RS)-5-(3,5-dichlorophényl)-5-(trifluorométhyl)-4,5-dihydro-
                                            1,2-isoxazol-3-yl]-2-méthyl-N-{2-oxo-2-[(2,2,2-
                                            trifluoroéthyl)amino]éthyl}benzamide

 fluralaner                                 4-[5-(3,5-diclorofenil)-5-(trifluorometil)-4,5-dihidro-1,2-oxazol-3-il]-
                                            2-metil-N-{2-oxo-2-[(2,2,2-trifluoroetil)amino]etil}benzamida

                                            C22H17Cl2F6N3O3

                                                       F 3C   O N
                                            Cl
                                                                                                 O                 and enantiomer
                                                                                       H                           et énantiomère
                                                                                       N                           y enantiómero
                                                                                                     N   CF3
                                                     Cl                                              H
                                                                           CH3     O




                                                                                                                                    59
Recommended INN: List 69                                       WHO Drug Information Vol. 27, No. 1, 2013


 futuximabum #
 futuximab                  immunoglobulin G1-kappa, anti-[Homo sapiens EGFR (epidermal
                            growth factor receptor, ERBB1, HER1) domain III], chimeric
                            monoclonal antibody;
                            gamma1 heavy chain (1-452) [Mus musculus VH (IGHV1S5*01 -
                            (IGHD)-IGHJ4*01) [8.8.16] (1-123) -Homo sapiens IGHG1*03 CHS
                            K2>del (124-452)], (226-214')-disulfide with kappa light chain (1'-
                            214') [Mus musculus V-KAPPA (IGKV10-96*01 -IGKJ1*02) [6.3.9]
                            (1'-107') -Homo sapiens IGKC*01 (108'-214')]; (232-232'':235-235'')-
                            bisdisulfide dimer

 futuximab                  immunoglobuline G1-kappa, anti-[Homo sapiens EGFR (récepteur
                            du facteur de croissance épidermique ERBB1, HER1) domaine III],
                            anticorps monoclonal chimérique;
                            chaîne lourde gamma1 (1-452) [Mus musculus VH (IGHV1S5*01 -
                            (IGHD)-IGHJ4*01) [8.8.16] (1-123) -Homo sapiens IGHG1*03 CHS
                            K2>del (124-452)], (226-214')-disulfure avec la chaîne légère kappa
                            (1'-214') [Mus musculus V-KAPPA (IGKV10-96*01 -IGKJ1*02) [6.3.9]
                            (1'-107') -Homo sapiens IGKC*01 (108'-214')]; dimère (232-
                            232'':235-235'')-bisdisulfure

 futuximab                  inmunoglobulina G1-kappa, anti-[EGFR de Homo sapiens (receptor
                            del factor de crecimiento epidérmico ERBB1, HER1) dominio III],
                            anticuerpo monoclonal quimérico;
                            cadena pesada gamma1 (1-452) [Mus musculus VH (IGHV1S5*01 -
                            (IGHD)-IGHJ4*01) [8.8.16] (1-123) -Homo sapiens IGHG1*03 CHS
                            K2>del (124-452)], (226-214')-disulfuro con la cadena ligera kappa
                            (1'-214') [Mus musculus V-KAPPA (IGKV10-96*01 -IGKJ1*02) [6.3.9]
                            (1'-107') -Homo sapiens IGKC*01 (108'-214')]; dímero (232-
                            232'':235-235'')-bisdisulfuro


                             Heavy chain / Chaîne lourde / Cadena pesada
                             EVQLQQPGSE LVRPGASVKL SCKASGYTFT                  SYWMHWVKQR       PGQGLEWIGN       50
                             IYPGSRSTNY DEKFKSKATL TVDTSSSTAY                  MQLSSLTSED       SAVYYCTRNG      100
                             DYYVSSGDAM DYWGQGTSVT VSSASTKGPS                  VFPLAPSSKS       TSGGTAALGC      150
                             LVKDYFPEPV TVSWNSGALT SGVHTFPAVL                  QSSGLYSLSS       VVTVPSSSLG      200
                             TQTYICNVNH KPSNTKVDKR VEPKSCDKTH                  TCPPCPAPEL       LGGPSVFLFP      250
                             PKPKDTLMIS RTPEVTCVVV DVSHEDPEVK                  FNWYVDGVEV       HNAKTKPREE      300
                             QYNSTYRVVS VLTVLHQDWL NGKEYKCKVS                  NKALPAPIEK       TISKAKGQPR      350
                             EPQVYTLPPS REEMTKNQVS LTCLVKGFYP                  SDIAVEWESN       GQPENNYKTT      400
                             PPVLDSDGSF FLYSKLTVDK SRWQQGNVFS                  CSVMHEALHN       HYTQKSLSLS      450
                             PG                                                                                 452

                             Light chain / Chaîne légère / Cadena ligera
                             DIQMTQTTSS LSASLGDRVT ISCRTSQDIG                  NYLNWYQQKP       DGTVKLLIYY 50
                             TSRLHSGVPS RFSGSGSGTD FSLTINNVEQ                  EDVATYFCQH       YNTVPPTFGG 100
                             GTKLEIKRTV AAPSVFIFPP SDEQLKSGTA                  SVVCLLNNFY       PREAKVQWKV 150
                             DNALQSGNSQ ESVTEQDSKD STYSLSSTLT                  LSKADYEKHK       VYACEVTHQG 200
                             LSSPVTKSFN RGEC                                                               214

                             Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
                             Intra-H 22-96        150-206 267-327        373-431
                                       22''-96'' 150''-206'' 267''-327'' 373''-431''
                             Intra-L 23'-88' 134'-194'
                                      23'''-88''' 134'''-194'''
                             Inter-H-L 226-214' 226''-214'''
                             Inter-H-H 232-232'' 235-235''

                             N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación
                             H CH2 84.4:
                             303, 303''



giminabantum
giminabant                 3-chloro-4-{(2R)-2-(4-chlorophenyl)-
                           4-[(1R)-1-(4-cyanophenyl)ethyl]piperazin-1-yl}benzonitrile




60
WHO Drug Information Vol. 27, No. 1, 2013                                                                 Recommended INN: List 69


 giminabant                                 3-chloro-4-{(2R)-2-(4-chlorophényl)-
                                            4-[(1R)-1-(4-cyanophényl)éthyl]pipérazin-1-yl}benzonitrile

 giminabant                                 3-cloro-4-{(2R)-2-(4-clorofenil)-4-[(1R)-1-(4-cianofenil)etil]piperazin-
                                            1-il}benzonitrilo

                                            C26H22Cl2N4
                                                                                                 CN

                                            NC
                                                                            N
                                                                    N               H Cl

                                                          H CH3


                                                                                            Cl

 golvatinibum
 golvatinib                                 N-[2-fluoro-4-({2-[4-(4-methylpiperazin-1-yl)piperidine-
                                            1-carboxamido]pyridin-4-yl}oxy)phenyl]-
                                            N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide

 golvatinib                                 N-[2-fluoro-4-({2-[4-(4-méthylpipérazin-1-yl)pipéridine-
                                            1-carboxamido]pyridin-4-yl}oxy)phényl]-
                                            N'-(4-fluorophényl)cyclopropane-1,1-dicarboxamide

 golvatinib                                 N-[2-fluoro-4-({2-[4-(4-metilpiperazin-1-il)piperidina-
                                            1-carboxamido]piridin-4-il}oxi)fenil]-N'-(4-fluorofenil)ciclopropano-
                                            1,1-dicarboxamida

                                            C33H37F2N7O4

                                            H3C
                                                  N
                                                          N
                                                                                H
                                                                        N       N                 O                              F
                                                                                                                    O   O
                                                                            O           N
                                                                                                                N           N
                                                                                                                H           H
                                                                                                          F



 ibrutinibum
 ibrutinib                                  1-{(3R)-3-[4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-
                                            d]pyrimidin-1-yl]piperidin-1-yl}prop-2-en-1-one

 ibrutinib                                  1-{(3R)-3-[4-amino-3-(4-phénoxyphényl)-1H-pyrazolo[3,4-
                                            d]pyrimidin-1-yl]pipéridin-1-yl}prop-2-én-1-one

 ibrutinib                                  1-{(3R)-3-[4-amino-3-(4-fenoxifenil)-1H-pirazolo[3,4-d]pirimidin-
                                            1-il]piperidin-1-il}prop-2-en-1-ona

                                            C25H24N6O2
                                                                        N
                                                                                N
                                                              H2N
                                                                                    N            N
                                                                                                              CH2
                                                                                N       H
                                                                                                      O
                                                      O




                                                                                                                                61
Recommended INN: List 69                               WHO Drug Information Vol. 27, No. 1, 2013




 idelalisibum
 idelalisib                5-fluoro-3-phenyl-2-{(1S)-1-[(7H-purin-6-yl)amino]propyl}quinazolin-
                           4(3H)-one

 idélalisib                5-fluoro-3-phényl-2-[(1S)-1-(7H-purin-6-ylamino)propyl]quinazolin-
                           4(3H)-one

 idelalisib                5-fluoro-3-fenil-2-[(1S)-1-(7H-purin-6-ilamino)propil]quinazolin-
                           4(3H)-ona

                           C22H18FN7O

                                                  N
                                            HN
                                  H3C       H          N
                                   N
                                             N     N
                                             H
                                        N

                              F     O




 imgatuzumabum #
 imgatuzumab               immunoglobulin G1-kappa, anti-[Homo sapiens EGFR (epidermal
                           growth factor receptor, ERBB1, HER1)], humanized monoclonal
                           antibody;
                           gamma1 heavy chain (1-449) [humanized VH (Homo sapiens
                           IGHV1-46*01 (83.70%) -(IGHD)-IGHJ6*01) [8.8.13] (1-120) -Homo
                           sapiens IGHG1*01 CHS K2>del (121-449)], (223-213')-disulfide with
                           kappa light chain (1'-213') [humanized V-KAPPA (Homo sapiens
                           IGKV1-17*01 (90.50%) -IGKJ2*01) [6.3.8] (1'-106') -Homo sapiens
                           IGKC*01 (107'-213"')]; (229-229":232-232")-bisdisulfide dimer

 imgatuzumab               immunoglobuline G1-kappa, anti-[Homo sapiens EGFR (récepteur
                           du facteur de croissance épidermique ERBB1, HER1)], anticorps
                           monoclonal humanisé;
                           chaîne lourde gamma1 (1-449) [VH humanisé (Homo sapiens
                           IGHV1-46*01 (83.70%) -(IGHD)-IGHJ6*01) [8.8.13] (1-120) -Homo
                           sapiens IGHG1*01 CHS K2>del (121-449)], (223-213')-disulfure
                           avec la chaîne légère kappa (1'-213') [V-KAPPA humanisé (Homo
                           sapiens IGKV1-17*01 (90.50%) -IGKJ2*01) [6.3.8] (1'-106') -Homo
                           sapiens IGKC*01 (107'-213"')]; dimère (229-229":232-232")-
                           bisdisulfure

 imgatuzumab               inmunoglobulina G1-kappa, anti-[ EGFR de Homo sapiens (receptor
                           del factor de crecimiento epidérmico ERBB1, HER1)], anticuerpo
                           monoclonal humanizado;
                           cadena pesada gamma1 (1-449) [VH humanizado (Homo sapiens
                           IGHV1-46*01 (83.70%) -(IGHD)-IGHJ6*01) [8.8.13] (1-120) -Homo
                           sapiens IGHG1*01 CHS K2>del (121-449)], (223-213')-disulfuro con
                           la cadena ligera kappa (1'-213') [V-KAPPA humanizado (Homo
                           sapiens IGKV1-17*01 (90.50%) -IGKJ2*01) [6.3.8] (1'-106') -Homo
                           sapiens IGKC*01 (107'-213"')]; dímero (229-229":232-232")-
                           bisdisulfuro




62
WHO Drug Information Vol. 27, No. 1, 2013                                                              Recommended INN: List 69


                                              Heavy chain / Chaîne lourde / Cadena pesada
                                              QVQLVQSGAE VKKPGSSVKV SCKASGFTFT                  DYKIHWVRQA       PGQGLEWMGY       50
                                              FNPNSGYSTY AQKFQGRVTI TADKSTSTAY                  MELSSLRSED       TAVYYCARLS      100
                                              PGGYYVMDAW GQGTTVTVSS ASTKGPSVFP                  LAPSSKSTSG       GTAALGCLVK      150
                                              DYFPEPVTVS WNSGALTSGV HTFPAVLQSS                  GLYSLSSVVT       VPSSSLGTQT      200
                                              YICNVNHKPS NTKVDKKVEP KSCDKTHTCP                  PCPAPELLGG       PSVFLFPPKP      250
                                              KDTLMISRTP EVTCVVVDVS HEDPEVKFNW                  YVDGVEVHNA       KTKPREEQYN      300
                                              STYRVVSVLT VLHQDWLNGK EYKCKVSNKA                  LPAPIEKTIS       KAKGQPREPQ      350
                                              VYTLPPSRDE LTKNQVSLTC LVKGFYPSDI                  AVEWESNGQP       ENNYKTTPPV      400
                                              LDSDGSFFLY SKLTVDKSRW QQGNVFSCSV                  MHEALHNHYT       QKSLSLSPG       449

                                              Light chain / Chaîne légère / Cadena ligera
                                              DIQMTQSPSS LSASVGDRVT ITCRASQGIN                  NYLNWYQQKP       GKAPKRLIYN 50
                                              TNNLQTGVPS RFSGSGSGTE FTLTISSLQP                  EDFATYYCLQ       HNSFPTFGQG 100
                                              TKLEIKRTVA APSVFIFPPS DEQLKSGTAS                  VVCLLNNFYP       REAKVQWKVD 150
                                              NALQSGNSQE SVTEQDSKDS TYSLSSTLTL                  SKADYEKHKV       YACEVTHQGL 200
                                              SSPVTKSFNR GEC                                                                213

                                              Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
                                              Intra-H 22-96        147-203       264-324  370-428
                                                        22''-96'' 147''-203'' 264''-324'' 370''-428''
                                              Intra-L 23'-88'       133'-193'
                                                       23'''-88''' 133'''-193'''
                                              Inter-H-L 223-213' 223''-213'''
                                              Inter-H-H 229-229'' 232-232''

                                              N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación
                                              H CH2 N84.4:
                                              300, 300''



 insulinum peglisprum
 insulin peglispro                           macrogol 20000 pegylated insulin lispro:
                                                 B
                                             [28 -(6-N-{[ω-methoxypoly(oxyethylene)]carbonyl}-L-lysine),
                                                B
                                             29 -L-proline]human insulin

 insuline péglispro                          insuline lispro pégylée avec du macrogol 20000:
                                                 B
                                             [28 -(6-N-{[ω-méthoxypoly(oxyéthylène)]carbonyl}-L-lysine),
                                                B
                                             29 -L-proline]insuline humaine

 insulina peglispro                          insulina lispro pegilada con macrogol 20000:
                                                 B
                                             [28 -(6-N-{[ω-metoxipoli(oxietileno)]carbonil}-L-lisina),
                                                B
                                             29 -L-prolina]insulina humana

                                              GIVEQCCTSI           CSLYQLENYC            N
                                              FVNQHLCGSH           LVEALYLVCG            ERGFFYTKPT
                                                                                                      N6
                                                                                                                      O
                                                                                                  O        O          n
                                                                                                                          CH3


lampalizumabum #
lampalizumab                                immunoglobulin Fab G1-kappa, anti-[Homo sapiens CFD
                                            (complement factor D)], humanized monoclonal antibody;
                                            VH -(CH1-hinge) gamma1 heavy chain (1-223) [humanized VH
                                            (Homo sapiens IGHV7-4-1*02 (88.80%) -(IGHD)-IGHJ5*01) [8.8.8]
                                            (1-115) -Homo sapiens IGHG1*01 CH1 (116-213), hinge 1-10 (214-
                                            223)], (218-214')-disulfide with kappa light chain (1'-214') [humanized
                                            V-KAPPA (Homo sapiens IGKV1-33*01 (77.90%) -IGKJ2*01 L124>V
                                            (104) [6.3.9] (1'-107') -Homo sapiens IGKC*01 (108'-214')]

lampalizumab                                immunoglobuline Fab G1-kappa, anti-[Homo sapiens CFD (facteur D
                                            du complément)], anticorps monoclonal humanisé;
                                            chaîne lourde VH -(CH1-charnière) gamma1 (1-223) [VH humanisé
                                            (Homo sapiens IGHV7-4-1*02 (88.80%) -(IGHD)-IGHJ5*01) [8.8.8]
                                            (1-115) -Homo sapiens IGHG1*01 CH1 (116-213), charnière 1-10
                                            (214-223)], (218-214')-disulfure avec la chaîne légère kappa (1'-214')
                                            [V-KAPPA humanisé (Homo sapiens IGKV1-33*01 (77.90%) -
                                            IGKJ2*01 L124>V (104) [6.3.9] (1'-107') -Homo sapiens IGKC*01
                                            (108'-214')]

                                                                                                                                          63
Recommended INN: List 69                                     WHO Drug Information Vol. 27, No. 1, 2013




 lampalizumab              inmunoglobulina Fab G1-kappa, anti-[CFD (factor D del
                           complemento) de Homo sapiens], anticuerpo monoclonal
                           humanizado;
                           cadena pesada VH -(CH1-bisagra) gamma1 (1-223) [VH
                           humanizado (Homo sapiens IGHV7-4-1*02 (88.80%) -(IGHD)-
                           IGHJ5*01) [8.8.8] (1-115) -Homo sapiens IGHG1*01 CH1 (116-213),
                           bisagra 1-10 (214-223)], (218-214')-disulfuro con la cadena ligera
                           kappa (1'-214') [V-KAPPA humanizado (Homo sapiens IGKV1-33*01
                           (77.90%) -IGKJ2*01 L124>V (104) [6.3.9] (1'-107') -Homo sapiens
                           IGKC*01 (108'-214')]

                           Heavy chain / Chaîne lourde / Cadena pesada
                           EVQLVQSGPE LKKPGASVKV SCKASGYTFT                  NYGMNWVRQA       PGQGLEWMGW 50
                           INTYTGETTY ADDFKGRFVF SLDTSVSTAY                  LQISSLKAED       TAVYYCEREG 100
                           GVNNWGQGTL VTVSSASTKG PSVFPLAPSS                  KSTSGGTAAL       GCLVKDYFPE 150
                           PVTVSWNSGA LTSGVHTFPA VLQSSGLYSL                  SSVVTVPSSS       LGTQTYICNV 200
                           NHKPSNTKVD KKVEPKSCDK THT                                                     223

                           Light chain / Chaîne légère / Cadena ligera
                           DIQVTQSPSS LSASVGDRVT ITCITSTDID                  DDMNWYQQKP       GKVPKLLISG 50
                           GNTLRPGVPS RFSGSGSGTD FTLTISSLQP                  EDVATYYCLQ       SDSLPYTFGQ 100
                           GTKVEIKRTV AAPSVFIFPP SDEQLKSGTA                  SVVCLLNNFY       PREAKVQWKV 150
                           DNALQSGNSQ ESVTEQDSKD STYSLSSTLT                  LSKADYEKHK       VYACEVTHQG 200
                           LSSPVTKSFN RGEC                                                               214

                           Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
                           Intra-H 22-96 142-198
                           Intra-L 23'-88' 134'-194'
                           Inter-H-L 218-214'

                           N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación
                           None




 latanoprostenum bunodum
 latanoprostene bunod      4-(nitrooxy)butyl (5Z)-7-{(1R,2R,3R,5S)-3,5-dihydroxy-
                           2-[(3R)-3-hydroxy-5-phenylpentyl]cyclopentyl}hept-5-enoate

 latanoprostène bunod      (5Z)-7-{(1R,2R,3R,5S)-3,5-dihydroxy-2-[(3R)-3-hydroxy-
                           5-phénylpentyl]cyclopentyl}hept-5-énoate de 4-(nitrooxy)butyle

 latanoprosteno bunod      (5Z)-7-{(1R,2R,3R,5S)-3,5-dihidroxi-2-[(3R)-3-hidroxi-
                           5-fenilpentil]ciclopentil}hept-5-enoato de 4-(nitrooxi)butilo

                           C27H41NO8

                                 OH
                             H        H
                                                                      O                       NO2
                                                                                          O
                                                                  O
                           HO         H
                                 H             H OH




 latromotidum
 latromotide               human kinesin-like protein KIF20A-(66-75)-peptide

 latromotide               membre 20A des protéines de la famille des kinésines humaines-
                           (66-75)-peptide

 latromotida               miembro 20A de las proteínas de la familia de las kinesinas
                           humanas-(66-75)-péptido



64
WHO Drug Information Vol. 27, No. 1, 2013                                                          Recommended INN: List 69




                                             C60H105N17O12

                                              H Lys   Val    Tyr       Leu   Arg   Val   Arg   Pro         Leu   Leu OH




 lifitegrastum
 lifitegrast                                 (2S)-2-{2-[(1-benzofuran-6-yl)carbonyl)]-5,7-dichloro-
                                             1,2,3,4-tetrahydroisoquinolin-6-carboxamido}-
                                             3-[3-(methanesulfonyl)phenyl]propanoic acid

 lifitégrast                                 acide (2S)-2-{2-[(1-benzofuran-6-yl)carbonyl)]-5,7-dichloro-
                                             1,2,3,4-tétrahydroisoquinoléin-6-carboxamido}-
                                             3-[3-(méthanesulfonyl)phényl]propanoïque

 lifitegrast                                 ácido (2S)-2-{2-[(1-benzofuran-6-il)carbonil)]-5,7-dicloro-
                                             1,2,3,4-tetrahidroisoquinolin-6-carboxamido}-
                                             3-[3-(metanosulfonil)fenil]propanoico

                                             C29H24Cl2N2O7S
                                                                                                   O
                                                                                                           CH3
                                                                                               O       S




                                                                             Cl     O
                                                                                               H
                                                                                         N     CO2H
                                                                                         H
                                                                   N
                                               O                                    Cl
                                                             O




ligelizumabum #
ligelizumab                                 immunoglobulin G1-kappa, anti-[Homo sapiens IGHE
                                            (immunoglobulin constant epsilon (IGHE) region of the heavy chain
                                            of IgE) CH3 1.3-9 (12 AA), 108-121 (12 AA) epitope], humanized
                                            monoclonal antibody;
                                            gamma1 heavy chain (1-453) [humanized VH (Homo sapiens
                                            IGHV1-69*11 (80.60%) -(IGHD)-IGHJ4*01) [8.8.16] (1-123) -Homo
                                            sapiens IGHG1*01 (124-453)], (226-214')-disulfide with kappa light
                                            chain (1'-214') [humanized V-KAPPA (Homo sapiens IGKV3-15*01
                                            (86.30%) -IGKJ4*01) [6.3.9] (1'-107') -Homo sapiens IGKC*01 (108'-
                                            214')]; (232-232":235-235")-bisdisulfide dimer

ligélizumab                                 immunoglobuline G1-kappa, anti-[Homo sapiens IGHE (région
                                            constante epsilon (IGHE) de la chaîne lourde des immunoglobulines
                                            IgE) épitope CH3 1.3-9 (12 AA), 108-121 (12 AA)], anticorps
                                            monoclonal humanisé;
                                            chaîne lourde gamma1 (1-453) [VH humanisé (Homo sapiens
                                            IGHV1-69*11 (80.60%) -(IGHD)-IGHJ4*01) [8.8.16] (1-123) - Homo
                                            sapiens IGHG1*01 (124-453)], (226-214')-disulfure avec la chaîne
                                            légère kappa (1'-214') [V-KAPPA humanisé (Homo sapiens IGKV3-
                                            15*01 (86.30%) -IGKJ4*01) [6.3.9] (1'-107') -Homo sapiens IGKC*01
                                            (108'-214')]; dimère (232-232":235-235")-bisdisulfure




                                                                                                                          65
Recommended INN: List 69                                     WHO Drug Information Vol. 27, No. 1, 2013


 ligelizumab               inmunoglobulina G1-kappa, anti-[ IGHE de Homo sapiens (región
                           constante epsilon (IGHE) de la cadena pesada de las
                           inmunoglobulinas IgE) epítopo CH3 1.3-9 (12 AA), 108-121 (12 AA)],
                           anticuerpo monoclonal humanizado;
                           cadena pesada gamma1 (1-453) [VH humanizada (Homo sapiens
                           IGHV1-69*11 (80.60%) -(IGHD)-IGHJ4*01) [8.8.16] (1-123) -Homo
                           sapiens IGHG1*01 (124-453)], (226-214')-disulfuro con la cadena
                           ligera kappa (1'-214') [V-KAPPA humanizado (Homo sapiens
                           IGKV3-15*01 (86.30%) -IGKJ4*01) [6.3.9] (1'-107') -Homo sapiens
                           IGKC*01 (108'-214')]; dímero (232-232":235-235")-bisdisulfuro


                           Heavy chain / Chaîne lourde / Cadena pesada
                           QVQLVQSGAE VMKPGSSVKV SCKASGYTFS                  WYWLEWVRQA       PGHGLEWMGE       50
                           IDPGTFTTNY NEKFKARVTF TADTSTSTAY                  MELSSLRSED       TAVYYCARFS      100
                           HFSGSNYDYF DYWGQGTLVT VSSASTKGPS                  VFPLAPSSKS       TSGGTAALGC      150
                           LVKDYFPEPV TVSWNSGALT SGVHTFPAVL                  QSSGLYSLSS       VVTVPSSSLG      200
                           TQTYICNVNH KPSNTKVDKK VEPKSCDKTH                  TCPPCPAPEL       LGGPSVFLFP      250
                           PKPKDTLMIS RTPEVTCVVV DVSHEDPEVK                  FNWYVDGVEV       HNAKTKPREE      300
                           QYNSTYRVVS VLTVLHQDWL NGKEYKCKVS                  NKALPAPIEK       TISKAKGQPR      350
                           EPQVYTLPPS RDELTKNQVS LTCLVKGFYP                  SDIAVEWESN       GQPENNYKTT      400
                           PPVLDSDGSF FLYSKLTVDK SRWQQGNVFS                  CSVMHEALHN       HYTQKSLSLS      450
                           PGK                                                                                453

                           Light chain / Chaîne légère / Cadena ligera
                           EIVMTQSPAT LSVSPGERAT LSCRASQSIG                  TNIHWYQQKP       GQAPRLLIYY 50
                           ASESISGIPA RFSGSGSGTE FTLTISSLQS                  EDFAVYYCQQ       SWSWPTTFGG 100
                           GTKVEIKRTV AAPSVFIFPP SDEQLKSGTA                  SVVCLLNNFY       PREAKVQWKV 150
                           DNALQSGNSQ ESVTEQDSKD STYSLSSTLT                  LSKADYEKHK       VYACEVTHQG 200
                           LSSPVTKSFN RGEC                                                               214

                           Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
                           Intra-H 22-96 150-206              267-327 373-431
                                    22''-96'' 150''-206'' 267''-327'' 373''-431''
                           Intra-L 23'-88'      134'-194'
                                    23'''-88''' 134'''-194'''
                           Inter-H-L 226-214' 226''-214'''
                           Inter-H-H 232-232'' 235-235''

                           N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación
                           H CH2 N84.4:
                           303, 303''



 lirilumabum #
 lirilumab                 immunoglobulin G4-kappa, anti-[Homo sapiens KIR2D subgroup
                           (killer cell immunoglobulin-like receptors from KIRD2 subgroup
                           including KIR2DL1 (nkat1, CD158A), KIR2DL2 (nkat6, CD158B1),
                           KIR2DL3 (nkat2, CD158B2), KIR2DS1 (CD158H) and KIR2DS2
                           (nkat5, CD158J)], Homo sapiens monoclonal antibody;
                           gamma4 heavy chain (1-450) [Homo sapiens VH (IGHV1-69*01
                           (95.90%) -(IGHD)-IGHJ6*01) [8.8.16] (1-123) -IGHG4*01 hinge
                           S10>P (231) (124-450)], (137-214')-disulfide with kappa light chain
                           (1'-214') [Homo sapiens V-KAPPA (IGKV3-11*01 (98.90%) -
                           IGKJ2*01) [6.3.9] (1'-107') -IGKC*01 (108'-214')]; (229-229'':232-
                           232'')-bisdisulfide dimer

 lirilumab                 immunoglobuline G4-kappa, anti-[Homo sapiens KIR2D sous-groupe
                           (récepteurs des cellules tueuses du sous-groupe KIR2D appartenant
                           à la superfamille des immunoglobulines et incluant KIR2DL1 (nkat1,
                           CD158A), KIR2DL2 (nkat6, CD158B1), KIR2DL3 (nkat2, CD158B2),
                           KIR2DS1 (CD158H) et KIR2DS2 (nkat5, CD158J)], Homo sapiens
                           anticorps monoclonal;
                           chaîne lourde gamma4 (1-450) [Homo sapiens VH (IGHV1-69*01
                           (95.90%) -(IGHD)-IGHJ6*01) [8.8.16] (1-123) -IGHG4*01 charnière
                           S10>P (231) (124-450)], (137-214')-disulfure avec la chaîne légère
                           kappa (1'-214') [Homo sapiens V-KAPPA (IGKV3-11*01 (98.90%) -
                           IGKJ2*01) [6.3.9] (1'-107') -IGKC*01 (108'-214')]; dimère (229-
                           229'':232-232'')-bisdisulfure



66
WHO Drug Information Vol. 27, No. 1, 2013                                                           Recommended INN: List 69




 lirilumab                                  inmunoglobulina G4-kappa, anti-[subgrupo KIR2D de Homo sapiens
                                            (receptores de células asesinas del subgrupo KIR2D perteneciente a
                                            la superfamilia de las inmunoglobulinas y que incluye KIR2DL1
                                            (nkat1, CD158A), KIR2DL2 (nkat6, CD158B1), KIR2DL3 (nkat2,
                                            CD158B2), KIR2DS1 (CD158H) et KIR2DS2 (nkat5, CD158J)],
                                            anticuerpo monoclonal de Homo sapiens;
                                            cadena pesada gamma4 (1-450) [Homo sapiens VH (IGHV1-69*01
                                            (95.90%) -(IGHD)-IGHJ6*01) [8.8.16] (1-123) -IGHG4*01 bisagra
                                            S10>P (231) (124-450)], (137-214')-disulfuro con la cadena ligera
                                            kappa (1'-214') [Homo sapiens V-KAPPA (IGKV3-11*01 (98.90%) -
                                            IGKJ2*01) [6.3.9] (1'-107') -IGKC*01 (108'-214')]; dímero (229-
                                            229'':232-232'')-bisdisulfuro


                                            Heavy chain / Chaîne lourde / Cadena pesada
                                            QVQLVQSGAE VKKPGSSVKV SCKASGGTFS                  FYAISWVRQA       PGQGLEWMGG       50
                                            FIPIFGAANY AQKFQGRVTI TADESTSTAY                  MELSSLRSDD       TAVYYCARIP      100
                                            SGSYYYDYDM DVWGQGTTVT VSSASTKGPS                  VFPLAPCSRS       TSESTAALGC      150
                                            LVKDYFPEPV TVSWNSGALT SGVHTFPAVL                  QSSGLYSLSS       VVTVPSSSLG      200
                                            TKTYTCNVDH KPSNTKVDKR VESKYGPPCP                  PCPAPEFLGG       PSVFLFPPKP      250
                                            KDTLMISRTP EVTCVVVDVS QEDPEVQFNW                  YVDGVEVHNA       KTKPREEQFN      300
                                            STYRVVSVLT VLHQDWLNGK EYKCKVSNKG                  LPSSIEKTIS       KAKGQPREPQ      350
                                            VYTLPPSQEE MTKNQVSLTC LVKGFYPSDI                  AVEWESNGQP       ENNYKTTPPV      400
                                            LDSDGSFFLY SRLTVDKSRW QEGNVFSCSV                  MHEALHNHYT       QKSLSLSLGK      450

                                            Light chain / Chaîne légère / Cadena ligera
                                            EIVLTQSPVT LSLSPGERAT LSCRASQSVS                  SYLAWYQQKP       GQAPRLLIYD 50
                                            ASNRATGIPA RFSGSGSGTD FTLTISSLEP                  EDFAVYYCQQ       RSNWMYTFGQ 100
                                            GTKLEIKRTV AAPSVFIFPP SDEQLKSGTA                  SVVCLLNNFY       PREAKVQWKV 150
                                            DNALQSGNSQ ESVTEQDSKD STYSLSSTLT                  LSKADYEKHK       VYACEVTHQG 200
                                            LSSPVTKSFN RGEC                                                               214

                                            Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
                                            Intra-H 22-96        150-206       264-324  370-428
                                                      22''-96'' 150''-206'' 264''-324'' 370''-428''
                                            Intra-L 23'-88' 134'-194'
                                                     23'''-88''' 134'''-194'''
                                            Inter-H-L 137-214' 137''-214'''
                                            Inter-H-H 229-229'' 232-232''

                                            N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación
                                            H CH2 N84.4:
                                            300, 300''




 lomibuvirum
 lomibuvir                                  5-(3,3-dimethylbut-1-yn-1-yl)-3-{(trans-4-hydroxycyclohexyl)[(trans-4-
                                            methylcyclohexyl)carbonyl]amino}thiophene-2-carboxylic acid

 lomibuvir                                  acide 5-(3,3-diméthylbut-1-yn-1-yl)-3-{(trans-4-
                                            hydroxycyclohexyl)[(trans-4-
                                            méthylcyclohexyl)carbonyl]amino}thiophène-2-carboxylique

 lomibuvir                                  ácido 5-(3,3-dimetilbut-1-in-1-il)-3-{(trans-4-hidroxiciclohexil)[(trans-
                                            4-metilciclohexil)carbonil]amino}tiofeno-2-carboxílico

                                            C25H35NO4S

                                                                           CO2H             OH
                                             H 3C                  S

                                            H3C
                                                    CH3                     N

                                                                       O

                                                                                            CH3



                                                                                                                                         67
Recommended INN: List 69                                   WHO Drug Information Vol. 27, No. 1, 2013


 lucitanibum
 lucitanib                  6-({7-[(1-aminocyclopropyl)methoxy]-6-methoxyquinolin-4-yl}oxy)-
                            N-methylnaphthalene-1-carboxamide

 lucitanib                  6-({7-[(1-aminocyclopropyl)méthoxy]-6-méthoxyquinoléin-4-yl}oxy)-
                            N-méthylnaphthalène-1-carboxamide

 lucitanib                  6-({7-[(1-aminociclopropil)metoxi]-6-metoxiquinolin-4-il}oxi)-
                            N-metilnaftaleno-1-carboxamida

                            C26H25N3O4


                                         O             N
                             H2N

                                    H3CO
                                                       O
                                                                      O
                                                                               CH3
                                                                           N
                                                                           H



 momelotinibum
 momelotinib                N-(cyanomethyl)-4-{2-[4-(morpholin-4-yl)anilino]pyrimidin-
                            4-yl}benzamide

 momélotinib                N-(cyanométhyl)-4-{2-[4-(morpholin-4-yl)anilino]pyrimidin-
                            4-yl}benzamide

 momelotinib                N-(cianometil)-4-{2-[4-(morfolin-4-il)anilino]pirimidin-4-il}benzamida

                            C23H22N6O2
                                                                       O

                                                                           N         CN
                                               H                           H
                                               N       N

                                                   N
                                   N
                             O


nivolumabum #
nivolumab                  immunoglobulin G4-kappa, anti-[Homo sapiens PDCD1
                           (programmed cell death 1, PD-1, PD1, CD279)], Homo sapiens
                           monoclonal antibody;
                           gamma1 heavy chain (1-440) [Homo sapiens VH (IGHV3-33*01
                           (91.80%) -(IGHD)-IGHJ4*01) [8.8.6] (1-113) -IGHG4*01 hinge
                           S10>P (221) (114-440)], (127-214')-disulfide with kappa light chain
                           (1'-214') [Homo sapiens V-KAPPA (IGKV3-11*01 (98.90%) -
                           IGKJ1*01) [6.3.9] (1'-107') -IGKC*01 (108'-214')]; (219-219'':222-
                           222'')-bisdisulfide dimer

nivolumab                  immunoglobuline G4-kappa, anti-[Homo sapiens PDCD1 (protéine 1
                           de mort cellulaire programmée, PD-1, PD1, CD279)], Homo sapiens
                           anticorps monoclonal;
                           chaîne lourde gamma1 (1-440) [Homo sapiens VH (IGHV3-33*01
                           (91.80%) -(IGHD)-IGHJ4*01) [8.8.6] (1-113) -IGHG4*01 charnière
                           S10>P (221) (114-440)], (127-214')-disulfure avec la chaîne légère
                           kappa (1'-214') [Homo sapiens V-KAPPA (IGKV3-11*01 (98.90%) -
                           IGKJ1*01) [6.3.9] (1'-107') -IGKC*01 (108'-214')]; dimère (219-
                           219'':222-222'')-bisdisulfure

68
WHO Drug Information Vol. 27, No. 1, 2013                                                           Recommended INN: List 69




 nivolumab                                  inmunoglobulina G4-kappa, anti-[PDCD1 de Homo sapiens (proteína
                                            1 de muerte celular programada, PD-1, PD1, CD279)], anticuerpo
                                            monoclonal de Homo sapiens;
                                            cadena pesada gamma1 (1-440) [Homo sapiens VH (IGHV3-33*01
                                            (91.80%) -(IGHD)-IGHJ4*01) [8.8.6] (1-113) -IGHG4*01 bisagra
                                            S10>P (221) (114-440)], (127-214')-disulfuro con la cadena ligera
                                            kappa (1'-214') [Homo sapiens V-KAPPA (IGKV3-11*01 (98.90%) -
                                            IGKJ1*01) [6.3.9] (1'-107') -IGKC*01 (108'-214')]; dímero (219-
                                            219'':222-222'')-bisdisulfuro

                                            Heavy chain / Chaîne lourde / Cadena pesada
                                            QVQLVESGGG VVQPGRSLRL DCKASGITFS                  NSGMHWVRQA       PGKGLEWVAV       50
                                            IWYDGSKRYY ADSVKGRFTI SRDNSKNTLF                  LQMNSLRAED       TAVYYCATND      100
                                            DYWGQGTLVT VSSASTKGPS VFPLAPCSRS                  TSESTAALGC       LVKDYFPEPV      150
                                            TVSWNSGALT SGVHTFPAVL QSSGLYSLSS                  VVTVPSSSLG       TKTYTCNVDH      200
                                            KPSNTKVDKR VESKYGPPCP PCPAPEFLGG                  PSVFLFPPKP       KDTLMISRTP      250
                                            EVTCVVVDVS QEDPEVQFNW YVDGVEVHNA                  KTKPREEQFN       STYRVVSVLT      300
                                            VLHQDWLNGK EYKCKVSNKG LPSSIEKTIS                  KAKGQPREPQ       VYTLPPSQEE      350
                                            MTKNQVSLTC LVKGFYPSDI AVEWESNGQP                  ENNYKTTPPV       LDSDGSFFLY      400
                                            SRLTVDKSRW QEGNVFSCSV MHEALHNHYT                  QKSLSLSLGK                       440

                                            Light chain / Chaîne légère / Cadena ligera
                                            EIVLTQSPAT LSLSPGERAT LSCRASQSVS                  SYLAWYQQKP       GQAPRLLIYD 50
                                            ASNRATGIPA RFSGSGSGTD FTLTISSLEP                  EDFAVYYCQQ       SSNWPRTFGQ 100
                                            GTKVEIKRTV AAPSVFIFPP SDEQLKSGTA                  SVVCLLNNFY       PREAKVQWKV 150
                                            DNALQSGNSQ ESVTEQDSKD STYSLSSTLT                  LSKADYEKHK       VYACEVTHQG 200
                                            LSSPVTKSFN RGEC                                                               214

                                            Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
                                            Intra-H 22-96 140-196              254-314 360-418
                                                     22''-96'' 140''-196'' 254''-314'' 360''-418''
                                            Intra-L 23'-88' 134'-194'
                                                     23'''-88''' 134'''-194'''
                                            Inter-H-L 127-214' 127''-214'''
                                            Inter-H-H 219-219'' 222-222''

                                            N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación
                                            H CH2 84.4:
                                            290, 290''




 ocaratuzumabum #
 ocaratuzumab                               immunoglobulin G1-kappa, anti-[Homo sapiens MS4A1 (membrane-
                                            spanning 4-domains subfamily A member 1, CD20)], humanized
                                            monoclonal antibody;
                                            gamma1 heavy chain (1-450) [humanized VH (Homo sapiens
                                            IGHV5-51*01 (83.70%) -(IGHD)-IGHJ2*01) R120>K (113), L123>T
                                            (116) [8.8.14] (1-121) -Homo sapiens IGHG1*01 CH2 P11>I (251),
                                            A124>Q (343), CHS K2>del (122-450)], (224-213')-disulfide with
                                            kappa light chain (1'-213') [humanized V-KAPPA (Homo sapiens
                                            IGKV3-20*01 (85.40%) -IGKJ2*01) [5.3.9] (1'-106') -Homo sapiens
                                            IGKC*01 (107'-213')]; (230-230":233-233")-bisdisulfide dimer

 ocaratuzumab                               immunoglobuline G1-kappa, anti-[Homo sapiens MS4A1 (membre 1
                                            de la sous-famille A à 4 domaines transmembranaires, CD20)],
                                            anticorps monoclonal humanisé;
                                            chaîne lourde gamma1 (1-450) [VH humanisé (Homo sapiens
                                            IGHV5-51*01 (83.70%) -(IGHD)-IGHJ2*01) R120>K (113), L123>T
                                            (116) [8.8.14] (1-121) -Homo sapiens IGHG1*01 CH2 P11>I (251),
                                            A124>Q (343), CHS K2>del (122-450)], (224-213')-disulfure avec la
                                            chaîne légère kappa (1'-213') [V-KAPPA humanisé (Homo sapiens
                                            IGKV3-20*01 (85.40%) -IGKJ2*01) [5.3.9] (1'-106') -Homo sapiens
                                            IGKC*01 (107'-213')]; dimère (230-230":233-233")-bisdisulfure




                                                                                                                                         69
Recommended INN: List 69                                      WHO Drug Information Vol. 27, No. 1, 2013


 ocaratuzumab              inmunoglobulina G1-kappa, anti-[MS4A1 de Homo sapiens
                           (miembro 1 de la subfamilia A de 4 dominios transmembranarios,
                           CD20)], anticuerpo monoclonal humanizado;
                           cadena pesada gamma1 (1-450) [VH humanizado (Homo sapiens
                           IGHV5-51*01 (83.70%) -(IGHD)-IGHJ2*01) R120>K (113), L123>T
                           (116) [8.8.14] (1-121) -Homo sapiens IGHG1*01 CH2 P11>I (251),
                           A124>Q (343), CHS K2>del (122-450)], (224-213')-disulfuro con la
                           cadena ligera kappa (1'-213') [V-KAPPA humanizado (Homo sapiens
                           IGKV3-20*01 (85.40%) -IGKJ2*01) [5.3.9] (1'-106') -Homo sapiens
                           IGKC*01 (107'-213')]; dímero (230-230":233-233")-bisdisulfuro

                           Heavy chain / Chaîne lourde / Cadena pesada
                           EVQLVQSGAE VKKPGESLKI SCKGSGRTFT                   SYNMHWVRQM      PGKGLEWMGA       50
                           IYPLTGDTSY NQKSKLQVTI SADKSISTAY                   LQWSSLKASD      TAMYYCARST      100
                           YVGGDWQFDV WGKGTTVTVS SASTKGPSVF                   PLAPSSKSTS      GGTAALGCLV      150
                           KDYFPEPVTV SWNSGALTSG VHTFPAVLQS                   SGLYSLSSVV      TVPSSSLGTQ      200
                           TYICNVNHKP SNTKVDKKVE PKSCDKTHTC                   PPCPAPELLG      GPSVFLFPPK      250
                           IKDTLMISRT PEVTCVVVDV SHEDPEVKFN                   WYVDGVEVHN      AKTKPREEQY      300
                           NSTYRVVSVL TVLHQDWLNG KEYKCKVSNK                   ALPAPIEKTI      SKQKGQPREP      350
                           QVYTLPPSRD ELTKNQVSLT CLVKGFYPSD                   IAVEWESNGQ      PENNYKTTPP      400
                           VLDSDGSFFL YSKLTVDKSR WQQGNVFSCS                   VMHEALHNHY      TQKSLSLSPG      450

                           Light chain / Chaîne légère / Cadena ligera
                           EIVLTQSPGT LSLSPGERAT LSCRASSSVP                   YIHWYQQKPG      QAPRLLIYAT 50
                           SALASGIPDR FSGSGSGTDF TLTISRLEPE                   DFAVYYCQQW      LSNPPTFGQG 100
                           TKLEIKRTVA APSVFIFPPS DEQLKSGTAS                   VVCLLNNFYP      REAKVQWKVD 150
                           NALQSGNSQE SVTEQDSKDS TYSLSSTLTL                   SKADYEKHKV      YACEVTHQGL 200
                           SSPVTKSFNR GEC                                                                213

                           Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
                           Intra-H 22-96 148-204              265-325  371-429
                                    22''-96'' 148''-204'' 265''-325'' 371''-429''
                           Intra-L 23'-87'      133'-193'
                                    23'''-87''' 133'''-193'''
                           Inter-H-L 224-213' 224''-213'''
                           Inter-H-H 230-230'' 233-233''

                           N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación
                           H CH2 N84.4:
                           301, 301''


 omarigliptinum
 omarigliptin              (2R,3S,5R)-2-(2,5-difluorophenyl)-5-[2-(methanesulfonyl)-
                           4,6-dihydropyrrolo[3,4-c]pyrazol-5(2H)-yl]oxan-3-amine

 omarigliptine             (2R,3S,5R)-2-(2,5-difluorophényl)-5-[2-(méthanesulfonyl)-
                           4,6-dihydropyrrolo[3,4-c]pyrazol-5(2H)-yl]oxan-3-amine

 omarigliptina             (2R,3S,5R)-2-(2,5-difluorofenil)-5-[2-(metanosulfonil)-
                           4,6-dihidropirrolo[3,4-c]pirazol-5(2H)-il]oxan-3-amina

                           C17H20F2N4O3S

                           F
                                            H   NH2
                                        H
                                                                  N           CH3
                                            O          N              N   S
                                    F                                         O
                                                   H                      O

 oprozomibum
 oprozomib                 O-methyl-N-(2-methyl-1,3-thiazol-5-carbonyl)-L-seryl-O-methyl-
                           N-{(2S)-1-[(2R)-2-methyloxiran-2-yl]-1-oxo-3-phenylpropan-2-yl}-
                           L-serinamide

 oprozomib                 O-méthyl-N-(2-méthyl-1,3-thiazol-5-carbonyl)-L-séryl-O-méthyl-
                           N-{(2S)-1-[(2R)-2-méthyloxiran-2-yl]-1-oxo-3-phénylpropan-2-yl}-
                           L-sérinamide




70
WHO Drug Information Vol. 27, No. 1, 2013                                                                Recommended INN: List 69


 oprozomib                                  O-metil-N-(2-metil-1,3-tiazol-5-carbonil)-L-seril-O-metil-N-{(2S)-1-[(2R)-2-
                                            metiloxiran-2-il]-1-oxo-3-fenilpropan-2-il}-L-serinamida

                                            C25H32N4O7S
                                                                                       O CH3
                                                      N                        O                       O
                                                                                        H
                                            H 3C                     H                     H
                                                                     N                     N                    CH3
                                                       S                           N
                                                                                   H
                                                                O              H          O          H O
                                                                           O
                                                                    H 3C


 orticumabum #
 orticumab                                  immunoglobulin G1-lambda, anti-[Homo sapiens oxLDL (oxidized low-
                                            density lipoprotein (LDL), malondialdehyde (MDA)-modified
                                            apolipoprotein (apo) B-100)], Homo sapiens monoclonal antibody;
                                            gamma1 heavy chain (1-451) [Homo sapiens VH (IGHV3-23*01 (89.80%)
                                            -(IGHD)-IGHJ4*01) [8.8.14] (1-121) -IGHG1*01 (122-451)], (224-215')-
                                            disulfide with lambda light chain (1'-216') [Homo sapiens V-LAMBDA
                                            (IGLV1-47*02 (89.80%) -IGLJ3*02) [8.3.11] (1'-110') -IGLC2*01 (111'-
                                            216')]; (230-230'':233-233'')-bisdisulfide dimer

 orticumab                                  immunoglobuline G1-lambda, anti-[Homo sapiens oxLDL (lipoprotéine de
                                            faible densité (LDL) oxydée, apolipoprotéine (apo) B-100 modifiée par la
                                            malondialdéhyde (MDA))], Homo sapiens anticorps monoclonal;
                                            chaîne lourde gamma1 (1-451) [Homo sapiens VH (IGHV3-23*01
                                            (89.80%) -(IGHD)-IGHJ4*01) [8.8.14] (1-121) -IGHG1*01 (122-451)],
                                            (224-215')-disulfure avec la chaîne légère lambda (1'-216') [Homo
                                            sapiens V-LAMBDA (IGLV1-47*02 (89.80%) -IGLJ3*02) [8.3.11] (1'-110')
                                            -IGLC2*01 (111'-216')]; dimère (230-230'':233-233'')-bisdisulfure

 orticumab                                  inmunoglobulina G1-lambda, anti-[oxLDL de Homo sapiens (lipoproteína
                                            de baja densidad (LDL) oxidada, apolipoproteína (apo) B-100 modificada
                                            por malondialdehído (MDA))], anticuerpo monoclonal de Homo sapiens;
                                            cadena pesada gamma1 (1-451) [Homo sapiens VH (IGHV3-23*01
                                            (89.80%) -(IGHD)-IGHJ4*01) [8.8.14] (1-121) -IGHG1*01 (122-451)],
                                            (224-215')-disulfuro con la cadena ligera lambda (1'-216') [Homo sapiens
                                            V-LAMBDA (IGLV1-47*02 (89.80%) -IGLJ3*02) [8.3.11] (1'-110') -
                                            IGLC2*01 (111'-216')]; dímero (230-230'':233-233'')-bisdisulfuro

                                            Heavy chain / Chaîne lourde / Cadena pesada
                                            EVQLLESGGG LVQPGGSLRL SCAASGFTFS                  NAWMSWVRQA       PGKGLEWVSS       50
                                            ISVGGHRTYY ADSVKGRSTI SRDNSKNTLY                  LQMNSLRAED       TAVYYCARIR      100
                                            VGPSGGAFDY WGQGTLVTVS SASTKGPSVF                  PLAPSSKSTS       GGTAALGCLV      150
                                            KDYFPEPVTV SWNSGALTSG VHTFPAVLQS                  SGLYSLSSVV       TVPSSSLGTQ      200
                                            TYICNVNHKP SNTKVDKKVE PKSCDKTHTC                  PPCPAPELLG       GPSVFLFPPK      250
                                            PKDTLMISRT PEVTCVVVDV SHEDPEVKFN                  WYVDGVEVHN       AKTKPREEQY      300
                                            NSTYRVVSVL TVLHQDWLNG KEYKCKVSNK                  ALPAPIEKTI       SKAKGQPREP      350
                                            QVYTLPPSRD ELTKNQVSLT CLVKGFYPSD                  IAVEWESNGQ       PENNYKTTPP      400
                                            VLDSDGSFFL YSKLTVDKSR WQQGNVFSCS                  VMHEALHNHY       TQKSLSLSPG      450
                                            K                                                                                  451

                                            Light chain / Chaîne légère / Cadena ligera
                                            QSVLTQPPSA SGTPGQRVTI SCSGSNTNIG                  KNYVSWYQQL       PGTAPKLLIY 50
                                            ANSNRPSGVP DRFSGSKSGT SASLAISGLR                  SEDEADYYCA       SWDASLNGWV 100
                                            FGGGTKLTVL GQPKAAPSVT LFPPSSEELQ                  ANKATLVCLI       SDFYPGAVTV 150
                                            AWKADSSPVK AGVETTTPSK QSNNKYAASS                  YLSLTPEQWK       SHRSYSCQVT 200
                                            HEGSTVEKTV APTECS                                                             216

                                            Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
                                            Intra-H 22-96 148-204              265-325  371-429
                                                     22''-96'' 148''-204'' 265''-325'' 371''-429''
                                            Intra-L 22'-89' 138'-197'
                                                     22'''-89''' 138'''-197'''
                                            Inter-H-L 224-215' 224''-215'''
                                            Inter-H-H 230-230'' 233-233''

                                            N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación
                                            H CH2 N84.4:
                                            301, 301''




                                                                                                                                              71
Recommended INN: List 69                                       WHO Drug Information Vol. 27, No. 1, 2013




parsatuzumabum #
parsatuzumab               immunoglobulin G1-kappa, anti-[Homo sapiens EGFL7 (epidermal
                           growth factor (EGF)-like repeat superfamily member 7, EGF-like-
                           domains protein 7)], humanized monoclonal antibody;
                           gamma1 heavy chain (1-453) [humanized VH (Homo sapiens
                           IGHV3-74*01 (80.60%) -(IGHD)-IGHJ6*01 T123>L (118) [8.8.16] (1-
                           123) -Homo sapiens IGHG1*03 CH1 R120>K (220) (124-453)], (226-
                           219')-disulfide with kappa light chain (1'-219') [humanized V-KAPPA
                           (Homo sapiens IGKV1-39*01 (81.00%) -IGKJ1*01) [11.3.9] (1'-112')
                           -Homo sapiens IGKC*01 (113'-219')]; (232-232":235-235")-
                           bisdisulfide dimer

parsatuzumab               immunoglobuline G1-kappa, anti-[Homo sapiens EGFL7 (membre 7
                           de la superfamille des protéines à domaines répétés facteur de
                           croissance épidermique (EGF)-like, protéine 7 à domaines EGF-
                           like)], anticorps monoclonal humanisé;
                           chaîne lourde gamma1 (1-453) [VH humanisé (Homo sapiens
                           IGHV3-74*01 (80.60%) -(IGHD)-IGHJ6*01 T123>L (118) [8.8.16] (1-
                           123) -Homo sapiens IGHG1*03 CH1 R120>K (220) (124-453)], (226-
                           219')-disulfure avec la chaîne légère kappa (1'-219') [V-KAPPA
                           humanisé (Homo sapiens IGKV1-39*01 (81.00%) -IGKJ1*01)
                           [11.3.9] (1'-112') -Homo sapiens IGKC*01 (113'-219')]; dimère (232-
                           232":235-235")-bisdisulfure

parsatuzumab               inmunoglobulina G1-kappa, anti-[ EGFL7 de Homo sapiens
                           (miembro 7 de la superfamilia de proteínas de dominios repetidos
                           factor de crecimiento epidérmico (EGF)-like, proteína 7 de dominios
                           EGF-like)], anticuerpo monoclonal humanizado;
                           cadena pesada gamma1 (1-453) [VH humanizada (Homo sapiens
                           IGHV3-74*01 (80.60%) -(IGHD)-IGHJ6*01 T123>L (118) [8.8.16] (1-
                           123) -Homo sapiens IGHG1*03 CH1 R120>K (220) (124-453)], (226-
                           219')-disulfuro con la cadena ligera kappa (1'-219') [V-KAPPA
                           humanizada (Homo sapiens IGKV1-39*01 (81.00%) -IGKJ1*01)
                           [11.3.9] (1'-112') -Homo sapiens IGKC*01 (113'-219')]; dímero (232-
                           232":235-235")-bisdisulfuro

                           Heavy chain / Chaîne lourde / Cadena pesada
                           EVQLVESGGG LVQPGGSLRL SCAASGYTFI                  DYYMNWVRQA       PGKGLEWVGD        50
                           INLDNSGTHY NQKFKGRFTI SRDKSKNTAY                  LQMNSLRAED       TAVYYCAREG       100
                           VYHDYDDYAM DYWGQGTLVT VSSASTKGPS                  VFPLAPSSKS       TSGGTAALGC       150
                           LVKDYFPEPV TVSWNSGALT SGVHTFPAVL                  QSSGLYSLSS       VVTVPSSSLG       200
                           TQTYICNVNH KPSNTKVDKK VEPKSCDKTH                  TCPPCPAPEL       LGGPSVFLFP       250
                           PKPKDTLMIS RTPEVTCVVV DVSHEDPEVK                  FNWYVDGVEV       HNAKTKPREE       300
                           QYNSTYRVVS VLTVLHQDWL NGKEYKCKVS                  NKALPAPIEK       TISKAKGQPR       350
                           EPQVYTLPPS REEMTKNQVS LTCLVKGFYP                  SDIAVEWESN       GQPENNYKTT       400
                           PPVLDSDGSF FLYSKLTVDK SRWQQGNVFS                  CSVMHEALHN       HYTQKSLSLS       450
                           PGK                                                                                 453

                           Light chain / Chaîne légère / Cadena ligera
                           DIQMTQSPSS LSASVGDRVT ITCRTSQSLV                  HINAITYLHW       YQQKPGKAPK 50
                           LLIYRVSNRF SGVPSRFSGS GSGTDFTLTI                  SSLQPEDFAT       YYCGQSTHVP 100
                           LTFGQGTKVE IKRTVAAPSV FIFPPSDEQL                  KSGTASVVCL       LNNFYPREAK 150
                           VQWKVDNALQ SGNSQESVTE QDSKDSTYSL                  SSTLTLSKAD       YEKHKVYACE 200
                           VTHQGLSSPV TKSFNRGEC                                                          219

                           Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
                           Intra-H 22-96        150-206       267-327  373-431
                                     22''-96'' 150''-206'' 267''-327'' 373''-431''
                           Intra-L 23'-93' 139'-199'
                                    23'''-93''' 139'''-199'''
                           Inter-H-L 226-219' 226''-219'''
                           Inter-H-H 232-232'' 235-235''

                           N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación
                           H CH2 N84.4:
                           303, 303''




72
WHO Drug Information Vol. 27, No. 1, 2013                                                  Recommended INN: List 69




 pefcalcitolum
 pefcalcitol                                2-{[(1S,3R,5Z,7E,20S)-1,3-dihydroxy-9,10-secopregna-
                                            5,7,10(19),16-tetraen-20-yl]oxy}-N-(2,2,3,3,3-
                                            pentafluoropropyl)acetamide

 pefcalcitol                                2-{[(1S,3R,5Z,7E,20S)-1,3-dihydroxy-9,10-sécoprégna-
                                            5,7,10(19),16-tetraén-20-yl]oxy}-N-(2,2,3,3,3-
                                            pentafluoropropyl)acétamide

 pefcalcitol                                2-{[(1S,3R,5Z,7E,20S)-1,3-dihidroxi-9,10-secopregna-5,7,10(19),16-
                                            tetraen-20-il]oxi}-N-(2,2,3,3,3-pentafluoropropil)acetamida

                                            C26H34F5NO4

                                                          H3C H        O
                                                                   O
                                                          CH3
                                                                         N
                                                                         H           CF3
                                                                             F
                                                                                 F
                                                          H


                                                          CH2

                                            HO                OH
                                                 H        H



 perakizumabum #
 perakizumab                                immunoglobulin G1-kappa, anti-[Homo sapiens IL17A (interleukin
                                            17A, IL-17A)], humanized monoclonal antibody;
                                            gamma1 heavy chain (1-452) [humanized VH (Homo sapiens
                                            IGHV3-7*01 (90.80%) -(IGHD)-IGHJ4*01) [8.8.15] (1-122) -Homo
                                            sapiens IGHG1*01 CH2 L1.3>A (239), L1.2>A (240) (123-452)],
                                            (225-215')-disulfide with kappa light chain (1'-215') [humanized
                                            V-KAPPA (Homo sapiens IGKV1-16*01 (82.10%) -IGKJ2*01)
                                            [6.3.10] (1'-108') -Homo sapiens IGKC*01 (109'-215')]; (231-
                                            231":234-234")-bisdisulfide dimer

 pérakizumab                                immunoglobuline G1-kappa, anti-[Homo sapiens IL17A (interleukine
                                            17A, IL-17A)], anticorps monoclonal humanisé;
                                            chaîne lourde gamma1 (1-452) [VH humanisé (Homo sapiens
                                            IGHV3-7*01 (90.80%) -(IGHD)-IGHJ4*01) [8.8.15] (1-122) -Homo
                                            sapiens IGHG1*01 CH2 L1.3>A (239), L1.2>A (240) (123-452)],
                                            (225-215')-disulfure avec la chaîne légère kappa (1'-215') [V-KAPPA
                                            humanisé (Homo sapiens IGKV1-16*01 (82.10%) -IGKJ2*01)
                                            [6.3.10] (1'-108') -Homo sapiens IGKC*01 (109'-215')]; dimère (231-
                                            231":234-234")-bisdisulfure

 perakizumab                                inmunoglobulina G1-kappa, anti-[IL17A de Homo sapiens
                                            (interleukina 17A, IL-17A)], anticuerpo monoclonal humanizado;
                                            cadena pesada gamma1 (1-452) [VH humanizado (Homo sapiens
                                            IGHV3-7*01 (90.80%) -(IGHD)-IGHJ4*01) [8.8.15] (1-122) -Homo
                                            sapiens IGHG1*01 CH2 L1.3>A (239), L1.2>A (240) (123-452)],
                                            (225-215')-disulfuro con la cadena ligera kappa (1'-215') [V-KAPPA
                                            humanizado (Homo sapiens IGKV1-16*01 (82.10%) -IGKJ2*01)
                                            [6.3.10] (1'-108') -Homo sapiens IGKC*01 (109'-215')]; dímero (231-
                                            231":234-234")-bisdisulfuro




                                                                                                                  73
Recommended INN: List 69                                      WHO Drug Information Vol. 27, No. 1, 2013




                            Heavy chain / Chaîne lourde / Cadena pesada
                            EVQLVESGGG LVQPGGSLRL SCAASGFTFS                  DYTMLWVRQA       PGKGLEWVAI        50
                            IKSGGSYSYY PDSVKGRFTI SRDNAKNSLY                  LQMNSLRAED       TAVYYCARDG       100
                            DYGSSYGAMD YWGQGTLVTV SSASTKGPSV                  FPLAPSSKST       SGGTAALGCL       150
                            VKDYFPEPVT VSWNSGALTS GVHTFPAVLQ                  SSGLYSLSSV       VTVPSSSLGT       200
                            QTYICNVNHK PSNTKVDKKV EPKSCDKTHT                  CPPCPAPEAA       GGPSVFLFPP       250
                            KPKDTLMISR TPEVTCVVVD VSHEDPEVKF                  NWYVDGVEVH       NAKTKPREEQ       300
                            YNSTYRVVSV LTVLHQDWLN GKEYKCKVSN                  KALPAPIEKT       ISKAKGQPRE       350
                            PQVYTLPPSR DELTKNQVSL TCLVKGFYPS                  DIAVEWESNG       QPENNYKTTP       400
                            PVLDSDGSFF LYSKLTVDKS RWQQGNVFSC                  SVMHEALHNH       YTQKSLSLSP       450
                            GK                                                                                  452

                            Light chain / Chaîne légère / Cadena ligera
                            DIQMTQSPSS LSASVGDRVT ITCRASQDIN                  SYLSWFQQKP       GKAPKSLIVR 50
                            ANRLVDGVPS RFSGSGSGQD YSLTISSLQP                  EDFATYYCLQ       YDAFPPYTFG 100
                            QGTKLEIKRT VAAPSVFIFP PSDEQLKSGT                  ASVVCLLNNF       YPREAKVQWK 150
                            VDNALQSGNS QESVTEQDSK DSTYSLSSTL                  TLSKADYEKH       KVYACEVTHQ 200
                            GLSSPVTKSF NRGEC                                                              215

                            Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
                            Intra-H 22-96        149-205       266-326  372-430
                                      22''-96'' 149''-205'' 266''-326'' 372''-430''
                            Intra-L 23'-88' 135'-195'
                                     23'''-88''' 135'''-195'''
                            Inter-H-L 225-215' 225''-215'''
                            Inter-H-H 231-231'' 234-234''

                            N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación
                            H CH2 N84.4:
                            302, 302''



 pictilisibum
 pictilisib                 2-{1H-indazol-4-yl}-6-{[4-(methanesulfonyl)piperazin-1-yl]methyl}-
                            4-(morpholin-4-yl)thieno[3,2-d]pyrimidine

 pictilisib                 2-(1H-indazol-4-yl)-6-{[4-(méthanesulfonyl)pipérazin-1-yl]méthyl}-
                            4-(morpholin-4-yl)-thiéno[3,2-d]pyrimidine

 pictilisib                 2-{1H-indazol-4-il}-6-{[4-(metanosulfonil)piperazin-1-il]metil}-
                            4-(morfolin-4-il)tieno[3,2-d]pirimidina

                            C23H27N7O3S2

                                                        O
                                 N
                            HN                      N
                                                                          O O
                                             N
                                                                           S
                                                        S                N   CH3
                                             N
                                                                 N



placulumabum #
placulumab                 immunoglobulin (V-kappa)2-Fc gamma1, anti-[Homo sapiens TNF
                           (tumor necrosis factor, TNF superfamily member 2, TNFSF2, TNF-
                           alpha, TNFA)], Homo sapiens monoclonal antibody;
                           V-kappa -(CH1>del) gamma1 chain (1-341) [Homo sapiens
                           V-KAPPA (IGKV1-39*01 (87.40%) -IGKJ1*01) [6.3.9] (1-107) -
                           IGHG1*01 [CH1 1.4-119>del, K120>R (108) (108-109), hinge 1-15
                           C5>S (114) (110-124), CH2 (125-234), CH3 (235-339), CHS (340-
                           341)]; (120-120':123-123')-bisdisulfide dimer




74
WHO Drug Information Vol. 27, No. 1, 2013                                                            Recommended INN: List 69


 placulumab                                 immunoglobuline (V-kappa)2-Fc gamma1, anti-[Homo sapiens TNF
                                            (facteur de nécrose tumorale, membre 2 de la superfamille du TNF,
                                            TNFSF2, TNF-alpha, TNFA)], Homo sapiens anticorps monoclonal;
                                            chaîne V-kappa -(CH1>del) gamma1 (1-341) [Homo sapiens
                                            V-KAPPA (IGKV1-39*01 (87.40%) -IGKJ1*01) [6.3.9] (1-107) -
                                            IGHG1*01 [CH1 1.4-119>del, K120>R (108) (108-109), charnière
                                            1-15 C5>S (114) (110-124), CH2 (125-234), CH3 (235-339), CHS
                                            (340-341)]; dimère (120-120':123-123')-bisdisulfure

 placulumab                                 inmunoglobulina (V-kappa)2-Fc gamma1, anti-[TNF de Homo
                                            sapiens (factor de necrosis tumoral, miembro 2 de la superfamilia
                                            del TNF, TNFSF2, TNF-alfa, TNFA)], anticuerpo monoclonal de
                                            Homo sapiens;
                                            cadena V-kappa -(CH1>del) gamma1 (1-341) [Homo sapiens
                                            V-KAPPA (IGKV1-39*01 (87.40%) -IGKJ1*01) [6.3.9] (1-107) -
                                            IGHG1*01 [CH1 1.4-119>del, K120>R (108) (108-109), bisagra 1-15
                                            C5>S (114) (110-124), CH2 (125-234), CH3 (235-339), CHS (340-
                                            341)]; dímero (120-120':123-123')-bisdisulfuro

                                            Heavy chain / Chaîne lourde / Cadena pesada
                                            DIQMTQSPSS LSASVGDRVT ITCRASQAID                  SYLHWYQQKP       GKAPKLLIYS       50
                                            ASNLETGVPS RFSGSGSGTD FTLTISSLLP                  EDFATYYCQQ       VVWRPFTFGQ      100
                                            GTKVEIKRVE PKSSDKTHTC PPCPAPELLG                  GPSVFLFPPK       PKDTLMISRT      150
                                            PEVTCVVVDV SHEDPEVKFN WYVDGVEVHN                  AKTKPREEQY       NSTYRVVSVL      200
                                            TVLHQDWLNG KEYKCKVSNK ALPAPIEKTI                  SKAKGQPREP       QVYTLPPSRD      250
                                            ELTKNQVSLT CLVKGFYPSD IAVEWESNGQ                  PENNYKTTPP       VLDSDGSFFL      300
                                            YSKLTVDKSR WQQGNVFSCS VMHEALHNHY                  TQKSLSLSPG       K               341

                                            Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
                                            Intra-H 23-88 155-215 261-319
                                                     23'-88' 155'-215' 261'-319'
                                            Inter-H-H 120-120' 123-123'

                                            N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación
                                            H CH2 N84.4:
                                            191, 191'



 pocapavirum
 pocapavir                                  1,3-dichloro-2-({4-[(2-chloro-
                                            4-methoxyphenoxy)methyl]phenyl}methoxy)benzene

 pocapavir                                  1,3-dichloro-2-({4-[(2-chloro-
                                            4-méthoxyphénoxy)méthyl]phényl}méthoxy)benzene

 pocapavir                                  1,3-dicloro-2-({4-[(2-cloro-4-metoxifenoxi)metil]fenil}metoxi)benceno

                                            C21H17Cl3O3
                                                                                       Cl


                                                                                        O
                                                                O                               Cl


                                            H3CO                Cl

 pradimotidum
 pradimotide                                human vascular endothelial growth factor receptor 1 (VEGFR-1)-
                                            (1058-1066)-peptide

 pradimotide                                récepteur 1 du facteur de croissance de l'endothélium vasculaire
                                            humain (VEGFR-1)-(1058-1066)-peptide

 pradimotida                                receptor 1 del factor de crecimiento endotelial vascular humano
                                            (VEGFR-1)-(1058-1066)-péptido


                                                                                                                                        75
Recommended INN: List 69                                          WHO Drug Information Vol. 27, No. 1, 2013




                           C53H78N10O14

                           H Ser       Tyr   Gly       Val       Leu   Leu       Trp       Glu    Ile OH

 quisinostatum
 quisinostat               N-hydroxy-2-[4-({[(1-methyl-1H-indol-
                           3-yl)methyl]amino}methyl)piperidin-1-yl]pyrimidine-5-carboxamide

 quisinostat               N-hydroxy-2-[4-({[(1-méthyl-1H-indol-
                           3-yl)méthyl]amino}méthyl)pipéridin-1-yl]pyrimidine-5-carboxamide

 quisinostat               N-hidroxi-2-[4-({[(1-metil-1H-indol-3-il)metil]amino}metil)piperidin-
                           1-il]pirimidina-5-carboxamida

                           C21H26N6O2
                                                                                       O
                                                                                                 OH
                                                                       N                   N
                             H3C                                                           H
                                   N                               N       N
                                              H
                                              N




 rabusertibum
 rabusertib                1-(2-chloro-3-fluorophenyl)-3-[4-chloro-2-hydroxy-3-(piperazine-
                           1-sulfonyl)phenyl]urea

 rabusertib                1-(5-bromo-4-méthyl-2-{[(2S)-morpholin-2-yl]méthoxy}phényl)-
                           3-(5-méthylpyrazin-2-yl)urée

 rabusertib                1-(2-cloro-3-fluorofenil)-3-[4-cloro-2-hidroxi-3-(piperazina-
                           1-sulfonil)fenil]urea

                           C18H22BrN5O3

                                             H         H
                            Br               N         N
                                                                       N
                                                   O         N
                           H 3C              O                             CH3
                                                             NH

                                             H
                                                       O



 relugolixum
 relugolix                 1-(4-{1-[(2,6-difluorophenyl)methyl]-5-[(dimethylamino)methyl]-
                           3-(6-methoxypyridazin-3-yl)-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-
                           d]pyrimidin-6-yl}phenyl)-3-methoxyurea

 rélugolix                 1-(4-{1-[(2,6-difluorophényl)méthyl]-5-[(diméthylamino)méthyl]-
                           3-(6-méthoxypyridazin-3-yl)-2,4-dioxo-1,2,3,4-tétrahydrothiéno[2,3-
                           d]pyrimidin-6-yl}phényl)-3-méthoxyurea

 relugolix                 1-(4-{1-[(2,6-difluorofenil)metil]-5-[(dimetilamino)metil]-
                           3-(6-metoxipiridazin-3-il)-2,4-dioxo-1,2,3,4-tetrahidrotieno[2,3-
                           d]pirimidin-6-il}fenil)-3-metoxiurea




76
WHO Drug Information Vol. 27, No. 1, 2013                                                    Recommended INN: List 69


                                             C29H27F2N7O5S
                                                                                F



                                              H 3C O      O
                                                                         F
                                                   HN                    S       N       O
                                                         HN
                                                                                     N

                                                                                 O       N
                                                                             N CH3            N   OCH3
                                                                      H 3C

 rilimogenum galvacirepvecum #
 rilimogene galvacirepvec                    recombinant replicating vaccinia viral vector expressing a modified
                                             prostate specific antigen (PSA) plus three co-stimulatory molecules,
                                             lymphocyte associated function antigen-3 (LFA-3), intracellular
                                             adhesion molecule-1 (ICAM-1) and B7.1.

 rilimogène galvacirépvec                    vecteur viral recombinant de la vaccine répliquant exprimant un
                                             antigène modifié spécifique de la prostate et trois protéines co-
                                             stimulantes (antigène 3 associé aux fonctions lymphocytaires (LFA-
                                             3), molécule d'adhésion intracellulaire-1 (ICAM-1) et B7.1)

 rilimogén galvacirepvec                     vector viral recombinante de la vacuna replicante que expresa un
                                             antígeno modificado especifico prostático y tres proteínas co-
                                             stimulantes (antígeno 3 asociado a las funciones limfocitarias (LFA-
                                             3), molécula d'adhesión intracelular-1 (ICAM-1) y B7.1)




 rilimogenum glafolivecum #
 rilimogene glafolivec                       recombinant non-replicating fowlpox viral vector expressing a
                                             modified prostate specific antigen (PSA) plus three co-stimulatory
                                             molecules, lymphocyte associated function antigen-3 (LFA-3),
                                             intracellular adhesion molecule-1 (ICAM-1) and B7.1

 rilimogène glafolivec                       vecteur viral recombinant non-répliquant de la variole aviaire
                                             exprimant un antigène modifié spécifique de la prostate et trois
                                             protéines co-stimulantes (antigène 3 associé aux fonctions
                                             lymphocytaires (LFA-3), molécule d'adhésion intracellulaire-1 (ICAM-
                                             1) et B7.1)

 rilimogén glafolivec                        vector viral recombinante no-replicante de la viruela aviar que
                                             expresa un antígeno modificado especifico prostático y tres
                                             proteínas co-stimulantes (antígeno 3 asociado a las funciones
                                             limfocitarias (LFA-3), molécula d'adhesión intracelular-1 (ICAM-1) y
                                             B7.1)



rovatirelinum
rovatirelin                                 (4S,5S)-5-methyl-N-{(2S)-1-[(2R)-2-methylpyrrolidin-1-yl]-1-oxo-
                                            3-[(1,3-thiazol-4-yl)methyl]propan-2-yl}-2-oxo-1,3-oxazolidine-
                                            4-carboxamide

rovatiréline                                (4S,5S)-5-méthyl-N-{(2S)-1-[(2R)-2-méthylpyrrolidin-1-yl]-1-oxo-
                                            3-[(1,3-thiazol-4-yl)méthyl]propan-2-yl}-2-oxo-1,3-oxazolidine-
                                            4-carboxamide




                                                                                                                    77
Recommended INN: List 69                                         WHO Drug Information Vol. 27, No. 1, 2013




 rovatirelina               4S,5S)-5-metil-N-{(2S)-1-[(2R)-2-metilpirrolidin-1-il]-1-oxo-
                            3-[(1,3-tiazol-4-il)metil]propan-2-il}-2-oxo-1,3-oxazolidina-
                            4-carboxamida

                            C16H22N4O4S

                             O       H
                                     N                   O     H
                                            H H                       CH3
                                              N
                                 O                           N
                                         H O        H
                                 H3C
                                                N

                                                    S



 sebelipasum alfa #
 sebelipase alfa            human lysosomal acid lipase/cholesteryl ester hydrolase (cholesteryl
                            esterase, lipase A, EC=3.1.1.13) glycosylated (produced in
                            transgenic Gallus)

 sébélipase alfa            lipase acide lysosomale/hydrolase d'esters de cholesterol
                            (cholestéryl estérase, lipase A, EC=3.1.1.13), enzyme humaine
                            glycosylée produite par Gallus transgénique

 sebelipasa alfa            lipasa ácida lisosómica/hidrolasa de los ésteres de colesterol
                            (colesteril esterasa, lipasa A, EC=3.1.1.13), enzima humana
                            glicosilada producida por Gallus transgénico

                             SGGKLTAVDP      ETNMNVSEII       SYWGFPSEEY       LVETEDGYIL       CLNRIPHGRK      50
                             NHSDKGPKPV      VFLQHGLLAD       SSNWVTNLAN       SSLGFILADA       GFDVWMGNSR      100
                             GNTWSRKHKT      LSVSQDEFWA       FSYDEMAKYD       LPASINFILN       KTGQEQVYYV      150
                             GHSQGTTIGF      IAFSQIPELA       KRIKMFFALG       PVASVAFCTS       PMAKLGRLPD      200
                             HLIKDLFGDK      EFLPQSAFLK       WLGTHVCTHV       ILKELCGNLC       FLLCGFNERN      250
                             LNMSRVDVYT      THSPAGTSVQ       NMLHWSQAVK       FQKFQAFDWG       SSAKNYFHYN      300
                             QSYPPTYNVK      DMLVPTAVWS       GGHDWLADVY       DVNILLTQIT       NLVFHESIPE      350
                             WEHLDFIWGL      DAPWRLYNKI       INLMRKYQ                                          378

                             Disulfide bridges location* / Positions* des ponts disulfure / Posiciones* de los puentes disulfuro
                             41-188 227-236 240-244
                             * predicted / prévues / previstas

                             Glycosylation sites (N) / sites de glycosylation (N)/ posiciones de glicosilación (N)
                             Asn-15 Asn-80 Asn-140 Asn-252 Asn-300




senrebotasum #
senrebotase                L-methionylglycyl-L-seryl-des-(445-glycine,446-L-tyrosine)-
                           [2-L-glutamic acid,432,442,444,447-tetra- L-aspartic acid]botulinum
                           neurotoxin A precursor 27-L-alanine variant light chain (433-41')-
                           disulfide with [14-L-arginine,15-L-lysine]human nociceptin fusion
                           protein with L-alanyl-L-leucyl-L-alanyltris(tetraglycyl-L-seryl)-
                           [3-L-valine,4-L-leucine,5-L-glutamine-418-L-leucine,419-L-aspartic
                           acid]botulinum neurotoxin A heavy chain-(1-419)-peptide

senrébotase                L-méthionylglycyl-L-séryl-dès-(445-glycine,446-L-tyrosine)-[2-L-acide
                           glutamique,432,442,444,447-tétra-L-acide aspartique]chaîne légère
                           du 27-L-alanine-variant du précurseur de la neurotoxine A botulique
                           (433-41')-disulfure avec le [14-L-arginine,15-L-lysine]nociceptine
                           humaine protéine de fusion avec le L-alanyl-L-leucyl-
                           L-alanyltris(tétraglycyl-L-seryl)-[3-L-valine,4-L-leucine,5-L-glutamine-
                           418-L-leucine,419-L-acide aspartique]chaîne lourde de la
                           neurotoxine A botulique-(1-419)-peptide




78
WHO Drug Information Vol. 27, No. 1, 2013                                                          Recommended INN: List 69




 senrebotasa                                 L-metionilglicil-L-seril-des-(445-glicina,446-L-tirosina)-[2-L-ácido
                                             glutámico,432,442,444,447-tetra-L-ácido aspártico]cadena ligera de
                                             la 27-L-alanina-variante del precursor de la neurotoxina botulínica A
                                             (433-41')-disulfuro con la [14-L-arginina,15-L-lisina]nociceptina
                                             humana proteína de fusión con el L-alanil-L-leucil-
                                             L-alaniltris(tetraglicil-L-seril)-[3-L-valina,4-L-leucina,5-L-glutamina-
                                             418-L-leucina,419-L-ácido aspártico]cadena pesada de la
                                             neurotoxina botulínica A-(1-419)-péptido

                                              Light chain / Chaîne légère / Cadena ligera
                                              MGSMEFVNKQ FNYKDPVNGV DIAYIKIPNA                  GQMQPVKAFK       IHNKIWVIPE      50
                                              RDTFTNPEEG DLNPPPEAKQ VPVSYYDSTY                  LSTDNEKDNY       LKGVTKLFER      100
                                              IYSTDLGRML LTSIVRGIPF WGGSTIDTEL                  KVIDTNCINV       IQPDGSYRSE      150
                                              ELNLVIIGPS ADIIQFECKS FGHEVLNLTR                  NGYGSTQYIR       FSPDFTFGFE      200
                                              ESLEVDTNPL LGAGKFATDP AVTLAHELIH                  AGHRLYGIAI       NPNRVFKVNT      250
                                              NAYYEMSGLE VSFEELRTFG GHDAKFIDSL                  QENEFRLYYY       NKFKDIASTL      300
                                              NKAKSIVGTT ASLQYMKNVF KEKYLLSEDT                  SGKFSVDKLK       FDKLYKMLTE      350
                                              IYTEDNFVKF FKVLNRKTYL NFDKAVFKIN                  IVPKVNYTIY       DGFNLRNTNL      400
                                              AANFNGQNTE INNMNFTKLK NFTGLFEFYK                  LLCVDGIITS       KTKSDDDDK       449

                                              Heavy chain / Chaîne lourde / Cadena pesada
                                              FGGFTGARKS ARKRKNQALA GGGGSGGGGS                  GGGGSALVLQ       CIKVNNWDLF      50'
                                              FSPSEDNFTN DLNKGEEITS DTNIEAAEEN                  ISLDLIQQYY       LTFNFDNEPE      100'
                                              NISIENLSSD IIGQLELMPN IERFPNGKKY                  ELDKYTMFHY       LRAQEFEHGK      150'
                                              SRIALTNSVN EALLNPSRVY TFFSSDYVKK                  VNKATEAAMF       LGWVEQLVYD      200'
                                              FTDETSEVST TDKIADITII IPYIGPALNI                  GNMLYKDDFV       GALIFSGAVI      250'
                                              LLEFIPEIAI PVLGTFALVS YIANKVLTVQ                  TIDNALSKRN       EKWDEVYKYI      300'
                                              VTNWLAKVNT QIDLIRKKMK EALENQAEAT                  KAIINYQYNQ       YTEEEKNNIN      350'
                                              FNIDDLSSKL NESINKAMIN INKFLNQCSV                  SYLMNSMIPY       GVKRLEDFDA      400'
                                              SLKDALLKYI YDNRGTLIGQ VDRLKDKVNN                  TLSTDIPFQL       SKYVDNQRLL      450'
                                              STLD                                                                               454'

                                              Disulfide bridge location / Position du pont disulfure / Posición del puente disulfuro
                                              433-41'



 sepranolonum
 sepranolone                                 3β-hydroxy-5α-pregnan-20-one

 sépranolone                                 3β-hydroxy-5α-prégnan-20-one

 sepranolona                                 3β-hidroxi-5α-pregnan-20-ona

                                             C21H34O2
                                                                          O
                                                                               CH3
                                                                      CH3
                                                                              H
                                                         CH3      H

                                                              H       H
                                              H
                                              HO         H

simtuzumabum #
simtuzumab                                  immunoglobulin G4-kappa, anti-[Homo sapiens LOXL2 (lysyl
                                            oxidase-like 2)], humanized monoclonal antibody;
                                            gamma4 heavy chain (1-443) [humanized VH (Homo sapiens
                                            IGHV1-2*02 (80.60%) -(IGHD)-IGHJ4*01 L123>T (111) [8.8.9] (1-
                                            116) -Homo sapiens IGHG4*01 hinge S10>P (224) (117-443)], (130-
                                            219')-disulfide with kappa light chain (1'-219') [humanized V-KAPPA
                                            (Homo sapiens IGKV2D-29*02 (86.00%) -IGKJ4*01) [11.3.9] (1'-
                                            112') -Homo sapiens IGKC*01 (113'-219')]; (222-222":225-225")-
                                            bisdisulfide dimer




                                                                                                                                       79
Recommended INN: List 69                                     WHO Drug Information Vol. 27, No. 1, 2013


 simtuzumab                immunoglobuline G4-kappa, anti-[Homo sapiens LOXL2 (protéine 2
                           lysyl oxidase-like)], anticorps monoclonal humanisé;
                           chaîne lourde gamma4 (1-443) [VH humanisé (Homo sapiens
                           IGHV1-2*02 (80.60%) -(IGHD)-IGHJ4*01 L123>T (111) [8.8.9] (1-
                           116) -Homo sapiens IGHG4*01 charnière S10>P (224) (117-443)],
                           (130-219')-disulfure avec la chaîne légère kappa (1'-219') [V-KAPPA
                           humanisé (Homo sapiens IGKV2D-29*02 (86.00%) -IGKJ4*01)
                           [11.3.9] (1'-112') -Homo sapiens IGKC*01 (113'-219')]; dimère (222-
                           222":225-225")-bisdisulfure

 simtuzumab                inmunoglobulina G4-kappa, anti-[LOXL2 de Homo sapiens (lysyl
                           oxidase-like 2)], anticuerpo monoclonal humanizado;
                           cadena pesada gamma4 (1-443) [VH humanizado (Homo sapiens
                           IGHV1-2*02 (80.60%) -(IGHD)-IGHJ4*01 L123>T (111) [8.8.9] (1-
                           116) -Homo sapiens IGHG4*01 bisagra S10>P (224) (117-443)],
                           (130-219')-disulfuro con la cadena ligera kappa (1'-219') [V-KAPPA
                           humanizado (Homo sapiens IGKV2D-29*02 (86.00%) -IGKJ4*01)
                           [11.3.9] (1'-112') -Homo sapiens IGKC*01 (113'-219')]; dímero (222-
                           222":225-225")-bisdisulfuro


                           Heavy chain / Chaîne lourde / Cadena pesada
                           QVQLVQSGAE VKKPGASVKV SCKASGYAFT                  YYLIEWVRQA       PGQGLEWIGV       50
                           INPGSGGTNY NEKFKGRATI TADKSTSTAY                  MELSSLRSED       TAVYFCARNW      100
                           MNFDYWGQGT TVTVSSASTK GPSVFPLAPC                  SRSTSESTAA       LGCLVKDYFP      150
                           EPVTVSWNSG ALTSGVHTFP AVLQSSGLYS                  LSSVVTVPSS       SLGTKTYTCN      200
                           VDHKPSNTKV DKRVESKYGP PCPPCPAPEF                  LGGPSVFLFP       PKPKDTLMIS      250
                           RTPEVTCVVV DVSQEDPEVQ FNWYVDGVEV                  HNAKTKPREE       QFNSTYRVVS      300
                           VLTVLHQDWL NGKEYKCKVS NKGLPSSIEK                  TISKAKGQPR       EPQVYTLPPS      350
                           QEEMTKNQVS LTCLVKGFYP SDIAVEWESN                  GQPENNYKTT       PPVLDSDGSF      400
                           FLYSRLTVDK SRWQEGNVFS CSVMHEALHN                  HYTQKSLSLS       LGK             443

                           Light chain / Chaîne légère / Cadena ligera
                           DIVMTQTPLS LSVTPGQPAS ISCRSSKSLL                  HSNGNTYLYW       FLQKPGQSPQ 50
                           FLIYRMSNLA SGVPDRFSGS GSGTDFTLKI                  SRVEAEDVGV       YYCMQHLEYP 100
                           YTFGGGTKVE IKRTVAAPSV FIFPPSDEQL                  KSGTASVVCL       LNNFYPREAK 150
                           VQWKVDNALQ SGNSQESVTE QDSKDSTYSL                  SSTLTLSKAD       YEKHKVYACE 200
                           VTHQGLSSPV TKSFNRGEC                                                          219

                           Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
                           Intra-H 22-96 143-199              257-317  363-421
                                    22''-96'' 143''-199'' 257''-317'' 363''-421''
                           Intra-L 23'-93' 139'-199'
                                    23'''-93''' 139'''-199'''
                           Inter-H-L 130-219' 130''-219'''
                           Inter-H-H 222-222'' 225-225''

                           N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación
                           H CH2 N84.4:
                           293, 293''




 sonidegibum
 sonidegib                 N-{6-[(2R,6S)-2,6-dimethylmorpholin-4-yl]pyridin-3-yl}-2-methyl-
                           4'-(trifluoromethoxy)-[1,1'-biphenyl]-3-carboxamide

 sonidégib                 N-{6-[(2R,6S)-2,6-diméthylmorpholin-4-yl]pyridin-3-yl}-2-méthyl-
                           4'-(trifluorométhoxy)-[1,1'-biphényl]-3-carboxamide

 sonidegib                 N-{6-[(2R,6S)-2,6-dimetilmorfolin-4-il]piridin-3-il}-2-metil-
                           4'-(trifluorometoxi)-[1,1'-bifenil]-3-carboxamida




80
WHO Drug Information Vol. 27, No. 1, 2013                                                                  Recommended INN: List 69


                                            C26H26F3N3O3
                                                                                                           H CH3

                                                                                                                     O
                                                    O                                                    N                   CH3
                                            F3C                            CH3     O
                                                                                                                         H
                                                                                                    N
                                                                                        N
                                                                                        H



 sonolisibum
 sonolisib                                  (4E)-4-{[(bis(prop-2-en-1-yl)amino]methylidene}-6-hydroxy-
                                            1α-(methoxymethyl)-3,7,17-trioxo-2-oxaandrosta-5,8-dien-
                                            11α-yl acetate

 sonolisib                                  acétate de (4E)-4-{[(bis(prop-2-én-1-yl)amino]méthylidène}-
                                            6-hydroxy-1α-(méthoxyméthyl)-3,7,17-trioxo-2-oxaandrosta-
                                            5,8-dién-11α-yle

 sonolisib                                  acetato de (4E)-4-{[(bis(prop-2-en-1-il)amino]metilideno}-6-hidroxi-
                                            1α-(metoximetil)-3,7,17-trioxo-2-oxaandrosta-5,8-dien-11α-ilo

                                            C29H35NO5
                                                           O        CH3
                                                                    H       CH3 O
                                                     O         O
                                            H3C
                                                     H         CH3
                                                     O
                                                                            H
                                                O                          O
                                                                    OH
                                                                             CH2
                                                                N
                                                    H 2C


 surotomycinum
 surotomycin                                N-[(2E)-3-(4-pentylphenyl)but-2-enoyl]-L-tryptophyl-D-asparaginyl-
                                            L-α-aspartyl-L-threonylglycyl-L-ornithyl-L-α-aspartyl-D-alanyl-
                                            L-α-aspartylglycyl-D-seryl-(3R)-3-methyl-L-α-glutamyl-
                                            3-(2-aminobenzoyl)-L-alanine 13→4-lactone

 surotomycine                               N-[(2E)-3-(4-pentylphényl)but-2-ènoyl]-L-tryptophyl-D-asparaginyl-
                                            L-α-aspartyl-L-thréonylglycyl-L-ornithyl-L-α-aspartyl-D-alanyl-
                                            L-α-aspartylglycyl-D-séryl-(3R)-3-méthyl-L-α-glutamyl-
                                            3-(2-aminobenzoyl)-L-alanine 13→4-lactone

 surotomicina                               N-[(2E)-3-(4-pentilfenil)but-2-enoil]-L-triptofil-D-asparaginil-
                                            L-α-aspartil-L-treonilglicil-L-ornitil-L-α-aspartil-D-alanil-
                                            L-α-aspartilglicil-D-seril-(3R)-3-metil-L-α-glutamll-3-(2-aminobenzoil)-
                                            L-alanina 13→4-lactona

                                            C77H101N17O26
                                            O
                                                     L-Trp     D-Asn       L-Asp    L-Thr     Gly       L-Orn        L-Asp       D-Ala     L-Asp
                                                                                      O             O
                                                         CH3
                                                                                               H             H
                                                                                               N             N           D-Ser           Gly
                                                                                    O
                                                                                                                 H
                                                                                         H          H
                                                                                                                 CH3

                                                                                              O            CO2H
                                                                     CH3                NH2



                                                                                                                                                   81
Recommended INN: List 69                                               WHO Drug Information Vol. 27, No. 1, 2013



                    99m
 technetium ( Tc) etarfolatidum
             99m                                       2
 technetium ( Tc) etarfolatide          (SPY-5-24)-[N -(4-{[(2-amino-4-oxo-1,4-dihydropteridin-
                                        6-yl)methyl]amino}benzoyl)-D-γ-glutamyl-(2S)-2-(amino-kN)-β-alanyl-
                                                                                 99m
                                        L-α-aspartyl-κN-L-cysteinato-κN,κS]oxido[ Tc]technetate

                99m                                    2
 technétium (        Tc) étarfolatide   (SPY-5-24)-[N -(4-{[(2-amino-4-oxo-1,4-dihydroptéridin-
                                        6-yl)méthyl]amino}benzoyl)-D-γ-glutamyl-(2S)-2-(amino-kN)-β-alanyl-
                                                                                 99m
                                        L-α-aspartyl-κN-L-cystéinato-κN,κS]oxido[ Tc]technétate

              99m                                      2
 tecnecio (     Tc) etarfolatida        (SPY-5-24)-[N -(4-{[(2-amino-4-oxo-1,4-dihidropteridin-
                                        6-il)metil]amino}benzoil)-D-γ-glutamil-(2S)-2-(amino-kN)-β-alanil-
                                                                                  99m
                                        L-α-aspartil-κN-L-cisteinato-κN,κS]oxido[ Tc]tecnetato

                                        C29H32N11O12STc

                                                                                     O     H     CO2H
                                                                                                                     O
                                                   O                                     N
                                                                                         H
                                                       N                                                  HN
                                              N                    N                                     O
                                                                   H                                                     H
                                        H2N        N   N                             HO2C
                                                   H                                                     N       O       NH2
                                                                                             H
                                                                                                         99m Tc


                                                                                             O           N               S

                                                                                                 HO2C
                                                                                                             H

 tenapanorum
 tenapanor                              N,N'-(10,17,-dioxo-3,6,21,24-tetraoxa-9,11,16,18-
                                        tetraazahexacosane-1,26-diyl)bis{[(4S)-6,8-dichloro-2-methyl-
                                        1,2,3,4-tetrahydroisoquinolin-4-yl]benzenesulfonamide}

 ténapanor                              N,N'-(10,17,-dioxo-3,6,21,24-tétraoxa-9,11,16,18-
                                        tétraazahexacosane-1,26-diyl)bis{[(4S)-6,8-dichloro-2-méthyl-
                                        1,2,3,4-tétrahydroisoquinoléin-4-yl]benzènesulfonamide}

 tenapanor                              N,N'-(10,17,-dioxo-3,6,21,24-tetraoxa-9,11,16,18-
                                        tetraazahexacosano-1,26-diol)bis{[(4S)-6,8-dicloro-2-metil-1,2,3,4-
                                        tetrahidroisoquinolin-4-il]bencenosulfonamida}

                                        C50H66Cl4N8O10S2

                                              Cl                                                                                 Cl
                                                            CH3    O                                 O       H 3C
                                                       N                                                             N

                                        Cl                  O              NH              HN                    O                    Cl
                                                   H                                                                         H
                                                                       O        NH    HN         O
                                                              NH                                         HN
                                                            S                                                 S
                                                           O O                                               O O


 trabodenosonum
                                         6
 trabodenoson                           N -cyclopentyladenosine 5'-nitrate
                                                       6
 trabodénoson                           5'-nitrate de N -cyclopentyladénosine
                                                       6
 trabodenosón                           5'-nitrato de N -ciclopentiladenosina



82
WHO Drug Information Vol. 27, No. 1, 2013                                                              Recommended INN: List 69


                                            C15H20N6O6


                                                                  HN

                                                                             N
                                                              N

                                                                   N         N
                                                    O
                                            O 2N                   O




                                                              OH        OH

 trempamotidum
 trempamotide                               human kinesin like protein KIF20B (M phase phosphoprotein 1)-
                                            (278-286)-peptide

 trempamotide                               membre 20B des protéines de la famille des kinésines humaines
                                            (phosphoprotéine 1 de la phase M)-(278-286)-peptide

 trempamotida                               miembro 20B de las proteínas de la familia de las kinesinas
                                            humanas (fosfoproteína 1 de la fase M)-(278-286)-péptido

                                            C58H80N10O18

                                            H Ile       Tyr       Asn    Glu     Tyr   Ile   Tyr    Asp   Leu OH

 trenonacogum alfa #
 trenonacog alfa                            human coagulation factor IX (EC 3.4.21.22, Christmas factor, plasma
                                            thromboplastin component), 148-threonine variant, produced in
                                            Chinese Hamster Ovary (CHO) cells (alfa glycoform)

 trénonacog alfa                            variant 148-thréonine du facteur IX humain de coagulation (EC
                                            3.4.21.22, facteur Christmas, facteur antihémophilique B) produit par
                                            culture de cellules ovariennes de hamster chinois (CHO) (glycoforme
                                            alfa)

 trenonacog alfa                            148-treonina-variante del factor IX humano de la coagulación
                                            sanguínea (EC 3.4.21.22, factor Christmas, factor antihemofílico B)
                                            producido por cultivo de células ováricas de hamster chinos (CHO)
                                            (glicoforma alfa)

                                            YNSGKLEEFV            QGNLERECME     EKCSFEEARE        VFENTERTTE   FWKQYVDGDQ     50
                                            CESNPCLNGG            SCKDDINSYE     CWCPFGFEGK        NCELDVTCNI   KNGRCEQFCK     100
                                            NSADNKVVCS            CTEGYRLAEN     QKSCEPAVPF        PCGRVSVSQT   SKLTRAETVF     150
                                            PDVDYVNSTE            AETILDNITQ     STQSFNDFTR        VVGGEDAKPG   QFPWQVVLNG     200
                                            KVDAFCGGSI            VNEKWIVTAA     HCVETGVKIT        VVAGEHNIEE   TEHTEQKRNV     250
                                            IRIIPHHNYN            AAINKYNHDI     ALLELDEPLV        LNSYVTPICI   ADKEYTNIFL     300
                                            KFGSGYVSGW            GRVFHKGRSA     LVLQYLRVPL        VDRATCLRST   KFTIYNNMFC     350
                                            AGFHEGGRDS            CQGDSGGPHV     TEVEGTSFLT        GIISWGEECA   MKGKYGIYTK     400
                                            VSRYVNWIKE            KTKLT                                                        415

                                            Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
                                            18-23     51-62      56-71     73-82      88-99 95-109
                                            111-124 132-289 206-222 336-350 361-389

                                            Modified residues / Résidus modifiés / Restos modificados
                                            E
                                            7-8-15-17-20-21-26-27-30-33-36-40             HO2C H            NH2
                                            4-carboxyGlu
                                                                                             HO2C               CO2H

                                            Glycosylation sites (N) / Sites de glycosylation (N) / Posiciones de glicosilación (N)
                                            Asn-157 Asn-167




                                                                                                                                         83
Recommended INN: List 69                                     WHO Drug Information Vol. 27, No. 1, 2013




 trifarotenum
 trifarotene                3''-tert-butyl-4'-(2-hydroxyethoxy)-4''-(pyrrolidin-
                            1-yl)[1,1':3',1'']terphenyl-4-carboxylic acid

 trifarotène                acide 3''-tert-butyl-4'-(2-hydroxyéthoxy)-4''-(pyrrolidin-
                            1-yl)[1,1':3',1'']terphényl-4-carboxylique

 trifaroteno                ácido 3''-terc-butil-4'-(2-hidroxietoxi)-4''-(pirrolidin-
                            1-il)[1,1':3',1'']terfenil-4-carboxílico

                            C29H33NO4
                                            O
                                HO




                                   N                                    CO2H
                                           CH3
                                   H3C
                                          CH3



 vercirnonum
 vercirnon                  4-[5-chloro-2-(4-tert-butylbenzenesulfonamido)benzoyl]pyridine
                            N-oxide

 vercirnon                  4-[5-chloro-2-(4-tert-butylbenzènesulfonamido)benzoyl]pyridine
                            N-oxide

 vercirnón                  N-óxido de 4-[5-cloro-2-(4-terc-
                            butilbencenosulfonamido)benzoil]piridina

                            C22H21ClN2O4S
                                                                            O
                              H3C CH3                                   N
                                                         O
                             H3C
                                                     H
                                                     N
                                                 S
                                                O O
                                                                   Cl



vintafolidum #
vintafolide                N-(4-{[(2-amino-4-oxo-1,4-dihydropteridin-
                           6-yl)methyl]amino}benzoyl)-L-γ-glutamyl-L-α-aspartyl-L-arginyl-
                           L-α-aspartyl-L-α-aspartyl-L-cysteine disulfide with methyl (5S,7R,9S)-
                           5-ethyl-9-[(3aR,4R,5S,5aR,10bR,13aR)-3a-ethyl-4,5-dihydroxy-
                           8-methoxy-6-methyl-5-({2-[(2-
                           sulfanylethoxy)carbonyl]hydrazinyl}carbonyl)-3a,4,5,5a,6,11,12,13a-
                           octahydro-1H-indolizino[8,1-cd]carbazol-9-yl]-5-hydroxy-
                           1,4,5,6,7,8,9,10-octahydro-2H-3,7-methanoazacycloundecino[5,4-
                           b]indol-9-carboxylate

vintafolide                N-(4-{[(2-amino-4-oxo-1,4-dihydroptéridin-
                           6-yl)méthyl]amino}benzoyl)-L-γ-glutamyl-L-α-aspartyl-L-arginyl-
                           L-α-aspartyl-L-α-aspartyl-3-{2-[2-({[2-({(3aR,4R,5S,5aR,10bR,13aR)-
                           3a-éthyl-9-[(5S,7R,9S)-5-éthyl-5-hydroxy-9-(méthoxycarbonyl)-
                           1,4,5,6,7,8,9,10-octahydro-2H-3,7-méthanoazacycloundécino[5,4-
                           b]indol-9-yl]-4,5-dihydroxy-8-méthoxy-6-méthyl-
                           3a,4,5,5a,6,11,12,13a-octahydro-1H-indolizino[8,1-cd]carbazol-
                           9-yl}carbonyl)hydrazino]carbonyl}oxy)éthyl]disulfanyl}-L-alanine


84
WHO Drug Information Vol. 27, No. 1, 2013                                                                  Recommended INN: List 69


 vintafolida                                N-(4-{[(2-amino-4-oxo-1,4-dihidropteridina-6-il)metil]amino}benzoil)-
                                            L-γ-glutamil-L-α-aspartil-L-arginil-L-α-aspartil-L-α-aspartil-3-{2-[2-({[2-
                                            ({(3aR,4R,5S,5aR,10bR,13aR)-3a-etil-9-[(5S,7R,9S)-5-etil-5-hidroxi-
                                            9-(metoxicarbonil)-1,4,5,6,7,8,9,10-octahidro-2H-3,7-
                                            metanoazacicloundecino[5,4-b]indol-9-il]-4,5-dihidroxi-8-metoxi-
                                            6-metil-3a,4,5,5a,6,11,12,13a-octahidro-1H-indolizino[8,1-
                                            cd]carbazol-9-il}carbonil)hidrazino]carbonil}oxi)etil]disulfanil}-
                                            L-alanina

                                                                             CH3
                                                               N            OH

                                                                               N    H        CH3
                                                                       H
                                                                                             OH
                                                       N                            H                      O
                                                       H                                     H H
                                                   O
                                            H3C                                                N
                                                           H3CO               N         OH         N           O
                                                       O                                           H
                                                                                  CH3        O                         S
                                                                                                       H           S
                                                                   O
                                                                           Asp Arg Asp Asp             N       CO2H
                                                                                                       H
                                                       H

                                                  HO2C         NH

                                                           O

                                                                              N              N
                                                                              H
                                                                                        N
                                                                                                  NH

                                                                                        O    N         NH2
 vocimagenum amiretrorepvecum #
 vocimagene amiretrorepvec                  recombinant replication-competent retrovirus vector encoding a
                                            human codon optimized yeast cytosine deaminase gene, carrying
                                            three stabilizing point mutations (A23L/ V108T/I140L) and translated
                                            via an EMCV IRES (encephalomyocarditis virus internal ribosomal
                                            entry site)

 vocimagène amirétrorépvec                  vecteur rétroviral recombinant répliquant codant le gène de la
                                            cytosine désaminase de levure optimisé par des codons humains,
                                            comprenant trois points de mutations stabilisants (A23L/
                                            V108T/I140L) et traduit sous le contrôle de la séquence IRES (site
                                            d'entrée interne du ribososme) du virus de l'encéphalomyocardite
                                            (EMCV)

 vocimagén amiretrorepvec                   vector retroviral recombinante replicante que codifica el gen de la
                                            citosina desaminasa de levadura optimizada por codones humanos,
                                            que comprende tres puntos de mutaciones estabilizadores (A23L/
                                            V108T/I140L) y traducido bajo el control de la secuencia IRES (sitio
                                            de entrada interna del ribososma) del virus de la encefalomiocarditis
                                            (EMCV)


 vorsetuzumabum #
 vorsetuzumab                               immunoglobulin G1-kappa, anti-[Homo sapiens CD70 (tumor
                                            necrosis factor superfamily member 7, TNFSF7, CD27LG, CD27L)],
                                            humanized monoclonal antibody;
                                            gamma1 heavy chain (1-448) [humanized VH (Homo sapiens
                                            IGHV1-2*02 (86.70%) -(IGHD)-IGHJ6*01) [8.8.11] (1-118) -Homo
                                            sapiens IGHG1*01 (119-448)], (221-218')-disulfide with kappa light
                                            chain (1'-218') [humanized V-KAPPA (Homo sapiens IGKV4-1*01
                                            (79.20%) -IGKJ1*01) [10.3.9] (1'-111') -Homo sapiens IGKC*01
                                            (112'-218')]; (227-227":230-230")-bisdisulfide dimer


                                                                                                                                 85
Recommended INN: List 69                                           WHO Drug Information Vol. 27, No. 1, 2013




 vorsétuzumab                   immunoglobuline G1-kappa, anti-[Homo sapiens CD70 (membre 7
                                de la superfamille du facteur de nécrose tumorale (TNF), TNFSF7,
                                CD27LG, CD27L)], anticorps monoclonal humanisé;
                                chaîne lourde gamma1 (1-448) [VH humanisé (Homo sapiens
                                IGHV1-2*02 (86.70%) -(IGHD)-IGHJ6*01) [8.8.11] (1-118) -Homo
                                sapiens IGHG1*01 (119-448)], (221-218'-disulfure avec la chaîne
                                légère kappa (1'-218') [V-KAPPA humanisé (Homo sapiens IGKV4-
                                1*01 (79.20%) -IGKJ1*01) [10.3.9] (1'-111') -Homo sapiens IGKC*01
                                (112'-218')]; dimère (227-227":230-230")-bisdisulfure

 vorsetuzumab                   inmunoglobulina G1-kappa, anti-[CD70 de Homo sapiens (miembro
                                7 de la superfamilia del factor de necrosis tumoral (TNF), TNFSF7,
                                CD27LG, CD27L)], anticuerpo monoclonal humanizado;
                                cadena pesada gamma1 (1-448) [VH humanizado (Homo sapiens
                                IGHV1-2*02 (86.70%) -(IGHD)-IGHJ6*01) [8.8.11] (1-118) -Homo
                                sapiens IGHG1*01 (119-448)], (221-218'-disulfuro con la cadena
                                ligera kappa (1'-218') [V-KAPPA humanizada (Homo sapiens IGKV4-
                                1*01 (79.20%) -IGKJ1*01) [10.3.9] (1'-111') -Homo sapiens IGKC*01
                                (112'-218')]; dímero (227-227":230-230")-bisdisulfuro

                                 Heavy chain / Chaîne lourde / Cadena pesada
                                 QVQLVQSGAE VKKPGASVKV SCKASGYTFT                  NYGMNWVRQA       PGQGLKWMGW       50
                                 INTYTGEPTY ADAFKGRVTM TRDTSISTAY                  MELSRLRSDD       TAVYYCARDY      100
                                 GDYGMDYWGQ GTTVTVSSAS TKGPSVFPLA                  PSSKSTSGGT       AALGCLVKDY      150
                                 FPEPVTVSWN SGALTSGVHT FPAVLQSSGL                  YSLSSVVTVP       SSSLGTQTYI      200
                                 CNVNHKPSNT KVDKKVEPKS CDKTHTCPPC                  PAPELLGGPS       VFLFPPKPKD      250
                                 TLMISRTPEV TCVVVDVSHE DPEVKFNWYV                  DGVEVHNAKT       KPREEQYNST      300
                                 YRVVSVLTVL HQDWLNGKEY KCKVSNKALP                  APIEKTISKA       KGQPREPQVY      350
                                 TLPPSRDELT KNQVSLTCLV KGFYPSDIAV                  EWESNGQPEN       NYKTTPPVLD      400
                                 SDGSFFLYSK LTVDKSRWQQ GNVFSCSVMH                  EALHNHYTQK       SLSLSPGK        448

                                 Light chain / Chaîne légère / Cadena ligera
                                 DIVMTQSPDS LAVSLGERAT INCRASKSVS                  TSGYSFMHWY       QQKPGQPPKL 50
                                 LIYLASNLES GVPDRFSGSG SGTDFTLTIS                  SLQAEDVAVY       YCQHSREVPW 100
                                 TFGQGTKVEI KRTVAAPSVF IFPPSDEQLK                  SGTASVVCLL       NNFYPREAKV 150
                                 QWKVDNALQS GNSQESVTEQ DSKDSTYSLS                  STLTLSKADY       EKHKVYACEV 200
                                 THQGLSSPVT KSFNRGEC                                                           218

                                 Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
                                 Intra-H 22-96        145-201 262-322        368-426
                                          22''-96'' 145''-201'' 262''-322'' 368''-426''
                                 Intra-L 23'-92' 138'-198'
                                          23'''-92''' 138'''-198'''
                                 Inter-H-L 221-218' 221''-218'''
                                 Inter-H-H 227-227'' 230-230''

                                 N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación
                                 H CH2 N84.4:
                                 298, 298''



vorsetuzumabum mafodotinum #
vorsetuzumab mafodotin         immunoglobulin G1-kappa auristatin F conjugate, anti-[Homo
                               sapiens CD70 (tumor necrosis factor superfamily member 7,
                               TNFSF7, CD27LG, CD27L)], humanized monoclonal antibody
                               conjugated to auristatin F;
                               gamma1 heavy chain (1-448) [humanized VH (Homo sapiens
                               IGHV1-2*02 (86.70%) -(IGHD)-IGHJ6*01) [8.8.11] (1-118) -Homo
                               sapiens IGHG1*01 (119-448)], (221-218')-disulfide (if not
                               conjugated) with kappa light chain (1'-218') [humanized V-KAPPA
                               (Homo sapiens IGKV4-1*01 (79.20%) -IGKJ1*01) [10.3.9] (1'-111') -
                               Homo sapiens IGKC*01 (112'-218')]; (227-227":230-230")-
                               bisdisulfide dimer; conjugated, on an average of 3 to 5 cysteinyl, to
                               monomethylauristatin F (MMAF), via a noncleavable
                               maleimidocaproyl (mc) linker
                               For the mafodotin part, please refer to the document "INN for
                               pharmaceutical substances: Names for radicals, groups and others"*.




86
WHO Drug Information Vol. 27, No. 1, 2013                                                           Recommended INN: List 69




 vorsétuzumab mafodotine                    immunoglobuline G1-kappa conjuguée à l'auristatine F, anti-[Homo
                                            sapiens CD70 (membre 7 de la superfamille du TNF, TNFSF7,
                                            CD27LG, CD27L)], anticorps monoclonal humanisé conjugué à
                                            l'auristatine F;
                                            chaîne lourde gamma1 (1-448) [VH humanisé (Homo sapiens
                                            IGHV1-2*02 (86.70%) -(IGHD)-IGHJ6*01) [8.8.11] (1-118) -Homo
                                            sapiens IGHG1*01 (119-448)], (221-218'-disulfure (si non conjugué)
                                            avec la chaîne légère kappa (1'-218') [V-KAPPA humanisé (Homo
                                            sapiens IGKV4-1*01 (79.20%) -IGKJ1*01) [10.3.9] (1'-111') -Homo
                                            sapiens IGKC*01 (112'-218')]; dimère (227-227":230-230")-
                                            bisdisulfure; conjugué, sur 3 à 5 cystéinyl en moyenne, au
                                            monométhylauristatine F (MMAF), via un linker maléimidocaproyl
                                            (mc) non clivable
                                            Pour la partie mafodotine, veuillez-vous référer au document "INN for
                                            pharmaceutical substances: Names for radicals, groups and others"*.

 vorsetuzumab mafodotina                    inmunoglobulina G1-kappa conjugada con auristatina F, anti-[CD70
                                            de Homo sapiens (miembro 7 de la superfamilia del TNF, TNFSF7,
                                            CD27LG, CD27L)], anticuerpo monoclonal humanizado conjugado
                                            con la auristatina F;
                                            cadena pesada gamma1 (1-448) [VH humanizado (Homo sapiens
                                            IGHV1-2*02 (86.70%) -(IGHD)-IGHJ6*01) [8.8.11] (1-118) -Homo
                                            sapiens IGHG1*01 (119-448)], (221-218'-disulfuro (si no está
                                            conjugado) con la cadena ligera kappa (1'-218') [V-KAPPA
                                            humanizado (Homo sapiens IGKV4-1*01 (79.20%) -IGKJ1*01)
                                            [10.3.9] (1'-111') -Homo sapiens IGKC*01 (112'-218')]; dímero (227-
                                            227":230-230")-bisdisulfuro; conjugado en 3 -5 restos cisteinil, por
                                            término medio, con monometilauristatina F (MMAF), mediante un
                                            enlace maleimidocaproil (mc) no escindible
                                            Para la fracción mafodotina, se pueden dirigir al documento "INN for
                                            pharmaceutical substances: Names for radicals, groups and
                                            others"*.


                                            Heavy chain / Chaîne lourde / Cadena pesada
                                            QVQLVQSGAE VKKPGASVKV SCKASGYTFT                  NYGMNWVRQA       PGQGLKWMGW        50
                                            INTYTGEPTY ADAFKGRVTM TRDTSISTAY                  MELSRLRSDD       TAVYYCARDY       100
                                            GDYGMDYWGQ GTTVTVSSAS TKGPSVFPLA                  PSSKSTSGGT       AALGCLVKDY       150
                                            FPEPVTVSWN SGALTSGVHT FPAVLQSSGL                  YSLSSVVTVP       SSSLGTQTYI       200
                                            CNVNHKPSNT KVDKKVEPKS CDKTHTCPPC                  PAPELLGGPS       VFLFPPKPKD       250
                                            TLMISRTPEV TCVVVDVSHE DPEVKFNWYV                  DGVEVHNAKT       KPREEQYNST       300
                                            YRVVSVLTVL HQDWLNGKEY KCKVSNKALP                  APIEKTISKA       KGQPREPQVY       350
                                            TLPPSRDELT KNQVSLTCLV KGFYPSDIAV                  EWESNGQPEN       NYKTTPPVLD       400
                                            SDGSFFLYSK LTVDKSRWQQ GNVFSCSVMH                  EALHNHYTQK       SLSLSPGK         448

                                            Light chain / Chaîne légère / Cadena ligera
                                            DIVMTQSPDS LAVSLGERAT INCRASKSVS                  TSGYSFMHWY       QQKPGQPPKL 50
                                            LIYLASNLES GVPDRFSGSG SGTDFTLTIS                  SLQAEDVAVY       YCQHSREVPW 100
                                            TFGQGTKVEI KRTVAAPSVF IFPPSDEQLK                  SGTASVVCLL       NNFYPREAKV 150
                                            QWKVDNALQS GNSQESVTEQ DSKDSTYSLS                  STLTLSKADY       EKHKVYACEV 200
                                            THQGLSSPVT KSFNRGEC                                                           218

                                            Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
                                            Intra-H 22-96        145-201 262-322        368-426
                                                     22''-96'' 145''-201'' 262''-322'' 368''-426''
                                            Intra-L 23'-92' 138'-198'
                                                     23'''-92''' 138'''-198'''
                                            Inter-H-L* 221-218' 221''-218'''
                                            Inter-H-H * 227-227'' 230-230''

                                            N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación
                                            H CH2 N84.4:
                                            298, 298''
                                            *Two or three of the inter-chain disulfide bridges are not present, the antibody being
                                            conjugated to an average of 3 to 5 drug linkers each via a thioether bond.
                                            * Deux ou trois des ponts disulfure ne sont pas présents, l'anticorps étant conjugué à
                                            une moyenne de 3 à 5 linker-principe actif chacun via une liaison thioéther.
                                            * Faltan dos o tres puentes disulfuro inter-catenarios por estar el anticuerpo conjugado,
                                            con sendos enlaces tioéter, a una media de 3 a 5 conectores de principio activo



                                                                                                                                        87
Recommended INN: List 69                                                             WHO Drug Information Vol. 27, No. 1, 2013




 zoptarelinum doxorubicinum
 zoptarelin doxorubicin                              [6-D-lysine]human gonadoliberin-1 (LHRH) and doxorubicin
                                                     covalently linked together with glutaric acid:
                                                     5-oxo-L-prolyl-L-histidyl-L-tryptophyl-L-seryl-L-tyrosyl-
                                                       6
                                                     N -[5-(2-{(2S,4S)-4-[(3-amino-2,3,6-trideoxy-α-L-lyxo-
                                                     hexopyranosyl)oxy]-2,5,12-trihydroxy-7-methoxy-6,11-dioxo-
                                                     1,2,3,4,6,11-hexahydrotetracen-2-yl}-2-oxoethoxy)-5-oxopentanoyl]-
                                                     D-lysine-L-leucyl-L-arginyl-L-prolylglycinamide

 zoptaréline doxorubicine                            [6-D-lysine]gonadolibérine-1 humaine (LHRH) et doxorubicine liées
                                                     de façon covalente par l'acide glutarique:
                                                     5-oxo-L-prolyl-L-histidyl-L-tryptophyl-L-séryl-L-tyrosyl-
                                                       6
                                                     N -[5-(2-{(2S,4S)-4-[(3-amino-2,3,6-tridésoxy-α-L-lyxo-
                                                     hexopyranosyl)oxy]-2,5,12-trihydroxy-7-méthoxy-6,11-dioxo-
                                                     1,2,3,4,6,11-hexahydrotétracén-2-yl}-2-oxoéthoxy)-5-oxopentanoyl]-
                                                     D-lysine-L-leucyl-L-arginyl-L-prolylglycinamide

 zoptarelina doxorubicina                            [6-D-lisina]gonadoliberina-1 humana (LHRH) y doxorubicina unidas
                                                     covalentemente mediante ácido glutárico:
                                                                                                              6
                                                     5-oxo-L-prolil-L-histidil-L-triptofil-L-seril-L-tirosil-N -[5-(2-{(2S,4S)-4-
                                                     [(3-amino-2,3,6-tridesoxi-α-l-lixo-hexopiranosil)oxi]-2,5,12-trihidroxi-
                                                     7-metoxi-6,11-dioxo-1,2,3,4,6,11-hexahidrotetracen-2-il}-2-oxoetoxi)-
                                                     5-oxopentanoil]-D-lisina-L-leucil-L-arginil-L-prolilglicinamida


                                                                          O         OH             O
                                                                                                        O     O
                                                                                                   OH

                                                                                         H
                                                                  OCH3 O            OH         O O                      O
                                                                                         CH3
                                                                                                                  NH
                                                                                    HO
                                                                                         NH2       H
                                                                  H
                                                      O     N           His   Trp   Ser      Tyr   N        Leu   Arg       Pro Gly   NH2
                                                            H                                      H
                                                                  O                                     O




* http://www.who.int/medicines/services/inn/publication/en/index.html

# Electronic structure available on Mednet: http://mednet.who.int/
# Structure électronique disponible sur Mednet: http://mednet.who.int/
# Estructura electrónica disponible en Mednet: http://mednet.who.int/



88
WHO Drug Information Vol. 27, No. 1, 2013                                                           Recommended INN: List 69




                            AMENDMENTS TO PREVIOUS LISTS
                    MODIFICATIONS APPORTÉES AUX LISTES ANTÉRIEURES
                        MODIFICACIONES A LAS LISTAS ANTERIORES



Recommended International Non Proprietary Names (Rec. INN): List 61
Dénominations communes internationales recommandées (DCI Rec.): Liste 61
Denominaciones Comunes Internacionales Recomendadas (DCI Rec.): Lista 61
(WHO Drug Information, Vol. 23, No. 1, 2009)

p. 53     bevasiranibum
          bevasiranib               replace the description, molecular formula and the structure by the following ones
          bévasiranib               remplacer la description, la formule moléculaire et la structure par les suivants
          bevasiranib               sustitúyase la descripción, la fórmula molecular y la estructura por los siguientes

                                    siRNA inhibitor of Vascular Endothelial Growth Factor (VEGF) production;
                                    duplex of adenylyl-(3'5')-cytidylyl-(3'5')-cytidylyl-(3'5')-uridylyl-(3'5')-cytidylyl-
                                    (3'5')-adenylyl-(3'5')-cytidylyl-(3'5')-cytidylyl-(3'5')-adenylyl-(3'5')-adenylyl-
                                    (3'5')-guanylyl-(3'5')-guanylyl-(3'5')-cytidylyl-(3'5')-cytidylyl-(3'5')-adenylyl-
                                    (3'5')-guanylyl-(3'5')-cytidylyl-(3'5')-adenylyl-(3'5')-cytidylyl-(3'5')-
                                    thymidylyl-(3'5')-thymidine and thymidylyl-(5'3')-thymidylyl-(5'3')-uridylyl-
                                    (5'3')-guanylyl-(5'3')-guanylyl-(5'3')-adenylyl-(5'3')-guanylyl-(5'3')-uridylyl-
                                    (5'3')-guanylyl-(5'3')-guanylyl-(5'3')-uridylyl-(5'3')-uridylyl-(5'3')-cytidylyl-
                                    (5'3')-cytidylyl-(5'3')-guanylyl-(5'3')-guanylyl-(5'3')-uridylyl-(5'3')-cytidylyl-
                                    (5'3')-guanylyl-(5'3')-uridylyl-(5'3')-guanosine

                                    petit ARN interférant (siRNA) inhibiteur de la production du facteur de croissance de
                                    l’endothélium vasculaire (VEGF) ;
                                    duplex d’adénylyl-(3'5')-cytidylyl-(3'5')-cytidylyl-(3'5')-uridylyl-(3'5')-cytidylyl-
                                    (3'5')-adénylyl-(3'5')-cytidylyl-(3'5')-cytidylyl-(3'5')-adénylyl-(3'5')-adénylyl-
                                    (3'5')-guanylyl-(3'5')-guanylyl-(3'5')-cytidylyl-(3'5')-cytidylyl-(3'5')-adénylyl-
                                    (3'5')-guanylyl-(3'5')-cytidylyl-(3'5')-adénylyl-(3'5')-cytidylyl-(3'5')-
                                    thymidylyl-(3'5')-thymidine et de thymidylyl-(5'3')-thymidylyl-(5'3')-uridylyl-
                                    (5'3')-guanylyl-(5'3')-guanylyl-(5'3')-adénylyl-(5'3')-guanylyl-(5'3')-uridylyl-
                                    (5'3')-guanylyl-(5'3')-guanylyl-(5'3')-uridylyl-(5'3')-uridylyl-(5'3')-cytidylyl-
                                    (5'3')-cytidylyl-(5'3')-guanylyl-(5'3')-guanylyl-(5'3')-uridylyl-(5'3')-cytidylyl-
                                    (5'3')-guanylyl-(5'3')-uridylyl-(5'3')-guanosine

                                    ARN pequeño de interferencia (siRNA) inhibidor de la producción del factor de
                                    crecimiento endotelial vascular (VEGF);
                                    dúplex de adenilil-(3'5')-citidilil-(3'5')-citidilil-(3'5')-uridilil-(3'5')-citidilil-(3'5')-
                                    adenilil-(3'5')-citidilil-(3'5')-citidilil-(3'5')-adenilil-(3'5')-adenilil-(3'5')-guanilil-
                                    (3'5')-guanilil-(3'5')-citidilil-(3'5')-citidilil-(3'5')-adenilil-(3'5')-guanilil-(3'5')-
                                    citidilil-(3'5')-adenilil-(3'5')-citidilil-(3'5')-timidill-(3'5')-timidina y timidill-(5'3')-
                                    timidill-(5'3')-uridilil-(5'3')-guanilil-(5'3')-guanilil-(5'3')-adenilil-(5'3')-guanilil-
                                    (5'3')-uridilil-(5'3')-guanilil-(5'3')-guanilil-(5'3')-uridilil-(5'3')-uridilil-(5'3')-
                                    citidilil-(5'3')-citidilil-(5'3')-guanilil-(5'3')-guanilil-(5'3')-uridilil-(5'3')-citidilil-
                                    (5'3')-guanilil-(5'3')-uridilil-(5'3')-guanosina

                                    C401H503N153O290P40

                                              (3'-5') A C C
                                                     . . . U C A C C A A G G C C A G C A C
                                                           . . . . . . . . . . . . . . . .                                   dT dT
                                     (5'-3') dT dT U G      G A G U G G U U C C G G U C G U G




                                                                                                                                   89
Recommended INN: List 69                                                     WHO Drug Information Vol. 27, No. 1, 2013




Recommended International Nonproprietary Names (Rec. INN): List 63
Dénominations communes internationales recommandées (DCI Rec.): Liste 63
Denominaciones Comunes Internacionales Recomendadas (DCI Rec.): Lista 63
(WHO Drug Information, Vol. 24, No. 1, 2010)

p. 70    ridaforolimusum
         ridaforolimus           replace the chemical name by the following one
         ridaforolimus           sustitúyase el nombre químico por el siguiente
                                 (1R,2R,4S)-4-[(2R)-2-
                                 {(3S,6R,7E,9R,10R,12R,14S,15E,17E,19E,21S,23S,26R,27R,34aS)-9,27-dihydroxy-
                                 10,21-dimethoxy-6,8,12,14,20,26-hexamethyl-1,5,11,28,29-pentaoxo-
                                 1,4,5,6,9,10,11,12,13,14,21,22,23,24,25,26,27,28,29,31,32,33,34,34a-
                                 tetracosahydro-3H-23,27-epoxypyrido[2,1-c][1,4]oxaazacyclohentriacontin-
                                 3-yl}propyl]-2-methoxycyclohexyl dimethylphosphinate

                                 dimetilfosfinato de (1R,2R,4S)-4-[(2R)-2-
                                 {(3S,6R,7E,9R,10R,12R,14S,15E,17E,19E,21S,23S,26R,27R,34aS)-9,27-dihidroxi-
                                 10,21-dimetoxi-6,8,12,14,20,26-hexametil-1,5,11,28,29-pentaoxo-
                                 1,4,5,6,9,10,11,12,13,14,21,22,23,24,25,26,27,28,29,31,32,33,34,34a-
                                 tetracosahidro-3H-23,27-epoxipirido[2,1-c][1,4]oxaazaciclohentriacontin-3-il}propil]-
                                 2-metoxiciclohexilo



Recommended International Non Proprietary Names (Rec. INN): List 65
Dénominations communes internationales recommandées (DCI Rec.): Liste 65
Denominaciones Comunes Internacionales Recomendadas (DCI Rec.): Lista 65
(WHO Drug Information, Vol. 25, No. 1, 2011)



p. 76    obinutuzumabum
         obinutuzumab            replace the structure by the following one
         obinutuzumab            remplacer la structure par la suivante
         obinutuzumab            sustitúyase la estructura por la siguiente

                                 Heavy chain / Chaîne lourde / Cadena pesada
                                 QVQLVQSGAE VKKPGSSVKV SCKASGYAFS                  YSWINWVRQA       PGQGLEWMGR      50
                                 IFPGDGDTDY NGKFKGRVTI TADKSTSTAY                  MELSSLRSED       TAVYYCARNV      100
                                 FDGYWLVYWG QGTLVTVSSA STKGPSVFPL                  APSSKSTSGG       TAALGCLVKD      150
                                 YFPEPVTVSW NSGALTSGVH TFPAVLQSSG                  LYSLSSVVTV       PSSSLGTQTY      200
                                 ICNVNHKPSN TKVDKKVEPK SCDKTHTCPP                  CPAPELLGGP       SVFLFPPKPK      250
                                 DTLMISRTPE VTCVVVDVSH EDPEVKFNWY                  VDGVEVHNAK       TKPREEQYNS      300
                                 TYRVVSVLTV LHQDWLNGKE YKCKVSNKAL                  PAPIEKTISK       AKGQPREPQV      350
                                 YTLPPSRDEL TKNQVSLTCL VKGFYPSDIA                  VEWESNGQPE       NNYKTTPPVL      400
                                 DSDGSFFLYS KLTVDKSRWQ QGNVFSCSVM                  HEALHNHYTQ       KSLSLSPGK       449

                                 Light chain / Chaîne légère / Cadena ligera
                                 DIVMTQTPLS LPVTPGEPAS ISCRSSKSLL                  HSNGITYLYW       YLQKPGQSPQ      50'
                                 LLIYQMSNLV SGVPDRFSGS GSGTDFTLKI                  SRVEAEDVGV       YYCAQNLELP      100'
                                 YTFGGGTKVE IKRTVAAPSV FIFPPSDEQL                  KSGTASVVCL       LNNFYPREAK      150'
                                 VQWKVDNALQ SGNSQESVTE QDSKDSTYSL                  SSTLTLSKAD       YEKHKVYACE      200'
                                 VTHQGLSSPV TKSFNRGEC                                                               219'

                                 Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
                                 22-96 22''-96'' 23'-93' 23'''-93''' 139'-199' 139'''-199''' 146-202 146''-202''
                                 219'-222 219'''-222'' 228-228'' 231-231'' 263-323 263''-323'' 369-427 369''-427''

                                 Glycosylation sites / Sites de glycosylation / Posiciones de glicosilación
                                 H CH2 N84.4
                                 299, 299" (enriched in bisected non-fucosylated oligosaccharides)



90
WHO Drug Information Vol. 27, No. 1, 2013                                                                               Recommended INN: List 69




p. 81     peginesatidum
          peginesatide              replace the description and the structure by the following ones
          péginésatide              remplacer la description et la structure par les suivants
          peginesatida              sustitúyase la descripción y la estructura por los siguientes

                                    pegylated erythropoietin receptor agonist;
                                      6.21 6.21'   2  6
                                    N ,N -{[(N ,N -bis{[ω-methoxypoly(oxyethylene)]carbonyl}-DL-lysyl-
                                    β-alanyl)imino]bis(methylenecarbonyl)}bis[acetylglycylglycyl-L-leucyl-L-tyrosyl-
                                    L-alanyl-L-cysteinyl-L-histidyl-L-methionylglycyl-L-prolyl-L-isoleucyl-L-threonyl-
                                    3-(naphtalen-1-yl)-L-alanyl-L-valyl-L-cysteinyl-L-glutaminyl-L-prolyl-L-leucyl-L-arginyl-
                                    N-methylglycyl-L-lysinamide] (6→15:6'→15')-bisdisulfure cyclic

                                    agoniste du récepteur de l'érythropoïétine, pégylé ;
                                                                                6.21 6.21'    2   6
                                    (6→15:6'→15')-bisdisulfure cyclique du N ,N -{[(N ,N -bis{[ω-
                                    méthoxypoly(oxyéthylène)]carbonyl}-DL-lysyl-
                                    β-alanyl)imino]bis(méthylènecarbonyl)}bis[acétylglycylglycyl-L-leucyl-L-tyrosyl-
                                    L-alanyl-L-cystéinyl-L-histidyl-L-méthionylglycyl-L-prolyl-L-isoleucyl-L-thréonyl-
                                    3-(naphtalén-1-yl)-L-alanyl-L-valyl-L-cystéinyl-L-glutaminyl-L-prolyl-L-leucyl-L-arginyl-
                                    N-méthylglycyl-L-lysinamide]

                                    agonista del receptor de la eritropoyetina, pegilado;
                                                                                    6.21  6.21'   2   6
                                    (6→15:6'→15')-bisdisulfuro cíclico del N ,N -{[(N ,N -bis{[ω-
                                    metoxipoly(oxietileno)]carbonil}-DL-lisil-
                                    β-alanil)imino]bis(metilenocarbonil)}bis[acetilglicilglicil-L-leucil-L-tirosil-L-alanil-
                                    L-cisteinil-L-histidil-L-metionilglicil-L-prolil-L-isoleucil-L-treonil-3-(naftalen-1-il)-L-alanil-
                                    L-valil-L-cisteinil-L-glutaminil-L-prolil-L-leucil-L-arginil-N-metilglicil-L-lisinamida]

                                              O
                                                        Gly Gly Leu Tyr Ala Cys His Met Gly
                                            H3C
                                              Pro Ile Thr Nal Val Cys Gln Pro Leu Arg Sar Lys NH2
                                              10                                                            20
                                                                          O                                       N6

                                                          O
                                                  H3 C                O       N                                          O
                                                                          a   H
                                                                                                                 N
                                     n = a + b # 900                              O
                                                                                      H                                  O
                                                                  O                                NH       O
                                      * DL-lysine         H3C                 O       N *
                                                                                  b   H
                                              O                                               O
                                                        Gly Gly Leu Tyr Ala Cys His Met Gly
                                            H3C                                          N6
                                              Pro Ile Thr Nal Val Cys Gln Pro Leu Arg Sar Lys NH2
                                              10'                                                           20'



                                     3-(naphthalen-1-
                                     yl)-L-alanyl
                                                                                             Sar        =
                                                                                                                  N
                                                                  H
                                                                                          N-methylglycyl          CH3    O
                                       Nal          =         N
                                                              H
                                                                  O




                                                                                                                                              91
Recommended INN: List 69                                                                   WHO Drug Information Vol. 27, No. 1, 2013




Recommended International Non Proprietary Names (Rec. INN): List 66
Dénominations communes internationales recommandées (DCI Rec.): Liste 66
Denominaciones Comunes Internacionales Recomendadas (DCI Rec.): Lista 66
(WHO Drug Information, Vol. 25, No. 3, 2011)

p. 332   turoctocogum alfa #
         turoctocog alfa         replace the description, the molecular formula and the structure by the following
         turoctocog alfa         remplacer la description, la formule moléculaire et la structure par les suivantes
         turoctocog alfa         sustitúyase la descripción, la fórmula molecular y la estructura por las siguientes

                                 human coagulation factor VIII-(1-750)-(1638-1648)-peptide compound with human
                                 coagulation factor VIIIa light chain, glycosylated
                                 des-(751-1637)-human coagulation factor VIII-(1-1648)-peptide containing 92 kDa
                                 factor VIIIa heavy chain compound with human coagulation factor VIIIa light chain
                                 glycosylated (glycoform alfa produced in CHO cells)

                                 facteur VIII de coagulation humain-(1-750)-(1638-1648)-peptide associé à la chaîne
                                 légère du facteur VIIIa de coagulation humain glycosylés
                                 dès-(751-1637)-facteur VIII de coagulation humain-(1-1648)-peptide contenant la
                                 chaîne lourde de 92 kDa du factor VIIIa associé à la chaîne légère du facteur VIIIa
                                 de coagulation humain glycosylés (glycoforme alfa produit par des cellules CHO)

                                 factor VIII de coagulación humano-(1-750)-(1648)-péptido asociado a la cadena
                                 ligera del factor VIIIa de coagulación humano, glicosilados
                                 des-(751-1637)-factor VIII de coagulación humano-(1-1648)-péptido que contiene la
                                 cadena pesada de 92kDa del factor VIIIa asociada a la cadena ligera del factor VIIIa
                                 de coagulación humano glicosilados (glicoforma alfa producida por células CHO)

                                 C7480H11381N1999O2195S68 (peptide)
                                 Heavy chain / Chaîne lourde / Cadena pesada
                                 ATRRYYLGAV ELSWDYMQSD LGELPVDARF                   PPRVPKSFPF       NTSVVYKKTL       50
                                 FVEFTDHLFN IAKPRPPWMG LLGPTIQAEV                   YDTVVITLKN       MASHPVSLHA       100
                                 VGVSYWKASE GAEYDDQTSQ REKEDDKVFP                   GGSHTYVWQV       LKENGPMASD       150
                                 PLCLTYSYLS HVDLVKDLNS GLIGALLVCR                   EGSLAKEKTQ       TLHKFILLFA       200
                                 VFDEGKSWHS ETKNSLMQDR DAASARAWPK                   MHTVNGYVNR       SLPGLIGCHR       250
                                 KSVYWHVIGM GTTPEVHSIF LEGHTFLVRN                   HRQASLEISP       ITFLTAQTLL       300
                                 MDLGQFLLFC HISSHQHDGM EAYVKVDSCP                   EEPQLRMKNN       EEAEDYDDDL       350
                                 TDSEMDVVRF DDDNSPSFIQ IRSVAKKHPK                   TWVHYIAAEE       EDWDYAPLVL       400
                                 APDDRSYKSQ YLNNGPQRIG RKYKKVRFMA                   YTDETFKTRE       AIQHESGILG       450
                                 PLLYGEVGDT LLIIFKNQAS RPYNIYPHGI                   TDVRPLYSRR       LPKGVKHLKD       500
                                 FPILPGEIFK YKWTVTVEDG PTKSDPRCLT                   RYYSSFVNME       RDLASGLIGP       550
                                 LLICYKESVD QRGNQIMSDK RNVILFSVFD                   ENRSWYLTEN       IQRFLPNPAG       600
                                 VQLEDPEFQA SNIMHSINGY VFDSLQLSVC                   LHEVAYWYIL       SIGAQTDFLS       650
                                 VFFSGYTFKH KMVYEDTLTL FPFSGETVFM                   SMENPGLWIL       GCHNSDFRNR       700
                                 GMTALLKVSS CDKNTGDYYE DSYEDISAYL                   LSKNNAIEPR       SFSQNSRHPS       750
                                 QNPPVLKRHQ R                                                                         761

                                 Light chain / Chaîne légère / Cadena ligera
                                                                                                             EI       1650
                                 TRTTLQSDQE       EIDYDDTISV       EMKKEDFDIY       DEDENQSPRS       FQKKTRHYFI       1700
                                 AAVERLWDYG       MSSSPHVLRN       RAQSGSVPQF       KKVVFQEFTD       GSFTQPLYRG       1750
                                 ELNEHLGLLG       PYIRAEVEDN       IMVTFRNQAS       RPYSFYSSLI       SYEEDQRQGA       1800
                                 EPRKNFVKPN       ETKTYFWKVQ       HHMAPTKDEF       DCKAWAYFSD       VDLEKDVHSG       1850
                                 LIGPLLVCHT       NTLNPAHGRQ       VTVQEFALFF       TIFDETKSWY       FTENMERNCR       1900
                                 APCNIQMEDP       TFKENYRFHA       INGYIMDTLP       GLVMAQDQRI       RWYLLSMGSN       1950
                                 ENIHSIHFSG       HVFTVRKKEE       YKMALYNLYP       GVFETVEMLP       SKAGIWRVEC       2000
                                 LIGEHLHAGM       STLFLVYSNK       CQTPLGMASG       HIRDFQITAS       GQYGQWAPKL       2050
                                 ARLHYSGSIN       AWSTKEPFSW       IKVDLLAPMI       IHGIKTQGAR       QKFSSLYISQ       2100
                                 FIIMYSLDGK       KWQTYRGNST       GTLMVFFGNV       DSSGIKHNIF       NPPIIARYIR       2150
                                 LHPTHYSIRS       TLRMELMGCD       LNSCSMPLGM       ESKAISDAQI       TASSYFTNMF       2200
                                 ATWSPSKARL       HLQGRSNAWR       PQVNNPKEWL       QVDFQKTMKV       TGVTTQGVKS       2250
                                 LLTSMYVKEF       LISSSQDGHQ       WTLFFQNGKV       KVFQGNQDSF       TPVVNSLDPP       2300
                                 LLTRYLRIHP       QSWVHQIALR       MEVLGCEAQD       LY                                2332

                                 Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
                                 153-179 248-329 528-554 630-711 1832-1858 1899-1903 2021-2169 2174-2326

                                 Sulfated residues (Y) / Résidus sulfatés (Y) / Restos sulfatados (Y)
                                 Tyr-346 Tyr-718 Tyr-719 Tyr-723 Tyr-1664 Tyr-1680

                                 Glycosylation sites (N, S) / Sites de glycosylation (N, S) / Posiciones de glicosilación (N, S)
                                 Asn-41 Asn-239 Ser-750 Asn-1810 Asn-2118



92
    WHO Drug Information Vol. 27, No. 1, 2013                                                     Recommended INN: List 69




    Recommended International Non Proprietary Names (Rec. INN): List 67
    Dénominations communes internationales recommandées (DCI Rec.): Liste 67
    Denominaciones Comunes Internacionales Recomendadas (DCI Rec.): Lista 67
    (WHO Drug Information, Vol. 26, No. 1, 2012)

    p. 72      mericitabinum
               mericitabine              replace the chemical name by the following one
               mericitabina              sustitúyase el nombre químico por el siguiente
                                         (2’R)-2’-deoxy-2’-fluoro-2’-methyl-3’,5’-bis-O-(2-methylpropanoyl)cytidine
                                         (2’R)-2’-desoxi-2’-fluoro-2’-metil-3’,5’-bis-O-(2-metilpropanoil)citidina




Procedure and Guiding Principles / Procédure et Directives / Procedimientos y principios generales
The text of the Procedures for the Selection of Recommended International Nonproprietary Names for Pharmaceutical
Substances and General Principles for Guidance in Devising International Nonproprietary Names for Pharmaceutical
Substances will be reproduced in proposed INN lists only.
Les textes de la Procédure à suivre en vue du choix de dénominations communes internationales recommandées pour les
substances pharmaceutiques et des Directives générales pour la formation de dénominations communes internationales
applicables aux substances pharmaceutiques seront publiés seulement dans les listes des DCI proposées.
El texto de los Procedimientos de selección de denominaciones comunes internacionales recomendadas para las sustancias
farmacéuticas y de los Principios generales de orientación para formar denominaciones comunes internacionales para
sustancias farmacéuticas aparece solamente en las listas de DCI propuestas.




                                                                                                                        93
